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SUMMARY  
 
Mycobacterium tuberculosis (M. tuberculosis) accounts for more adult deaths than 
any other infectious agents. The present study included 162 patients with tuberculous 
pericarditis; 50% of the tuberculous pericarditis patients studied were human 
immunodeficiency virus (HIV) positive, compared to only 4.2% of patients who 
presented with non-tuberculous pericardial effusions. A steady year-to-year rise in 
HIV prevalence was observed in this 6-year study. Although the prognosis of 
pericardial tuberculosis (TB) is excellent with appropriate medical treatment, 
untreated pericardial TB has a mortality of 80-85%. It is thus important to diagnose 
tuberculous pericarditis efficiently. Traditionally, the diagnosis of pericardial TB is 
established by positive mycobacterial culture and/or histological evidence of 
necrotising granulomatous inflammation of the pericardium. Our study confirmed the 
insensitivity of pericardial fluid culture and pericardial biopsy in the diagnosis of 
pericardial TB, and at the time of clinical decision-making, results were usually not 
available. To overcome these difficulties, we explored various alternative strategies 
and this resulted in two diagnostic tools, namely a diagnostic rule and a diagnostic 
algorithm or classification tree.  
 
By means of classification and regression tree analysis, we allocated a weighted 
diagnostic index to each of five independently predictive features (fever, night sweats, 
weight loss, serum globulin >40 g/L and peripheral blood leukocyte count 
<10x109/L). A total diagnostic index of 6 or more corresponded to 82-86% sensitivity 
and 76-87% specificity for a diagnosis of tuberculous pericarditis.  
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When possible, pericardial fluid should be aspirated to determine adenosine 
deaminase (ADA) levels and pericardial differential leukocyte counts. Fluid should 
also be sent for Gram stain and culture. The proposed diagnostic classification tree 
utilises the independently predictive attributes of pericardial adenosine deaminase 
levels, pericardial fluid lymphocyte/neutrophil ratios, peripheral leukocyte counts and 
the HIV status. Applying this prediction model to our entire data set of 233 patients 
resulted in 96% sensitivity and 97% specificity for the correct diagnosis of 
tuberculous pericarditis.  
 
Generally, patients were critically ill at the time of enrolment; 90% of tuberculous 
pericarditis presented with echocardiographic features of cardiac tamponade. Echo-
guided percutaneous pericardiocentesis with an indwelling catheter and intermittent 
daily aspiration was highly effective and safe. It is likely that the combination of this 
drainage technique and the early initiation of anti-tuberculous chemotherapy 
contributed to the almost complete absence of constriction in the patients studied, and 
our data do not support the routine use of adjunctive corticosteroids in patients with 
tuberculous pericarditis.  
 
Tuberculous exudates result from a Th1 mediated immune response characterised by 
lymphocyte dominance, significantly elevated levels of gamma-interferon (IFN-γ) and 
undetectable levels of interleukin-4 (IL-4). IFN-γ levels were not influenced by HIV 
status in spite of the severely diminished pericardial CD4+ lymphocyte counts 
observed in this study. It is thus likely that in HIV positive patients IFN-γ production 
is partly maintained by activated CD8+ T cells, which were significantly elevated in 
HIV positive patients compared to HIV negative tuberculous pericarditis patients. 
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This finding underlines the importance of IFN-γ in the human immune response 
against M. tuberculosis. We also demonstrated that the presence of ADA in 
pericardial fluids reflects the activity of the cellular immune response. Both IFN-γ and 
ADA can be utilised as sensitive and specific diagnostic tools for pericardial TB. 
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OPSOMMING 
 
Mycobacterium tuberculosis (M. tuberculosis) is verantwoordelik vir meer volwasse 
sterftes as enige ander infektiewe organisme. Die huidige studie sluit 162 pasiënte met 
tuberkuleuse perikarditis in; 50% van hierdie pasiënte was menslike immuungebrek 
virus (MIV) positief, in vergelyking met slegs 4.2% van pasiënte in wie nie-
tuberkuleuse perikardiale effusies voorgekom het. ŉ Bestendige jaar-tot-jaar toename 
in MIV voorkoms is waargeneem tydens hierdie 6-jaarlange studie. Alhoewel die 
prognose van perikardiale tuberkulose (TB) met toepaslike mediese behandeling 
uitstekend is, het onbehandelde perikardiale TB ŉ mortaliteit van 80 – 85%. Dit is dus 
belangrik om tuberkuleuse perikarditis effektief te diagnoseer. Tradisioneel word die 
diagnose van perikardiale TB vasgestel deur middel van positiewe mikobakteriële 
kulture en/of histologiese bewys van nekrotiserende granulomateuse inflammasie van 
die perikardium. Ons studie bevestig die gebrek aan sensitiwiteit van perikardiale 
vogkulture en perikardiale biopsie in die diagnose van perikardiale TB, en ten tye van 
kliniese besluitneming was die resultate gewoonlik nog nie beskikbaar nie. Om 
hierdie probleme te oorkom, het ons verskeie alternatiewe strategieë ondersoek. Dit 
het gelei tot die ontwikkeling van twee diagnostiese hulpmiddels, naamlik  ŉ 
diagnostiese reël en ŉ diagnostiese algoritme of klassifikasie vloeidiagram. 
 
Deur middel van klassifikasie en regressie vloeidiagram analise, het ons ŉ 
diagnostiese indeks toegeken aan elk van die vyf onafhanklike voorspelbare 
eienskappe (koors, nagsweet, gewigsverlies, serum globulien >40 g/L en perifere 
bloedleukosiettelling <10x109/L). ŉ Totale diagnostiese indeks van 6 of meer het 
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ooreengestem met ŉ sensitiwiteit van 82-86% en ŉ spesifisiteit van 76-87% vir ŉ 
diagnose van tuberkuleuse perikarditis. 
 
Wanneer moontlik, behoort perikardiale vog geaspireer te word om adenosien 
deaminase (ADA) vlakke en perikardiale differensiële leukosiettellings te bepaal. Vog 
behoort ook gestuur te word vir Gramkleuring en kultuur. Die voorgestelde 
diagnostiese klassifikasie vloeidiagram gebruik die onafhanklike voorspelbare 
bydraes van perikardiale ADA vlakke, perikardiale vog limfosiet/neutrofiel 
verhoudings, perifere leukosiettellings en die MIV status. Toepassing van hierdie 
voorspellingsmodel op ons totale datastel van 233 pasiënte, het gelei tot 96% 
sensitiwiteit en 97% spesifisiteit vir die korrekte diagnose van tuberkuleuse 
perikarditis. 
 
Oor die algemeen was die pasiënte ernstig siek met toetrede tot die studie, 90% van 
tuberkuleuse perikarditis het voorgedoen met eggokardiografiese kenmerke van 
kardiale tamponade. Eggogerigte perkutane perikardiosentese deur middel van ŉ 
inblywende kateter en intermitterende daaglikse aspirasie was hoogs effektief en 
veilig. Die kombinasie van hierdie dreineringstegniek en die vroeë aanvang van anti-
tuberkuleuse chemoterapie het waarskynlik bygedra tot die byna volledige 
afwesigheid van konstriksie in die pasiënte wat bestudeer is, en ons data steun nie die 
roetine gebruik van bykomende kortikosteroïede in pasiënte met tuberkuleuse 
perikarditis nie. 
 
Tuberkuleuse eksudate is die gevolg van ŉ Th1-gemedieerde immuunrespons, wat 
gekenmerk word deur limfosiet oorheersing, betekenisvol verhoogde vlakke van 
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gamma-interferon (IFN-γ) en onmeetbare vlakke van interleukin-4 (IL-4). IFN-γ 
vlakke is nie beïnvloed deur die MIV status nie, ten spyte van die erg verlaagde 
perikardiale CD4+ limfosiettellings waargeneem in hierdie studie. Dit is dus hoogs 
waarskynlik dat in MIV positiewe pasiënte die produksie van IFN-γ gedeeltelik 
gehandhaaf word deur geaktiveerde CD8+ T-selle, wat betekenisvol verhoog was in 
die MIV positiewe pasiënte, in vergelyking met MIV negatiewe tuberkuleuse 
perikarditis pasiënte. Hierdie bevinding beklemtoon die belang van IFN-γ in die 
menslike immuunrespons teen M. tuberculosis. Ons het getoon dat die 
teenwoordigheid van ADA in perikardiale vog die aktiwiteit van die sellulêre 
immuunrespons reflekteer. Beide IFN-γ en ADA kan gebruik word as sensitiewe 
hulpmiddels vir die diagnose van perikardiale TB. 
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 Chapter 1 
TUBERCULOUS PERICARDITIS IN THE ERA OF THE 
HIV PANDEMIC 
 
More than a hundred years after Robert Koch’s discovery of Mycobacterium 
tuberculosis (M. tuberculosis) in 1882, tuberculosis (TB) remains a major cause of 
morbidity and mortality among the world’s poor and those infected with the human 
immunodeficiency virus (HIV). It is estimated that one third of the world’s population 
is infected with M. tuberculosis, which is transmitted by person-to-person spread via 
droplets inhaled by the susceptible host (Coovadia and Benatar, 1991; Raviglione et 
al, 1995). The acid-fast tubercle bacilli elicit a non-specific acute response and are 
ingested by macrophages in the lung. Due to cell mediated immunity the tubercle 
bacilli are confined intracellularly within granulomatous lesions where they can 
persist for years (latent infection). However, if not adequately contained, M. 
tuberculosis causes active tuberculous disease (Murray et al, 1990; Dolin et al, 1994; 
Raviglione et al, 1995). In sub-Saharan Africa, HIV infection rates among TB 
patients are, on average, over three times higher than those in the general population 
and the resurgence of TB has been explained by the high HIV seroprevalence (Narain 
et al, 1992; Cantwell and Binkin, 1997) 
 
The World Health Organization (WHO) reported 8.8 million new cases of TB in 2003 
(140 / 100 000 population), of which 3.9 million were smear positive and 674 000 co-
infected with HIV (WHO report, 2005). An estimated 1.7 million people died from 
TB in 2003, including 229 000 individuals co-infected with HIV (WHO report, 2005). 
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In 2003, the TB incidence rate was falling or stable in five out of six WHO regions, 
but growing at 1% per year globally, due to the quickly rising incidence of TB in the 
African countries with high HIV prevalence rates (WHO report, 2005). In 2003, 
South Africa had a TB incidence of 536 cases/100 000 population per year and an 
estimated TB mortality of 73/100 000 population per year. In the age group 15-49 
years the HIV seroprevalence in patients with active TB was estimated to be 61% 
(WHO report, 2005). In South Africa, the HIV infection rate among pregnant women 
attending antenatal services in 2003 was 27.9%, with variation among the nine 
provinces ranging from as high as 37.5% in KwaZulu-Natal to as low as 13.1% in the 
Western Cape Province (UNAIDS, 2004). By the end of 2003, an estimated 5.3 
million South Africans (95% CI 4.5–6.2 million) were HIV positive, the largest 
number of individuals living with the virus in a single country (UNAIDS, 2004). This 
is the greatest health challenge facing South Africa and it fuels the TB epidemic and 
has serious social, economic and health implications.   
 
THE NATURAL HISTORY OF HIV INFECTION 
The principal cells targeted by HIV are CD4+ helper T cells and, to a lesser degree, 
cells of the monocyte-macrophage lineage (Fauci, 1993; Fauci et al, 1996). As a 
consequence of persistent viral replication there is a vicious cycle of immune 
activation and cytokine secretion that results in the depletion of CD4+ T cells, 
destruction of lymphoid tissue and the onset of life-threatening infections (Fauci, 
1993; Fauci et al, 1996). TB is the leading cause of morbidity and mortality in HIV-
infected South Africans (Badri et al, 2002). The progression of HIV infection can be 
conceptualised as three stages: a first phase of primary infection, a second clinically 
latent period when viral replication continues, and a third phase of advanced disease 
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(Fauci et al, 1996). Active TB can occur in any one of these stages (Badri et al, 2002). 
Primary infection generally refers to the period (few weeks to months) from initial 
infection until the immune response to HIV gains some measure of control over viral 
replication. Approximately 30-70% of newly infected individuals experience an acute 
mononucleosis-like syndrome with signs and symptoms during acute HIV infection 
that may include fever, malaise, rash, lymphadenopathy, pharyngitis, headache, 
diarrhoea and occasionally arthralgia and neurological manifestations (Tindall et al, 
1991; Clark et al, 1991; Pantaleo et al, 1993). This constellation of features is referred 
to as the "acute retroviral syndrome”. It is characterised by extremely high levels of 
plasma viraemia and a precipitous decline in CD4+ lymphocyte cell counts associated 
with a high risk for active TB (Clark et al, 1991; Piatak et al, 1993; Pantaleo et al, 
1994; Badri et al, 2002). The initial high levels of HIV replication and plasma 
viraemia generally decrease with the appearance of the specific immune response and 
viral levels gradually stabilise within six months to one year at a virologic “set-point“, 
which correlates with HIV-mediated disease progression (Mellors et al, 1995; Mellors 
et al, 1996). The relative stabilisation of the viraemia generally signifies the beginning 
of a clinically latent period that is characterised by chronic immune activation and 
persistent viral replication despite a lack of consistent signs or symptoms of disease 
(Pantaleo et al, 1996). During this phase, the number of circulating CD4+ lymphocyte 
T cells slowly declines by about 50-80 cells/μL per year, signalling the onset of 
progressive immunodeficiency.  The pivotal role of cytotoxic T lymphocytes (CTL) in 
controlling virus replication continues throughout the latent phase of infection 
(Haynes et al, 1992; Haynes et al, 1996). Eventually, the effective CTL response 
declines and plasma viraemia escalates. Neutralising antibodies are also present 
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throughout the asymptomatic phase of disease, albeit at relatively low 1evels 
(Montefiori et al, 1996).  
 
Advanced disease is characterised by an acquired immunodeficiency syndrome 
(AIDS) defining illness or a decline in the levels of circulating CD4+ lymphocyte T 
cells below 200 cells/μL (Centers for Disease Control, 1992).  Plasma viraemia 
usually increases during this stage of disease (Pantaleo et al, 1996) and is associated 
with a sharp decrease in CD4+ lymphocyte T cell counts. The natural history and 
pathogenic processes of HIV infection are highly variable and are influenced by viral 
and human genetic factors, virulence of HIV variants and host immunologic response 
to the virus (Pantaleo et al, 1996; Haynes et al, 1996; Pantaleo et al, 1997).  
 
EFFECT OF ACTIVE TB ON PROGRESSION OF HIV 
Despite adequate anti-tuberculous therapy, many individuals co-infected with TB and 
HIV have an accelerated course of HIV disease and shortened survival (Whalen et al, 
1995). Active TB provokes activation of the immune system, which results in high 
serum levels of pro-inflammatory cytokines and increased expression of cellular 
activation markers that facilitate HIV replication (Wallis et al, 1993; Whalen et al, 
1995; Bouscarat et al, 1996) 
 
THE EFFECTS OF HIV INFECTION ON CLINICAL TB 
Due to the gradual loss of CD4+ T lymphocytes and the associated inadequate cellular 
immunity, HIV-infected individuals are at an extraordinarily high risk of developing 
clinical TB (Barnes et al, 1991). Effects of HIV include increased susceptibility to 
reactivation of latent tuberculous infection, rapid progression following primary 
 5
infection, increased risk of recurrent disease, increased re-infection rates and also a 
change in the clinical picture, including a higher proportion of extrapulmonary TB 
and involvement at more than one site, a lower rate of tuberculin skin test positivity, 
more frequent atypical chest radiographs, and a marked increase in mortality 
(Chaisson et al, 1987; Barnes et al, 1991; Snider and Roper, 1992; Barnes et al, 1993; 
Houston et al, 1994; Sonnenberg et al, 2001,  Churchyard et al, 2003). In countries 
with a high TB incidence, recurrent TB accounts for a significant proportion of all 
cases (Weyer and Kleeberg, 1992; Churchyard et al, 2001) and HIV infection is the 
strongest risk factor for recurrent TB, especially in those with a low CD4+ 
lymphocyte count (Pulido et al, 1997; Johnson et al, 1997; Mallory et al, 2000; 
Sonnenberg et al, 2001).  Recurrent TB results from recrudescence of disease with the 
original infecting organism or re-infection with a new strain of M. tuberculosis (Van 
Rie et al, 1999; Sonnenberg et al, 2001). HIV-negative persons infected with M. 
tuberculosis have an estimated 5-10% lifetime risk (0.2% per year) of progression to 
active TB (Dolin et al, 1994; Rieder et al, 1998) compared to a cumulative lifetime 
risk of 30% or more (2.6-13.3% per year) for HIV-infected individuals (Selwyn et al, 
1989; Braun et al, 1991; Allen et al, 1992; Guelar et al, 1993; Antonucci et al, 1995; 
Mlika-Cabanne et al, 1995). The additional active TB cases lead to increased M. 
tuberculosis transmission within the community, thereby constituting an additional 
means by which HIV increases TB morbidity (Narain et al, 1992). The incidence of 
extrapulmonary TB in a community depends on two factors: (i) the prevalence of TB 
in that community and (ii) the degree of immune deficiency in TB infected 
individuals (Chaisson et al, 1987; Barnes et al, 1991; Mlika-Cabanne et al, 1995). In 
HIV negative patients tuberculous pericarditis was estimated to occur in 1-2% of 
instances of pulmonary TB (Larrieu et al, 1980). Since the early 1980s, the proportion 
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of patients with extrapulmonary TB has drastically increased as a result of the HIV 
epidemic (Harries, 1990; Narain et al, 1992). Several reports have documented the 
relationship between pericardial TB and HIV infection, with seropositivity being 
observed in 67-92% of patients (Cegielski et al, 1990; Pozniak et al, 1994; Maher and 
Harries, 1997). Tuberculous pericarditis usually presents with a history of dyspnoea, 
fever and features suggestive of congestive cardiac failure (Strang, 1984). In the 
context of HIV, congestive features could be caused by a number of other HIV-
associated conditions, the most important of these being viral carditis, HIV-associated 
dilated cardiomyopathy, primary pulmonary hypertension with right ventricular 
failure and cor pulmonale secondary to chronic disease (Patel and Frishman, 1995; 
Barbaro 2001).   
 
TUBERCULOUS PERICARDITIS 
Although it is an important cause of morbidity and mortality in countries where TB is 
endemic, tuberculous pericarditis receives scant attention in the world literature. It is 
the most common cause of pericardial effusions among HIV-infected and 
underprivileged populations of sub-Saharan Africa (Desai, 1979; Strang, 1984; 
Cegielski et al, 1991; Cegielski et al, 1994; Maher and Harries, 1997), as well as 
Afro-Americans in the United States of America (Reynolds et al, 1992; Kwan et al, 
1993; Lorell, 1997). In the Eastern Cape Province (Transkei region) of South Africa, 
tuberculous pericarditis is such a common cause of cardiac failure that it is known as 
“Transkei heart” (Strang, 1984). The HIV epidemic of sub-Saharan Africa is likely to 
worsen this situation (Fowler, 1991, Cantwell et al, 1992; Reynolds et al, 1992; Kwan 
et al, 1993; Hakim et al, 2000). It is important to diagnose tuberculous pericarditis 
efficiently because it is treatable. If left untreated, however, it has a mortality 
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approaching 85% as a result of cardiac tamponade, constriction or disseminated TB 
(Harvey and Whitehill, 1937; Desai, 1979).  
  
Tuberculous pericardial disease most often develops as the result of the breakdown of 
TB-infected mediastinal lymph nodes, particularly those at the tracheobronchial 
bifurcation (Spodick, 1956; Rooney et al, 1970; Ortbals, 1979; Cherian et al, 2003a; 
Cherian, 2004). The spread is either direct or via lymph channels that merge at points 
where the parietal pericardium and the pleura separate (Cherian, 2004). Studies in 
humans (Eliskova et al, 1995), in macaque monkeys (Eliskova et al, 1992) and in 
dogs (Miller et al, 1988) demonstrated that lymphatic drainage of the pericardium is 
mainly to the anterior mediastinal tracheobronchial, lateropericardial, and posterior 
mediastinal lymph nodes and not into the hilar nodes. Computerised tomography (CT) 
of the chest may demonstrate enlarged mediastinal lymph nodes, which have been 
reported to occur in virtually 100% of patients with pericardial TB (Cherian et al, 
2003b). Enlarged nodes disappeared or regressed with specific anti-tuberculous 
therapy (Cherian et al, 2003b).  
 
Less commonly, pericardial TB results from breakdown and contiguous spread of a 
necrotic tuberculous lesion in the lung, pleura, or spine or from early haematogenous 
spread from the primary tuberculous infection (Peel, 1948; Auerbach, 1950; Cherian 
et al, 2003a).   
 
Pathologically, a number of stages are recognised in the development of tuberculous 
pericarditis. The early stage is characterised by a fibrinous serosal exudate that 
contains lymphocytes. The middle phase manifests granuloma formation, and the 
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presence of viable acid-fast bacilli, and this is usually followed by absorption of the 
effusion, pericardial thickening, and proliferation of granulomata accompanied by 
caseating necrosis. At this stage, viable acid-fast bacilli are often no longer detected. 
In the late stage, fibrous pericarditis develops as the granulomatous reaction is 
replaced by fibrous tissue and collagen (Peel, 1948; Lorell, 1997; Nardell et al, 2004). 
These changes may be followed by the accumulation of cholesterol crystals and the 
development of pericardial calcification (Lorell, 1997). According to the literature, 
constrictive pericarditis develops ultimately in almost all patients with untreated 
tuberculous pericarditis and in up to half of the patients who receive anti-tuberculous 
chemotherapy (Schrire, 1959; Hageman et al, 1964; Long et al, 1989; Komsuoglu et 
al, 1994). Before the advent of effective chemotherapy, TB pericarditis was usually 
fatal, either in the acute stage due to cardiac tamponade or disseminated TB, or later 
as a result of constriction (Harvey and Whitehill, 1937). With the advent of effective 
anti-tuberculous chemotherapy in the 1940s, the mortality had decreased to about 35% 
of cases by 1970 (Shapiro, 1953; Schepers, 1962; Hageman et al, 1964; Rooney et al, 
1970). 
 
DIAGNOSIS OF PERICARDIAL TB  
The clinical presentation is variable and includes acute pericarditis with or without 
effusion, cardiac tamponade, silent large pericardial effusion with a relapsing course, 
toxic symptoms with persistent fever, acute constrictive pericarditis, subacute 
constriction, effusive-constrictive, or chronic constrictive pericarditis (Permanyer-
Miralda et al, 1985; Spodick, 1997). 
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The predominant symptoms of pericardial TB include dyspnoea, cough, chest pain, 
night sweats, orthopnoea, weight loss and ankle oedema. The most frequent signs are 
cardiomegaly, hepatomegaly, fever and tachycardia. Other findings may include 
pericardial rub, pulsus paradoxus, distended neck veins, pleural effusion and soft heart 
sounds (Schepers, 1962; Hageman et al, 1964; Rooney et al, 1970; Fowler and 
Manitas, 1973; Gooi and Smith 1978; Ortbals and Avioli, 1979; Desai, 1979; Fowler, 
1991).  
 
The prevalence of tuberculous pericarditis varies widely with geographic location and 
so the positive predictive value of characteristic clinical features varies as well 
(Trautner and Darouiche, 2001).  In sub-Saharan African countries where TB and HIV 
co-infection is endemic, and where access to pericardial biopsy and microbiologic 
studies is difficult, symptoms and signs of pericardial effusion in HIV-infected 
individuals may be enough to initiate anti-tuberculous therapy (Cegielski et al, 1994; 
Pozniak et al, 1994; Strang, 1997). In other countries, however, numerous other 
infectious and non-infectious causes may present with similar features (Montgomerie 
et al, 1975) and further diagnostic work-up is indicated. Echocardiography is the 
definitive investigation for the presence of pericardial effusion, and is useful to 
distinguish tamponade from subacute constriction (Strang et al, 2004; Quarashi et al, 
2005).  
 
The tuberculin skin test is performed by intradermal injection of purified protein 
derivative (PPD). It was reported in all patients with pericardial TB in one report 
(Rooney et al, 1970) and in 239/240 in another (Strang et al, 1988). Although a 
positive tuberculin skin test result increases the suspicion of pericardial TB, it is 
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important to realise that a negative result does not exclude tuberculous disease, and 
the response to tuberculin may be affected by the time of presentation (Fowler and 
Manitas, 1973; Rooney et al, 1970; Alvarez and McCabe, 1984; Pozniak et al, 1994; 
Trautner and Darouiche, 2001).  The tuberculin skin test may be false negative in 25–
33% of tests (Sagrista-Sauleda et al, 1991) and false positive in 30–40% of patients 
(Fowler, 1991). The more sensitive and accurate enzyme-linked immunospot 
(ELISPOT) test detects T-cells specific for M. tuberculosis antigen (Ewer et al, 2003; 
Liebeschuetz et al, 2004). This test is, however, only useful to detect infection, and 
does not differentiate between latent infection and active disease.  
 
Pericardial fluid smears for acid–fast bacilli are usually negative (Cherian, 2004). The 
reported diagnostic yield of pericardiocentesis in tuberculous pericarditis ranges from 
29–77% (Rooney et al, 1970; Fowler and Manitas, 1973; Gooi and Smith, 1978; 
Quale et al, 1987; Strang et al, 1988; Sagrista-Sauleda et al, 1988; Fowler, 1991; 
Uthaman et al, 1997; Trautner and Darouiche, 2001). Mycobacterial culture may take 
up to eight weeks and results are usually only available after patients have already 
been discharged from hospital (Rooney et al, 1970; Fowler and Manitas, 1973; 
Trautner and Darouiche, 2001). Pericardial biopsy may have a better diagnostic yield 
than pericardial fluid culture, but is invasive and requires surgical expertise. 
Histological evidence of granulomatous inflammation with the demonstration of acid-
fast bacilli would be a definite diagnostic criterion. The typical granuloma is, 
however, not always found and the pericardial biopsy may show non-specific findings, 
even when M. tuberculosis is found in the pericardial fluid (Strang et al, 1988; 
Cherian et al, 2003b; Cherian, 2004). Pericardial biopsy specimens should also be sent 
for mycobacterial culture and, where available, polymerase chain reaction (PCR) for 
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M. tuberculosis to optimise the diagnostic yield (Cegielski et al, 1997; Trautner and 
Daroiche, 2001).  
 
Fibre-optic pericardioscopy facilitates visualisation of the parietal pericardium and 
epicardium on the anterior, posterior and inferior surfaces of the heart allowing 
selective biopsies beyond the small region of pericardium that is usually accessible 
with a subxiphoid incision (Maisch et al, 1992).  Pericardioscopy with optically 
guided epicardial biopsy offers the potential for analysis of small tissue samples for 
myopericarditis using conventional histology as well as new molecular techniques of 
PCR and in situ hybridisation (Maisch, 1994; Ziskind et al, 1994). In patients with 
suspected but undocumented malignancy, pericardial biopsy increases the yield of a 
positive diagnosis of malignancy compared with pericardial fluid cytology alone 
(Maisch and Drude, 1992; Maisch, 1994; Ziskind et al, 1994).  Nugue et al (1996) 
reported improved diagnostic accuracy for tuberculous pericarditis by using 
pericardioscopy and pericardial biopsy. 
 
Analyses of the pericardial fluid specific gravity ( 1.015), protein level ( 30 g/L; 
pericardial fluid/serum protein ratio 0.5), pericardial fluid LDH ( 200 U/L) and 
pericardial fluid/ serum LDH ratio 0.6) can separate exudates from transudates but 
are not directly diagnostic (Burgess et al, 2002a). Tuberculous pericardial fluid 
demonstrates high specific gravity, high protein levels, and high white cell count 
(Fowler, 1991). In suspected cases of pericardial TB, adenosine deaminase (ADA) 
activity, pericardial lysozyme and PCR analyses for M. tuberculosis may assist in 
confirming the diagnosis, whereas cytology and tumour markers (carcinoembryonic 
antigen [CEA], alpha-feto protein [AFP], carbohydrate antigens) are more important 
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for the diagnosis of suspected malignant disease (Meyers et al, 1997; Permanyer-
Miralda et al, 1985; Garcia et al, 1994; Seo et al, 1993; Koh et al, 1994; Komsuoglu 
et al, 1995; Aggeli et al, 2000; Dogan et al, 1999; Lee et al, 2002). Differentiation of 
tuberculous and neoplastic effusions is virtually absolute with low levels of ADA and 
high levels of CEA (Koh et al, 1994). In one study, very high ADA levels suggested 
prognostic value for pericardial constriction (Komsuoglu et al, 1995). PCR assays for 
the detection of M. tuberculosis have been used to diagnose pericardial TB (Cegielski 
et al, 1997; Rana et al, 1999; Lee et al, 2002). Cegielski et al (1997) performed PCR 
with pericardial fluid and with pericardial biopsy specimens. PCR gave one false 
positive result for a patient with septic pericarditis (n=19). The sensitivity of PCR was 
higher with tissue specimens (12 out of 15; 80%) than with fluid specimens (2 out of 
13; 15%; p=0.002). The diagnostic accuracy of PCR (tissue specimens) approached 
the results of conventional methods, but PCR was much faster than culture. The 
sensitivity of PCR with pericardial fluid was poor (Cegielski et al, 1997). False 
positive results remain a concern (Cegielski et al, 1997; Lee et al, 2002). Besides 
diagnosing TB, PCR analysis is also useful for the detection of cardiotropic viruses 
and to discern viral from autoreactive pericarditis (Maisch et al, 2002a). 
Perimyocardial tuberculous involvement is associated with high serum titres of 
antimyolemmal and antimyosin antibodies (Maisch et al, 1982). The use of interferon-
gamma (IFN-γ) provided the basis for rapid and efficient diagnosis of pleural TB 
(Villegas et al, 2000) and of pericardial TB (Burgess et al, 2002b).  
 
For the differentiation of tuberculous pericarditis from septic pericarditis, a pericardial 
fluid Gram stain has a specificity of 99%, but a sensitivity of only 38% for exclusion 
of bacterial infection in comparison to bacterial cultures (Maisch et al, 2004). In 
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suspected septic pericarditis, Gram staining and at least three cultures of pericardial 
fluid for aerobes and anaerobes as well as blood cultures are mandatory (Maisch et al, 
2004). Pericardial fluid white blood cell (WBC) counts are highest in inflammatory 
diseases, particularly of bacterial and rheumatologic origin (Meyers et al, 1997).   
 
DIFFERENTIAL DIAGNOSIS OF HIV-ASSOCIATED CARDIAC DISEASE 
HIV-related cardiac disease is often masked or mimicked by pulmonary conditions, 
such as pulmonary TB, community acquired pneumonia or infection with 
Pneumocystis jeroveci. Radiological differentiation between cardiac failure and 
pulmonary disease is sometimes impossible. In patients with inappropriate 
tachycardia and/or increased cardio-thoracic ratio on chest radiograph, any form of 
ultrasonography may be useful to confirm the diagnosis of pericardial effusion and to 
evaluate its significance (Wragg and Strang, 2000; Quarashi et al, 2005). In 
industrialised countries echocardiographic evidence of pericardial effusion has been 
reported to be present in 22-53% of HIV-infected patients, and at autopsy in 15-59% 
of cases (Fink et al, 1984; Hecht et al, 1986; Anderson and Virmani, 1990; 
Heidenreich et al, 1995). It may be related to opportunistic infections, Kaposi’s 
sarcoma or non-Hodgkin’s lymphoma, but often a clear aetiology is not found 
(Heidenreich et al, 1995). Even in the USA tuberculous aetiology has to be 
considered in patients presenting with large pericardial effusions, especially in HIV-
infected individuals and those that have come from or travelled to a TB endemic 
region (Reynolds et al, 1992; Kwan et al, 1993; Nardell et al, 2004). Pericardial TB 
needs to be differentiated from pericarditis caused by other opportunistic infections 
(bacterial, fungal, protozoal or viral) and also from acute HIV pericarditis, which 
presents like idiopathic pericarditis (Acierno, 1990; Reynolds et al, 1992; Kwan et al, 
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1993). Advances in pericardioscopy and optically directed pericardial and epicardial 
biopsy offer the potential for the diagnosis of both viral and tuberculous pericarditis 
using molecular techniques of in situ hybridisation and PCR (Satoh et al, 1993; Saatci 
et al, 1993; Maisch, 1994).  
 
HIV-associated myocarditis may result in acute cardiac failure, arrhythmias, or 
conduction disturbances and the development of a chronic dilated cardiomyopathy 
(Herskowitz, 1996). HIV-associated cardiomyopathy is characterised by global 
systolic functional impairment with or without left ventricular dilatation (Magula and 
Mayosi, 2003). The cardiomyopathy is not related to any specific opportunistic 
infection and not associated with classic cardiac risk factors such as diabetes mellitus 
or hypertension. It has been postulated that the myocardial damage results from 
cytokines released by HIV-infected lymphocytes and monocyte-macrophages that 
invade the myocardium (Patel and Frishman, 1995; Herskowitz, 1996). 
Cardiomyopathy is associated with more advanced immunosuppression and the 
majority of patients with severe cardiomyopathy have CD4+ lymphocyte counts <200 
cells/μL (Herskowitz, 1996; Barbaro, 2002; Nzuobontane et al, 2002). HIV-
associated cardiomyopathy has also been linked to treatment with zidovudine (AZT) 
and to nutritional deficiencies (Hoffman et al, 1999; Barbaro, 2001). AZT may cause 
mitochondrial dysfunction by inhibiting mitochondrial deoxyribonucleic acid (DNA) 
replication (Lewis et al, 2000). Reversible cardiac dysfunction is associated with 
prolonged high-dose therapy with doxorubicin and interferon alpha (Rerkpattanapiatt 
et al, 2000) used to treat Kaposi’s sarcoma, and foscarnet which is used to treat 
cytomegalovirus (CMV) infection (Bristow et al, 1978; Brown et al, 1993).  
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The prevalence of infective endocarditis in HIV-infected patients is similar to that in 
other patients who abuse intravenous drugs (Rerkpattanapiatt et al, 2000). Right-sided 
valves are predominantly affected and the most common pathogens are 
Staphylococcus aureus, Candida albicans, Aspergillus fumigatus, Histoplasma 
capsulatum, and Cryptococcus neoformans (Barbaro et al, 1998; Rerkpattanapiatt et 
al, 2000). Late stage HIV-disease with significant immunodeficiency is associated 
with an increased mortality (Rerkpattanapiatt et al, 2000). Non-bacterial thrombotic 
endocarditis (marantic endocarditis) is most common in patients with HIV-wasting 
syndrome. It is characterised by endocardial vegetations, consisting of platelets within 
a fibrin mesh with few inflammatory cells, and may cause systemic or pulmonary 
embolisation (Rerkpattanapiatt et al, 2000). 
 
A strong association between HIV infection and primary pulmonary hypertension 
(PPHT) has been recognised (Rerkpattanapiatt et al, 2000), and this condition needs to 
be echocardiographically excluded in HIV-positive patients who present with features 
of right ventricular failure. 
 
TREATMENT OF TUBERCULOUS PERICARDIAL EFFUSION 
The goal of therapy for tuberculous pericarditis is not only to treat the acute symptoms 
of tamponade, but also to prevent progression from the effusive to the constrictive 
stage, in which a fibrotic and calcified pericardium entraps the heart (Desai, 1979; 
Fewell et al, 1971). The mortality rate in untreated acute effusive tuberculous 
pericarditis approaches 85%  (Desai, 1979) and pericardial constriction occurs in 30–
50% (Sagrista-Sauleda et al, 1988; Long et al, 1989). Three issues arise in the 
treatment of tuberculous pericarditis: (i) the duration of anti-tuberculous therapy, (ii) 
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the use of adjuvant corticosteroids, and (iii) the need for open surgical drainage versus 
closed pericardiocentesis. Various anti-tuberculous drug combinations of different 
time periods (6, 9 and 12 months) have been applied without clear differences in the 
treatment outcome (Sagrista-Sauleda et al, 1988; Strang et al, 1988; Fowler, 1991; 
Koh et al, 1994). Prevention of constriction in chronic pericardial effusion of 
undetermined aetiology by empiric anti-tuberculous treatment was not successful 
(Dwivedi et al, 1997), and therefore only patients with proven or highly likely 
tuberculous pericarditis should be treated with anti-tuberculous drugs. The use of 
adjuvant corticosteroids remains controversial (Strang et al, 1988; Alzeer and 
Fitzgerald, 1993; Senderovitz and Viskum, 1994; Mayosi et al, 2002; Ntsekhe et al, 
2003; Strang et al, 2004; Yang et al, 2005). A meta-analysis of patients with effusive 
and constrictive tuberculous pericarditis (Mayosi et al, 2002; Ntsekhe et al, 2003) 
suggested that anti-tuberculous treatment combined with steroids might be associated 
with fewer deaths and less frequent need for pericardiocentesis or pericardiectomy, but 
that published trials were too few and too small to be conclusive. The Cochrane 
systematic review (last updated in 2002) included only four trials: two randomised 
controlled trials performed in the Transkei (Strang et al, 1987; Strang et al, 1988), one 
non-randomised trial (Schrire, 1959), and a fourth study involving only HIV-infected 
patients (Hakim et al, 2000).  Pericardiectomy is indicated if, in spite of combination 
therapy, constriction develops (Maisch et al, 2004).  
 
Standard management of pericardial effusion includes pericardiocentesis. 
Echocardiographically guided pericardiocentesis is safe and can be performed at the 
bedside (Tsang et al, 2002a; Strang et al, 2004). Echocardiography should identify the 
safest route where the pericardium can be entered intercostally or subcostally. After 
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attempted complete drainage the catheter is kept in situ and prolonged pericardial 
drainage is performed until the volume of effusion obtained by intermittent pericardial 
aspiration falls to 25 mL per day (Tsang et al, 2002b). The most serious 
complications of pericardiocentesis are laceration and perforation of the myocardium 
and the coronary vessels. In addition, patients can experience air embolism, 
pneumothorax, arrhythmias (usually vasovagal bradycardia) and puncture of the 
peritoneal cavity or abdominal viscera (Seferovi  et al, 2000). Internal mammary 
artery fistulas, acute pulmonary oedema and purulent pericarditis are rarely reported. 
The safety was improved with echocardiographic or fluoroscopic guidance. Recent 
large echocardiographic series reported an incidence of major complications of 1.3–
1.6% (Tsang et al, 1998; Tsang et al, 1999; Tsang et al, 2002a; Tsang et al, 2002b).  
 
The literature favours surgical fenestration to pericardiocentesis for the management 
of tuberculous pericarditis (Strang et al, 1988; Hakim et al, 2000; Trautner and 
Darouiche, 2001; Quraishi et al, 2005). The open procedure has the potential 
advantage that pericardial tissue is obtained for mycobacterial culture and 
histopathological diagnosis (Trautner and Darouiche, 2001). 
 
THE PREVENTION AND TREATMENT OF TB 
The reduction and prevention of pericardial TB depends on the global control of TB. 
Fuelled by the concomitant HIV pandemic, TB control measures rely more than ever 
on improved case finding, earlier treatment of smear positive individuals and better 
cure rates of the highest possible number of diseased individuals (Kochi, 1991). This 
includes those with extrapulmonary TB, which is more difficult to diagnose and treat 
and more frequently present in HIV positive than HIV negative patients (Nunn et al, 
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1991; Narain et al, 1992). TB control contributes to the elimination of poverty, 
especially in poorer countries (Department for International Development, 1997). 
Since TB affects the poorest societies disproportionately, the countries with the 
highest prevalence of the disease have the fewest resources to deal with it (Gwatkin 
and Guillot, 1998). Anti-tuberculous chemotherapy is an effective and affordable 
intervention that improves quality and duration of life.  The WHO promotes the 
directly observed therapy, short-course (DOTS) strategy, which is based on political 
commitment, effective diagnosis and prioritisation of cases with the greatest need, 
standardised evidence-based protocols and a strategy to ensure that these strategies 
are properly adhered to, a regular supply of quality drugs is available, and an effective 
system for recording and reporting that focuses upon outcomes (Global Tuberculosis 
Programme, 1994). A total of 182 countries were implementing the DOTS strategy 
during 2003, and by the end of 2003, 77% of the world’s population lived in countries 
covered by DOTS (WHO, 2005). In total, 17.1 million TB patients, including 8.6 
million smear-positive patients, were treated in DOTS programmes between 1995 and 
2003.  
  
One of the keys to the prevention of TB is the early diagnosis and effective treatment 
of infectious patients who are coughing up TB bacilli. In order for treatment to be 
effective, it is essential that the correct combination of drugs be given for an 
appropriate period of time. Only actively replicating organisms are killed by 
chemotherapy, and differences in mycobacterial metabolic rate are associated with 
differences in mycobacterial susceptibility to anti-tuberculous drugs. To prevent the 
emergence of drug-resistant mutants, anti-tuberculous therapy should always consist 
of at least two effective drugs (Haas and Des Prez, 1995).  Short-course regimens are 
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divided into an initial or bactericidal phase and a continuation or sterilising phase. 
First-line anti-tuberculous drugs include isoniazid (INH), rifampicin (RMP), 
pyrazinamide (PZA), ethambutol (EMB) and streptomycin (SM). Therapy should not 
be stopped unless one is certain that the disease is controlled and the smears/cultures 
are negative. The treatment regimens of the South African National TB Control 
Programme have been summarized in Tables 1.1 and 1.2. New adult patients 
(including those with extrapulmonary TB) require treatment for a full six months and 
“retreatment” patients for a full eight months. 
 
THE USE OF ADJUNCTIVE CORTICOSTEROIDS IN TB   
Corticosteroids have been shown to be useful in fulminant miliary disease, obstructive 
lymphadenopathy, adrenal TB and in patients with tuberculous meningitis stages 2 
and 3 (Prasad, 2000). Their benefit in pleurisy is minimal (Ferrer, 1997; Morehead, 
1998) and their role in pericardial disease is unclear (Hakim et al, 2000; Mayosi et al, 
2002; Ntsekhe et al, 2003; Strang et al, 2004; Yang et al, 2005). 
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Table 1.1 Regimen 1 for the treatment of new adult TB patients (before 
2004) 
 
 
Intensive phase:  2 months  
Body weight 
under 50 kg 
Body weight 
over 50 kg 
 
RMP / INH / PZA 120/80/250 mg FCT 
 
 
4 tablets 
 
5 tablets 
 
EMB 400 mg tablet 
 
 
2 tablets 
 
3 tablets 
 
Daily number of tablets 
 
6 
 
8 
 
Continuation phase:  4 months  
  
 
RMP / INH 150/100 mg FCT 
 
RMP / INH 300/150 mg FCT 
 
 
3 tablets 
 
- 
 
- 
 
2 tablets 
 
Daily number of tablets 
 
3 
 
2 
 
RMP = rifampicin 
INH = isoniazid 
PZA = pyrazinamide 
EMB = ethambutol  
FCT = fixed combination tablet 
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Table 1.2 Regimen 2 for the retreatment of adult TB patients (before 2004) 
 
Intensive phase:  2 months  Body weight 
under 50 kg 
Body weight 
over 50 kg 
 
Streptomycin (intramuscular injection) 
 
750 mg 
 
1000 mg 
 
RMP / INH / EMB 120/75/300 mg FCT 
 
3 tablets 
 
4 tablets 
 
PZA 500 mg tablet 
 
2 tablets 
 
3 tablets 
 
Daily number of tablets 5 7 
Third month   
 
RMP / INH / EMB 120/75/300 mg FCT 
 
3 tablets 
 
4 tablets 
 
 
PZA 500 mg tablet 
 
2 tablets 
 
3 tablets 
 
Daily number of tablets 5 7 
Continuation phase:  5 months    
 
RMP / INH / EMB 120/75/300 mg FCT 
 
3 tablets 
 
 
4 tablets 
Daily number of tablets 3 4 
 
RMP = rifampicin 
INH = isoniazid 
PZA = pyrazinamide 
EMB = ethambutol,  
FCT = fixed combination tablet 
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TREATMENT OF TB IN HIV-INFECTED PATIENTS 
Treatment of TB in patients with HIV infection is extremely effective when begun 
promptly and regimens contain rifampicin (Small et al, 1991; Chaisson et al, 1996). 
The use of highly active antiretroviral therapy (HAART) in the treatment of patients 
co-infected with TB and HIV is problematic because there are potential complex drug 
interactions, overlapping adverse reactions, potential non-adherence due to the pill 
burden, and drug malabsorption (Burman and Jones, 2001). Despite these potential 
problems, HAART substantially reduces new AIDS events and death in co-infected 
patients (Badri et al, 2002; Dheda et al, 2004). Those with CD4+ lymphocyte counts 
<100 cells/μL have a high event risk during the intensive phase of anti-tuberculous 
treatment (Dheda et al, 2004). Paradoxical deterioration due to the immune 
reconstitution inflammatory syndrome (IRIS) has been reported to occur in 11-36% of 
patients with TB who start HAART (Narita et al, 1998; Wendel et al, 2001). 
Secondary preventive therapy with INH reduces TB recurrence in HIV infected 
patients: the absolute impact seems to be greatest among individuals with low CD4+ 
lymphocyte counts (Churchyard et al, 2003).  
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Chapter 2 
PATIENTS AND METHODS 
 
The primary aim of the study was to optimise the management of patients with 
tuberculous pericarditis. To achieve this we analysed the hospital based epidemiology 
of pericardial disease, studied various aspects of the immunopathogenesis of 
pericardial tuberculosis (TB), evaluated a variety of diagnostic tests and conducted a 
randomised controlled trial to establish the optimal therapeutic management of 
patients with tuberculous pericarditis. During the period from February 1995 to June 
2001, all adolescent and adult patients presenting to the Cardiology Unit with large 
pericardial effusions (defined as epi-pericardial separation of more than 10 mm) were 
included in this study and followed for one year. All patients gave written informed 
consent for participation in the study, which was approved by the Ethics Committee 
of Stellenbosch University. Demographic, clinical and echocardiographic data were 
obtained at baseline.  
 
DIAGNOSTIC PROTOCOL 
All patients had a full clinical assessment, a structured history was taken and a 
standardised diagnostic work-up (Table 2.1) was performed. A positive TB contact 
was defined as prolonged exposure to another person with active TB or individuals 
on TB treatment. Prolonged exposure included working, co-habiting and/or 
socialising with an infectious person for more than one month.  
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Table 2.1. Diagnostic protocol for patients requiring pericardiocentesis 
 
Pericardial fluid  
Adenosine deaminase activity (ADA)  
Lactate dehydrogenase (LDH) 
Total protein 
Glucose 
Cytology 
Differential white blood cell count 
Gram / Ziehl-Neelsen (ZN) stain and direct microscopy       
Culture (BACTEC™) for TB, fungi and bacteria 
Peripheral blood 
Renal function, liver function and thyroid function tests (T4 and TSH) 
Full blood count cell count and differential white blood cell count 
ELISA tests for HIV (screening and confirmatory) 
CD4+ and CD8+ lymphocyte count  (HIV positive patients)   
C-reactive protein (CRP),  
Antinuclear factor (ANF) 
Rheumatoid factor (RF) 
Antistreptolysin–O titre (ASOT) 
Blood culture (BACTEC™) for bacteria, fungi and TB 
Other investigations 
Chest radiograph (CXR) - posterior-anterior and lateral views 
Echocardiography (M-mode and four chamber view)  
Electrocardiography (12-lead surface ECG) 
Sputum collection for Gram and ZN staining, microscopy and culture 
Tuberculin skin tests with purified protein derivative (n=52) 
Pericardial biopsy and histopathology (n=36) 
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All patients with large pericardial effusions were subjected to CXR, 12-lead surface 
ECG (MAC, Marquett Electronics, inc; Milwakee, Wisconsin; paper speed 25 
mm/sec) and a two-dimensional echocardiographic study (Hewlett Packard, Sonos 
2000 Phased Array Imaging System). Sputum was collected on three consecutive 
days, stained with auramine or Ziehl-Neelsen (ZN) stain and examined by 
fluoromicroscopy or direct microscopy. Sputum was also cultured for M. 
tuberculosis. Evaluation of the pericardial fluid included: (i) differential WBC count; 
(ii) cytopathological analysis; (iii) total protein; (iv) lactate dehydrogenase (LDH), 
and (v) adenosine deaminase (ADA) activity.  
 
A sample of the aspirated pericardial fluid (5-10 mL) was sent to the Department of 
Microbiology for Gram and ZN staining and microscopic examination. In addition, 
an aliquot of pericardial fluid (7 mL) was injected into a BACTECTM medium 
immediately after completion of the pericardiocentesis procedure and cultured 
routinely in an automated radiometric BACTECTM MGITTM 960 system (Becton 
Dickenson and Co, Hood USA). In addition, we evaluated the diagnostic utility of 
polymerase chain reaction (PCR) for the detection of M. tuberculosis and measuring 
interferon-gamma (IFN-γ) in pericardial aspirates. 
 
The demographic and clinical data were recorded prospectively and hospital records 
were reviewed to reach a diagnosis. Effusions were classified into diagnostic groups 
according to pre-determined criteria. 
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ECHOCARDIOGRAPHY 
Echocardiography was used to determine the following: (i) the location of the 
effusion (anterior, apical, posterior, inferior, circumferential), (ii) the size of the 
effusion by measuring the epi-pericardial distance (mm), (iii) the presence of epi- and 
pericardial thickening and measuring the maximal pericardial thickness (mm), (iv) 
the presence of tamponade and/or constriction, and (v) the safest route for the 
pericardiocentesis procedure. A standard protocol was used with examinations in the 
left parasternal long and short axes, apical two and four chamber and subcostal views. 
Additional views were dictated by the requirements of the individual case. Patients 
who gave informed consent were treated by echocardiographically guided 
pericardiocentesis under local anaesthesia. The term “large pericardial effusion” 
refers to the pericardial effusions that were echocardiographically characterised by 
>10 mm separation between the pericardium and the epicardium during diastole. 
Tamponade was defined by the presence of predetermined echocardiographic and /or 
clinical features. The echocardiographic features were defined as: (i) inversion of 
>30% of the right atrial wall during late diastole and/or early systole, and/or (ii) 
inward motion of the right ventricular wall in early diastole persisting after mitral 
valve opening (Gubermann et al, 1981). Apart from these echocardiographic 
findings, the patient was also considered to have tamponade if he/she complained of 
dyspnoea and had at least three of the following five physical signs that were relieved 
by pericardiocentesis: (i) tachycardia (ventricular rate >100/min); (ii) hypotension 
(systolic blood pressure <100 mm Hg); (iii) pulsus paradoxus (>10 mm Hg decrease 
in peak systolic pressure on inspiration); (iv) positive Kussmaul’s sign (accentuation 
of jugular venous distension during inspiration), and/or (v) elevation of the jugular 
venous pressure ≥4 cm above the sternal angle. 
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BASELINE BIOCHEMISTRY 
Pericardial aspirates obtained by echo-guided pericardiocentesis were analysed for 
biochemistry. Biochemical parameters on pericardial fluid and serum were 
determined using a multi-channel analyser (Bayer Technicon DAX 48). Total protein 
concentration (g/L) was estimated using the biuret method and albumin concentration 
(g/L) was measured using bromocresol green (both spectrophotometric methods). 
LDH concentration (U/L) was measured using an enzymatic ultra-violet optimised 
method. Pericardial aspirates were classified as exudates if they fulfilled more than 
one of the following criteria: protein level 30 g/L, pericardial fluid/serum protein 
ratio 0.5, pericardial fluid LDH 200 U/L, and pericardial fluid/ serum LDH ratio 
0.6 (Burgess et al, 2002a). 
 
DETERMINATION OF ADA 
ADA activity (U/L) was determined according to the method described by Giusti 
(1974). Adenosine is deaminated by ADA and the free ammonia is deaminated by 
Berthelot’s reaction. One unit (1 U) of ADA is defined as the amount of enzyme 
required to release 1 μmol of ammonia per minute from adenosine at standard assay 
conditions. The enzyme is stable for at least 24 hours at 25°C, 7 days at 4°C and 3 
months at -20°C (Ellis and Goldberg, 1970; Heinz, 1984). 
 
PERICARDIAL FLUID MICROSCOPY AND CULTURE  
Pericardial aspirates were obtained by closed pericardiocentesis procedure and a 
sample of the effusion was sent to the Department of Microbiology for Gram and ZN 
staining and microscopic examination. An aliquot of 7 mL of pericardial fluid was 
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injected into a bottle of BACTECTM medium immediately after completion of the 
pericardiocentesis procedure and cultured routinely in an automated radiometric 
BACTECTM MGITTM 960 system (Becton Dickenson and Co, Hood USA), which 
uses added materials for detection of mycobacterial growth by radiometric or 
colorimetric systems. The MGIT Mycobacteria Growth Indicator Tube contains 7 mL 
of modified Middlebrook 7H9 broth base with growth supplement and PANTA 
antibiotic mixture. All types of clinical specimens, pulmonary as well as 
extrapulmonary (except blood), were processed for primary isolation in the MGIT 
tube.  
 
SPUTUM MICROSCOPY AND TB CULTURE 
When possible, three morning samples of expectorated sputum were examined by 
fluoromicroscopy after preparation and auramine-rhodamine staining. Sputum 
samples were prepared and fixed to slides in methanol for one minute. These were 
stained with auramine for 20 minutes, and rinsed thereafter with water. The slides 
were decolourised with 0.5% acid-alcohol solution for two minutes, followed by 
rinsing with water. The slides were counterstained with potassium permanganate for 
30 seconds, followed by rinsing with water. Excess water was drained from slides and 
they were placed on a hotplate to dry. Auramine positive slides were ZN stained to 
confirm the presence of acid-fast bacilli (AFB). Smear negative sputum specimens 
were cultured for TB using an automated BACTEC 12B radiometric broth with and 
without PANTA antibiotic supplement.  
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TUBERCULIN SKIN TESTING 
During the first 18 months of the study, tuberculin skin testing was part of the 
standardised diagnostic protocol. Initially patients underwent tuberculin skin testing 
with purified protein derivative (PPD). An experienced operator injected 0.1 mL of 
PPD intradermally; tests were interpreted 48-72 hours after administration of antigen 
and the transverse diameter of induration was measured (mm).  An interim analysis 
performed at the end of the first 18 months suggested that tuberculin skin testing and 
pericardial biopsy did not contribute to the decision-making process and were 
therefore removed from the standardised diagnostic protocol. 
 
PERICARDIAL FLUID CYTOLOGY 
A sample of the pericardial effusion (5-50 mL) was sent to the Department of 
Anatomical Pathology for cytological analysis. The pericardial fluid aspirates were 
fixed by addition of an equal amount of 50% ethanol. The fluid was spun down and 
smears were prepared from sediments using routine methods (Wiener et al, 1991). 
Each specimen was stained according to the Papanicolaou method. Fluids that arrived 
at the laboratory in an unfixed state were used to prepare air-dried smears and these 
were stained according to the May-Grünwald-Giemsa method. The slides were then 
mounted and examined microscopically. The different cells were counted per hundred 
cells on various fields throughout the slide. A total of 300 cells were counted and then 
an average taken. The differential white blood cell counts were reported as 
percentages.  
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PERICARDIAL HISTOPATHOLOGY 
During the first 18 months of the study pericardial biopsy was part of the standardised 
diagnostic protocol. A biopsy was performed when an aetiological diagnosis could not 
be made within seven days after initial pericardiocentesis or alternatively as a 
therapeutic procedure in all patients in whom adequate drainage could not be achieved 
by closed pericardiocentesis. Thereafter, patients were only referred for surgical 
pericardiocentesis when therapeutically indicated, including patients with loculated or 
posterior effusions, recurring effusions, or worsening effusive–constrictive 
pericarditis.  
 
A pericardial biopsy was taken of accessible tissue under general anaesthesia. The 
biopsy tissue was sent for histopathological evaluation. One sample of each specimen 
was formalin-fixed (using 10% buffered formalin solution) and processed, using 
routine histochemical techniques. Each piece of tissue was sectioned and stained with 
haematoxylin-eosin (H&E) and ZN stains. Two independent histopathologists who 
were not aware of the final diagnosis examined the mounted sections.  
 
FLOW CYTOMETRIC PHENOTYPIC LEUKOCYTE ANALYSES  
By using fluorescent labelled antibody, a variety of cell surface markers are 
recognised and specific cells can be identified easily and effectively.  The presence 
and quantity of immune cells in the pericardial fluid was determined and compared to 
that of the peripheral circulation.  We analysed the phenotypes of lymphocyte 
subpopulations, using specific monoclonal antibodies with colour conjugates, 
including fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridine chlorophyll 
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(Per-CP) and allophycocyanin  (APC; Becton Dickinson, Bactlab Systems). The 
following panels were included:  
• CD45-PerCP/ CD3-FITC/ CD4-APC/ CD8-PE for total T Lymphocytes, T-helper 
cells (Th cells) and cytotoxic (or suppressor) T cells and 
• CD45-PerCP/ CD3-FITC/ CD19-APC/ CD16+56-PE for T cells, B cells and 
natural killer cells (NK cells).  
The monoclonal antibodies were diluted 1:4 and 20 μL of the dilution added to 50 μL 
of pericardial fluid or whole blood. After incubation in the dark for 15 minutes at 
room temperature, the cells were incubated with 450 μL of a 1:10 dilution of 
Fluorescent Activated Cell Sorter (FACS) Lysing Solution (Becton Dickinson, 
Bactlab Systems) for an additional 10 minutes in the dark. The Lysing Solution helps 
to fix the surface epitopes and optimise the permeabilisation process. After 
centrifugation for 5 minutes at 1800 revolutions per minute (rpm), the cells were 
washed with 2 mL phosphate-buffered saline, and fixed with 500 μL of a fixing 
buffer, consisting of a 1:20 dilution of formalin with phosphate-buffered saline. The 
tubes were kept at 4°C in the dark and analysed within one week. Analysis was 
performed in a flow cytometer (FACScan, Becton Dickinson, Bactlab Systems), 
equipped with the analytical software programme, Lysis II. The cells were counted by 
the flow cytometer and results were expressed as percentage of the cells positive for 
the antigen detected by the monoclonal antibodies. 
 
DETERMINATION OF CYTOKINE CONCENTRATIONS 
At the time of pericardiocentesis, pericardial fluid was collected on ice and frozen 
within 30 minutes at -70°C for the analysis of cytokines. The concentration of a 
variety of cytokines was determined on pericardial fluid and serum samples using 
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commercially available immunoassays developed by BiotrakTM (Amersham 
Pharmacia Biotech, UK).  
   
Determination of interleukin-4 
The Biotrak™ human interleukin-4 [(h)IL-4] ELISA system (Amersham Pharmacia 
Biotech, UK) provides a simple, specific, reliable and precise quantitative 
determination of (h)IL-4 in plasma and serum. The assay system is based on a solid 
phase ELISA that utilizes an antibody for (h)IL-4 bound to the wells of a micro titre 
plate, together with a biotinylated antibody to (h)IL-4 and streptavidin conjugated to 
HRP. The assay employs the quantitative "sandwich" enzyme immunoassay 
technique. An antibody specific for (h)IL-4 has been coated on the micro titre plate 
provided in the kit. Samples (50 μL serum) are pipetted into the wells along with 
biotinylated antibody reagent (50 μL) and incubated for 2 hours (25°C). If present, the 
(h)IL-4 is bound by the immobilised antibody and the biotinylated antibody. After 
washing away any unbound sample proteins and biotinylated antibody, a streptavidin-
HRP conjugate (100 μL) is added to the wells and the plate incubated for 30 minutes 
(25°C). Any (h)IL-4, which was bound by both the immobilised and the biotinylated 
antibody during the first incubation, will be bound by the streptavidin conjugate. 
Following a wash to remove unbound conjugate, a tetramethylbenzidine substrate 
solution (100 μL) is added to the wells and during the incubation of 30 minutes 
(25°C), colour develops in proportion to the amount of (h)IL-4 bound in the initial 
step. In addition to the samples to be assayed, a series of wells is prepared using 
known concentrations of the (h)IL-4 standard (0-400 pg/mL). A curve, plotting the 
optical density at 450 nm versus the concentrations of the standard wells, is prepared. 
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By comparing the optical density of the samples to this standard curve, the 
concentration of the (h)IL-4 in the unknown samples is then determined. 
 
Determination of interleukin-10 
The Biotrak™ human interleukin-10 [(h)IL-10] ELISA system (Amersham Pharmacia 
Biotech, UK) provides a simple, specific, reliable and precise quantitative 
determination of (h)IL-10 in plasma and serum. This solid phase ELISA assay is done 
in exactly the same way as the assay described for Biotrak™ human interleukin-4, but 
instead of using an antibody for (h)IL-4, it utilizes an antibody for (h)IL-10. In 
addition to the samples to be assayed, a series of wells is prepared using known 
concentrations of the (h)IL-10 standard (0-600 pg/mL). A curve, plotting the optical 
density at 450 nm versus the concentrations of the standard wells, is prepared. By 
comparing the optical density of the samples to this standard curve, the concentration 
of the (h)IL-10 in the unknown samples is then determined. 
 
Determination of tumour necrosis factor-alpha 
The Biotrak™ human tumour necrosis factor-alpha [(h)TNF-α] ELISA system 
(Amersham Pharmacia Biotech, UK) provides a simple, specific, reliable and precise 
quantitative determination of (h)TNF-α in plasma and serum. This solid phase ELISA 
assay is done in exactly the same way as the assay described for Biotrak™ human 
interleukin-4, but instead of using an antibody for (h)IL-4, it utilizes an antibody for 
(h)TNF-α. In addition to the samples to be assayed, a series of wells is prepared using 
known concentrations of the (h)TNF-α standard (0-1000 pg/mL). A curve, plotting 
the optical density at 450 nm versus the concentrations of the standard wells, is 
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prepared. By comparing the optical density of the samples to this standard curve, the 
concentration of the (h)TNF-α in the unknown samples is then determined. 
 
Determination of gamma-interferon 
The Biotrak™ human gamma-interferon [(h)IFN-γ] ELISA system (Amersham 
Pharmacia Biotech, UK) provides a simple, specific, reliable and precise quantitative 
determination of (h)IFN-γ in plasma and serum. This solid phase ELISA assay is done 
in exactly the same way as the assay described for Biotrak™ human interleukin-4, but 
instead of using an antibody for (h)IL-4, it utilizes an antibody for (h) IFN-γ. In 
addition to the samples to be assayed, a series of wells is prepared using known 
concentrations of the (h)IFN-γ standard (0-1000 pg/mL). A curve, plotting the optical 
density at 450 nm versus the concentrations of the standard wells, is prepared. By 
comparing the optical density of the samples to this standard curve, the concentration 
of the (h)IFN-γ in the unknown samples is then determined.  
 
PCR FOR M. TUBERCULOSIS   
A commercially available PCR assay was used, namely the Roche AmplicorTM PCR 
for M. tuberculosis test for detection of the IS6110 sequence of M. tuberculosis in 
pericardial fluid specimens applying standard techniques and procedures (Carpentier 
et al, 1995; Yuen et al, 1993; Shah et al, 1998). Aliquots of pericardial fluid were 
frozen and stored at –70°C and batches of 12 consecutive effusions were analysed by 
PCR. 
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PREDETERMINED DIAGNOSTIC CRITERIA  
Each diagnostic group was defined by the presence of a pericardial effusion and one 
or more criteria in the absence any other obvious cause associated with pericardial 
effusions:  
 
Tuberculous pericarditis 
• Isolation of M. tuberculosis from the drained pericardial effusion or pericardial 
biopsy specimen; 
• Demonstration of granulomatous inflammation on histopathological examination 
of the pericardial biopsy sample; 
• Presence of a lymphocytic pericardial exudate and identification of M. 
tuberculosis in sputum, pleural fluid or lymph node aspirate by ZN stain / culture, 
and a sustained response to anti-tuberculous therapy; 
• Presence of a lymphocytic pericardial exudate and demonstration of necrotising 
granulomatous inflammation on histopathological examination of extracardiac 
tissue, and a sustained response to anti-tuberculous therapy (TB therapy), and/or 
• Presence of a lymphocytic pericardial exudate and a chest X-ray suggestive of 
active TB, compatible clinical features, and a good response to TB therapy. 
 
Septic pericardial effusions 
• Pericardial effusions associated with acute febrile illness and responsiveness to 
antibiotic treatment or identification of the organism in the pericardial fluid by 
Gram stain and/or culture; 
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• Polymorphonuclear pericardial exudate in the presence of other obvious 
infectious conditions (e.g. pneumonia) in the absence of any other cause 
associated with pericardial effusions. 
 
Malignant pericardial effusions 
• Presence of cytological and / or histological evidence of a neoplastic process 
involving the pericardium, and / or 
• Evidence of an extracardiac malignancy with exclusion of other cause known to 
be associated with pericardial effusions. 
 
Uraemic pericarditis 
• Pericardial effusion in the presence serum creatinine ≥ 300 μmol/L and urea >30 
mmol/L) in the absence of other causes known to cause pericarditis, and / or 
• Presence of pericardial effusion in dialysis patient known with renal failure, in the 
absence of other causes associated with pericardial effusion. 
 
Pericardial effusions associated with cardiac surgery or trauma 
• Pericardial effusion occurring within three months post-cardiac surgery 
or, 
• Pericardial effusion occurring within three months after chest trauma in 
the absence of any other obvious cause for pericardial effusion. 
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Pericardial effusion associated with congestive cardiac failure: 
• Presence of a pericardial transudate in combination with echocardiographic 
evidence of dilated ventricles and decreased ejection fraction <40%. 
 
Pericarditis associated with systemic inflammatory and connective tissue diseases 
• Systemic lupus erythematosus (according to the American College of 
Rheumatology [ACR] criteria); 
• Mixed connective tissue disease (according to ACR criteria);  
• Rheumatoid arthritis (according to the ACR criteria);  
• Scleroderma (according to the ACR criteria);  
• Acute rheumatic fever (according to the revised Duckett-Jones criteria).  
 
Pericardial effusion associated with hypothyroidism 
• Defined as those pericardial effusions occurring in the presence of biochemical 
evidence for hypothyroidism, i.e. serum thyroxine (T4) <10 mmol/L and thyroid 
stimulating hormone (TSH) levels > 5.6 pmol/L. 
 
Idiopathic pericarditis 
• Defined as those pericardial effusions for which after full diagnostic work-up 
there was no demonstrable cause. 
 
Pericardial effusions of indeterminate origin 
• Patients having multiple superimposed diseases or effusions of unknown origin, 
that is all possible aetiological causes could not be excluded. 
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THERAPEUTIC MANAGEMENT PROTOCOL 
Each patient underwent echocardiographically guided pericardiocentesis and daily 
intermittent drainage by indwelling pigtail catheter. After initial complete drainage, 
the pigtail catheter was kept in situ to allow daily intermittent drainage and it was 
only removed when the daily aspirate amounted to less than 100 mL or when it 
became blocked. Previous studies have demonstrated that the use of extended catheter 
drainage is associated with decreased risk of recurrence of effusion and use of surgery 
for management (Kopecky et al, 1986; Tsang et al, 1998; Tsang et al, 1999). 
 
 For the pericardiocentesis, patients were usually positioned supine with the head and 
upper body slightly elevated. In patients experiencing orthopnoea due to the supine 
position, the echocardiographic examination and the pericardiocentesis was 
performed with the patient sitting upright. The ideal entry site for the drainage 
procedure was the point on the body surface where the effusion is closest to the 
ultrasound transducer and the fluid accumulation is maximal. The distance from the 
skin to the pericardial space was assessed and the needle trajectory defined by the 
angulation of the handheld transducer. A straight trajectory was selected that avoided 
vital structures such as the liver, myocardium and the lung. The intended point was 
marked on the skin and the direction of the ultrasound beam noted. A wide area 
around the intended puncture site was cleaned with an antiseptic solution (povidone-
iodine followed by chlorhexidine) and this area was subsequently covered with a 
transparent plastic sheet. Pericardiocenteses were initiated with a 16- or 18-gauge, 
sheathed “intracath” needle with an attached syringe after infiltrating the skin with 
local  (2% lignocaine) using a 20-gauge needle. The “intracath” needle was 
positioned at the predetermined entry site, held at the intended angle and then slowly 
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advanced in the direction of the fluid-filled space while exerting gentle negative 
pressure by the attached syringe. To prevent potential injury of the neurovascular 
bundle, which runs along the inferior margin of each rib, the needle was always 
introduced in proximity of the upper margin of the rib. On entering the fluid, the 
needle was advanced by a further 2 mm before the Teflon sheath was pushed over the 
needle and the steel core withdrawn, so that only the sheath remained in the fluid 
space. A flexible guide wire was inserted through the sheath. After making a small 
stab incision of the skin at the entry site, a dilator and introducer sheath (6 to 8 
French) were advanced over the wire into the pericardial sac. Predilatation of the 
chest wall passage facilitated insertion of the introducer sheath-dilator and minimised 
burring of the sheath tip. The guide-wire and dilator were removed and only the 
sheath left in the pericardial sac. In our view, the introducer sheath technique is 
superior to direct catheter passage over the guide-wire, because it prevents potential 
dislodging of the guide wire by the catheter tip. Once the introducer sheath and guide 
wire were placed successfully in the pericardial space, a 6 or 7 French thin-walled 
pigtail angiocatheter (65 cm) was inserted. The sheath could then be withdrawn 
leaving only the pigtail catheter in the pericardial space that needed to be drained. The 
catheter was attached to a 50-mL syringe via a three-way stopcock for initial 
complete drainage by manual suction. When no further fluid passed, 
echocardiography was repeated to confirm successful and satisfactory removal of 
fluid. Antiseptic ointment was applied to the entry site and after covering the catheter 
with a sterile dressing it was secured carefully to the chest wall.  
 
After the pericardiocentesis patients were admitted to a general medical ward where 
their condition could be monitored clinically, but without continuous ECG 
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monitoring. While the catheter was in situ, the patients were encouraged to be 
ambulatory and upper body movement was usually not restricted. The patients were 
monitored clinically for an increase in the volume of, or a change in, appearance of 
the aspirated fluid, the development of acute chest pain and a change in the vital signs, 
such as development of tachycardia, hypotension, tachypnoea or fever. Following the 
initial pericardiocentesis, pericardial fluid was aspirated aseptically through the three-
way stopcock at 24-hour intervals, or more frequently, if clinically indicated. After the 
aspiration, heparinised saline solution (3-5 mL of a solution of 5000 IU of heparin 
diluted in 200 mL of normal saline) was injected to prevent catheter blockage. 
Maintaining an aseptic technique, the syringe and tap were covered at the end of the 
procedure with a sterile latex glove to avoid contamination. A new, sterile glove was 
applied after each daily aspiration. The catheter was removed when the daily amount 
of aspirated fluid had decreased to less than 100 mL and the patient was 
haemodynamically stable. Echocardiography was not routinely performed at this 
stage. Pericardial fenestration and open drainage were only considered if the closed 
pericardiocentesis failed to alleviate cardiac compression satisfactorily or if the daily 
aspirate continued to exceed 100 mL after five days of intermittent drainage. 
 
Empiric anti-tuberculous chemotherapy was commenced if after rigorous 
investigation no alternative diagnosis could be reached within the first seven days 
after the pericardiocentesis. Anti-tuberculous treatment was initiated in hospital and 
after discharge continued at the TB clinic closest to the affected individual’s home. 
The National TB Control Programme guidelines were followed and treatment 
regimens for new adult patients and retreatment patients are summarised in Tables 
1.1.and 1.2. The clinical response was evaluated over a period of one year and follow-
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up visits were scheduled for one month, three months, six months and one year after 
the pericardiocentesis. Patients were reminded by letter and/or telephonically about 
their follow-up date and received a travel allowance for attending their appointment. 
Patients who were found to be HIV positive were referred to the Infectious Diseases 
Clinic at Tygerberg Academic Hospital for staging and treatment. Each patient was 
started on oral cotrimoxazole as primary prophylaxis for Pneumocystis carinii. Due to 
unavailability of highly active antiretroviral therapy (HAART) at our hospital at the 
time of this study, none of the patients was treated with HAART.  
 
Patients with non-tuberculous pericarditis were treated according to their aetiological 
diagnosis. Septic pericarditis was treated with broad-spectrum antibiotics until 
specific culture results and sensitivity patterns were known. Two patients with 
purulent pericarditis required surgical drainage. Uraemic patients were referred to the 
renal unit for dialysis. Patients with pericardial effusions associated with connective 
tissue diseases were managed in collaboration with the rheumatology unit and their 
management was primarily directed at the underlying cause and included 
corticosteroids and chloroquine in the majority of cases. Patients with neoplastic 
pericardial involvement were referred for further management to the most appropriate 
specialists, including oncologists, radiotherapists, surgeons, pulmonologists and 
haematologists. Depending on the individual situation, management varied between 
chemotherapy, radiotherapy, palliative care or a combination thereof.  
 
STATISTICAL ANALYSIS 
Statistical analysis was done with the Mann-Whitney U, the Wilcoxon two-sample, 
the Kruskall-Wallis One-Way ANOVA, the Bonferroni two-way ANOVA, and Chi-
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squared tests. A p-value < 0.05 was considered statistically significant. The 
correlation between two variables was plotted on a scatter plot and the Pearson 
product moment method or Spearman rank correlation coefficients were used to 
express the relationship.  The significance of the correlation was denoted by a p-value 
< 0.05. All statistical analyses were done using Statistica version 7.0.  
 
For the determination of the utility of the various diagnostic tests we included only 
those patients who had a valid test result and/or had not been exposed to anti-
tuberculous therapy and/or any drugs associated with the development of pericarditis 
during a period of three months preceding pericardiocentesis. The results of the 
various laboratory and diagnostic tests were compared between patients with 
tuberculous effusions and patients with non-tuberculous patients, and the diagnostic 
value of the observation studied was assessed in terms of the sensitivity, specificity, 
positive predictive vale (PPV), negative predictive value (NPV), and diagnostic 
efficiency, expressed as percentage. Sensitivity was defined as TP/(TP+FN) x 100; 
specificity as TN/(TN+FP) x 100; PPV as TP/(TP+FP) x 100, NPV as TN/(TN+FN) x 
100, and diagnostic efficiency was defined as (TP+TN)/(TP+FP+TN+FN) x 100, 
where TP = true positive, TN = true negative, FP = false positive and FN = false 
negative. These were compared by means of receiver operating characteristic (ROC) 
curves (Beck and Schultz, 1986) and the cut-off value that maximised the true-
positive rate was selected. 
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Chapter 3 
EPIDEMIOLOGY OF LARGE PERICARDIAL 
EFFUSIONS AT TYGERBERG HOSPITAL 
 
Tuberculosis (TB) is the leading cause of pericarditis in South Africa and a number of 
other developing countries (Desai, 1979; Strang 1984; Cegielski 1990; Fowler, 1991; 
Hakim et al, 2000). This is in contrast to first world countries where TB is responsible 
for less than 4% of acute pericarditis (Fowler, 1991). In spite of economic 
developments and the availability of effective chemotherapy, the burden of TB is 
increasing. This increase has been partially attributable to the spread of human 
immunodeficiency virus (HIV) and is characterised by an increasing proportion of 
extrapulmonary cases (Narain et al, 1992). Estimates by the Medical Research 
Council’s National Tuberculosis Research Program put the burden of TB in South 
Africa for 2001 at 323 342 new cases, 41.1% of which were infectious and 52.5% of 
which were also HIV positive (Weyer and Fourie, 2001). The purpose of this study 
was to establish the prevalence of large, clinically significant pericardial effusions in 
the Western Cape Province of South Africa. Furthermore, we wanted to determine the 
incidence of various types of effusions, in particular tuberculous pericarditis in 
relation to demography, potential risk factors of lifestyle and HIV co-infection. 
 
PATIENTS AND METHODS  
A prospective study was carried out at Tygerberg Hospital, South Africa. Patients 
presenting with large pericardial effusions between February 1995 and June 2001 were 
enrolled. All patients gave written informed consent for participation in the study, 
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which was approved by the Ethics Committee of Stellenbosch University. A 
pericardial tap was performed under echocardiographic guidance through a pigtail 
catheter and fluid sent for biochemistry, microbiology, cytology and differential white 
cell count. Each patient also underwent an HIV test. Patients were allocated to 
diagnostic groups according to pre-determined criteria (Chapter 2). Patients were 
specifically asked about their smoking habits, alcohol consumption as well as their 
employment status, including the type of work they were doing. In the case of women, 
excessive use of alcohol was defined as a regular weekly intake of more than 14 units 
of alcohol and in men, more than 21 units of alcohol per week. A person was 
considered “employed” if he/she was working in return for wages. A person >15 years, 
who was not employed but was available for work and had the desire to work, was 
categorised as “unemployed”. For the purpose of this study we expanded the definition 
of unemployment to include those who were not available for work, such as pensioners 
and people receiving disability grants. Students, whether still at school or at a tertiary 
institution, were categorised as “students” and were not considered to be economically 
active. At the time of opening a hospital folder, patients declared their income and 
these figures were used to categorise enrolled individuals into various income groups 
according to the quintiles contained in the income and expenditure survey and the 
October household survey (Hirschowitz and Orkin, 1996). Patients were classified as 
having had TB if they had previously been treated for TB. A positive TB contact was 
defined as prolonged exposure to another person with active TB or individuals on TB 
treatment. Prolonged exposure included working in the same room as, and/or co-
habiting with, an infectious person.  
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RESULTS 
A total of 233 consecutive patients were enrolled in this study. Eighty-four patients 
(36.1%) were HIV positive; 81 of these (96.4%) had tuberculous pericarditis, two 
(2.4%) had septic pericarditis and one (1.2%) had uraemic pericarditis, probably 
secondary to HIV associated renal disease. Only two patients were not tested for HIV; 
these were classified as HIV negative for the purposes of this study. There were 132 
males (56.7%) and 101 females (43.3%) that presented with large pericardial 
effusions. The majority of patients were black (n=121; 51.9%), followed by patients 
of mixed racial ancestry (n=101; 43.3%). Only 4.7% of the study population was 
Caucasian (n=11). There was a high rate of HIV infection amongst black patients; 
55.6% (n=30) of black females were HIV positive, compared to 13 females (27.7%) 
of other ethnic origin; 43.3% (n=29) of black males were HIV positive compared to 
18.5% (n=12) of males of other ethnic origin. There was only one white male who 
was HIV positive.  
 
The prevalence of HIV coinfection increased from year to year, beginning with ten 
cases in the first year of the study and amounting to 19 cases in 2000, as presented in 
Figure 3.1. The age at presentation ranged from 13 to 85 years, the mean (SD) was 
38.0 (14.6) years. More than 65.0% of the study population and 84.5% of the HIV 
positive individuals were aged between 15 and 39 years.  
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Figure 3.1. Annual number of newly diagnosed HIV positive tuberculous 
pericarditis patients seen at Tygerberg Hospital, 1995-2000 
 
HIV+ = human immunodeficiency virus positive  
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The mean (SD) age of the HIV positive patients was significantly lower (p<0.05) than 
the HIV negative patients [31.9 (8.4) years versus 41.6 (14.1) years]. In addition, HIV 
positive females were significantly younger (p<0.05) than their HIV positive male 
counterparts [29.2 (7.2) years versus 34.0 (9.1) years]. The demographic data have 
been summarised in Table 3.1. 
 
Socio-economic and social history data 
Eighty individuals (including five housewives) were employed (34.3%), whereas 115 
patients (49.4%) were unemployed. A further 15 patients were students (6.4%), 13 
received a state pension (5.6%) and 10 received a state disability grant (4.3%). A total 
of 54.9% of individuals in the age groups 15-49 years was unemployed. The 
prevalence of HIV amongst unemployed individuals was 49.0% compared to 30.0% 
amongst employed individuals. 65.0% of HIV positive patients were unemployed, 
whereas 31.0% of the HIV infected were employed and 4.0% were students. The 
difference between employment status in HIV positive and HIV negative patients was 
statistically significant (p<0.005).  
 
The majority of unemployed HIV positive individuals had never been employed and 
their unemployment status was not the result of being ill due to HIV infection. The 
majority of patients categorised as employed were in the low-income brackets of less 
than R6868 (≈USD 1000) per year. Only 24 (10.3%) patients earned more than R6868 
per year, including three patients who earned more than R52801 per year. None of 
these patients were infected with either HIV or TB. 
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Table 3.1. Patient demographics 
 
 Male (n=132) Female (n=101) 
 HIV positive HIV negative  HIV positive HIV negative
Number n=41   (31%) n=91   (69%) n=43   (43%) n=58   (57%)
Mean (SD) age (years) 34.0 (9.1) 39.9 (13.9) 29.9 (7.2) 45.0 (14.5) 
Ethnic origin 
- African black 
- Mixed race 
- Caucasian 
 
29   (70.7%) 
11   (26.8%) 
 1    (2.4%) 
 
38   (41.8%) 
46   (50.5%) 
 7    (7.7%) 
 
30   (69.8%) 
13   (30.2%) 
  0     (0%) 
 
24 (41.4%) 
 3   (51.7%) 
31   (5.3%) 
 
HIV = human immunodeficiency virus 
SD = standard deviation 
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Thirty-seven patients (15.9%) had previously received anti-tuberculous therapy. Of 
the 84 HIV positive patients, 9.5% had previously had TB, compared to 19.5% of 
HIV negative patients. Fifty-three individuals (22.7%) gave a history of a positive TB 
contact, including 23 of the 84 HIV positive patients (27.4%) and 30 of the 149 HIV 
negative patients (20.1%). Amongst the tuberculous pericarditis patients, excessive 
amounts of alcohol were consumed by similar percentages of HIV positive and of 
HIV negative individuals (35.9% versus 34.9%; p=0.89), whereas the percentage of 
smokers amongst the HIV negative subgroup tended to be higher than percentage of 
smokers in the HIV positive patient population (45.8% versus 43.6%). 
 
Aetiology of large pericardial effusions 
Tuberculous pericarditis was the most common cause of pericardial effusions (69.5%, 
n=162), while malignancy accounted for 9.4% (n=22) of all effusions. The 
aetiological data are presented in Figure 3.2. The group of “miscellaneous” effusions 
(n=20) included the following: idiopathic (n=7), post-traumatic (n=5), post-surgical 
(n=2) and multifactorial/uncertain, including congestive cardiac failure and 
underlying sepsis (n=6). The incidence of the various types of pericardial effusions 
differed according to age. TB was the most common cause of pericardial effusions in 
all age groups, but its prominence decreased in those older than 50 years. It accounted 
for 83.0% of all pericardial effusions in the age group 15-29 years and for 78.0% of 
those aged 30-39 years. The HIV prevalence in these TB patients was found to be 
57.6% and 69.4%, respectively. This strong correlation with HIV diminished with 
increased age; the prevalence of HIV among tuberculous effusions was 44.0% in the 
40-49 year age group, 12.5% in the 50-59 year group and 0% in the age group older 
than 60 years. Most patients who presented with malignancy were in the 50-59 year 
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age group, where it accounted for 32.0% of cases. TB was the most prevalent cause 
for pericardial effusions amongst the most marginalised groups, accounting for 52.5% 
(n=53) of effusions from patients of mixed race and 90.1% (n=109) of effusions from 
black patients. Amongst males, TB was the aetiological agent in 75.8% (n=100) of 
pericardial effusions, whereas TB accounted for 61.4% (n=62) of pericarditis amongst 
females. Half of all tuberculous effusions occurred in individuals that were co-
infected with HIV, and 96.4% of the 84 HIV positive individuals required 
pericardiocentesis because of TB (n=81). Of note was the difference observed 
between females with tuberculous effusions and their male counterparts with regards 
to HIV. 
 
In the female TB group, 67.7% of those affected were HIV positive, whereas in the 
male TB group, only 39.0% were co-infected with HIV. 
 
Malignancy (18 out of 22 malignant effusions) and connective tissue disease (CNTD; 
10 out of 12 patients with CNTD) were more frequently diagnosed in individuals of 
Caucasian or mixed racial ancestry. Nine cases of CNTD (75.0%) were diagnosed in 
women, whereas uraemic pericarditis was seen more frequently in males (n=7; 
58.3%). 
 
i) Tuberculous pericarditis 
TB accounted for 69.5% of the 233 effusions (n=162), including 100 (61.7%) males 
and 62 (38.3%) females. Eighty-one patients (50.0%) were HIV positive, including 42 
females (51.9%) and 39 males (48.1%).  Of the HIV negative tuberculous patients, a 
significantly higher proportion (p<0.01) was male (75.3%) than female (24.7%).  
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Figure 3.2.  Aetiological causes of large pericardial effusions 
 
TB = tuberculosis 
HIV- = human immunodeficiency virus negative 
HIV+ = human immunodeficiency virus negative  
CNTD = connective tissue disease   
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The mean (SD) age at presentation differed significantly between HIV positive and 
HIV negative patients with TB [31.9 (8.4) years versus 39.7 (15.9) years; (p<0.05)]. 
The difference in age was most striking among the group of black females, in whom 
the mean (SD) age at presentation was 44.7 (16.1) years in HIV negative patients 
compared to 29.3 (7.8) years in HIV positive patients.   
 
The one-year mortality rate in this group of patients was 17.3%, and was significantly 
higher in the HIV positive patients (22.2%) compared to those not infected with HIV 
(12.3%). 
 
ii) Malignant pericardial effusions 
Twenty-two patients had pericardial effusions due to an underlying malignancy. The 
majority of these patients had bronchus carcinomas (n=7), including small cell 
carcinoma (n=1), squamous cell carcinoma (n=1) and unspecified bronchus 
carcinoma (n=5). Haematological malignancies accounted for three effusions, 
including T-cell lymphoma (n=1), diffuse large cell lymphoma (n=1) and chronic 
myelomonocytic leukaemia (CMML; n=1). Another patient known with B cell 
lymphoma developed a pericardial effusion secondary to septicaemia and complicated 
by uraemia; this patient was included under the miscellaneous group. Other 
malignancies associated with pericardial effusions included adenocarcinoma (n=3), 
breast carcinoma (n=2), cervical cancer (n=1), neuroendocrine tumour (n=1), 
thymoma (n=1), neuroblastoma (n=1), multicentric liver carcinoma (n=1), 
mesothelioma (n=1), and unspecified (n=1). The mean (SD) age of this group was 
49.7 (13.8) years; 14 of the 22 patients (63.6%) were older than 50 years of age.   
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Despite the high prevalence of HIV in the study population, none of these patients 
was coinfected with HIV. In addition, none of the other classically HIV-associated 
malignancies (such as Kaposi’s sarcoma and anal carcinoma) was found. Twenty (out 
of 22) patients with neoplastic pericardial effusions died within one year of diagnosis; 
the one-year mortality rate for this group was 90.9%. 
 
iii) Pericarditis associated with CNTD 
Twelve patients had underlying CNTD, including systemic lupus erythematosus 
(SLE, n=7), scleroderma (n=1), mixed connective tissue disease (MCTD, n=1), 
rheumatoid arthritis (RA, n=1) and acute rheumatic fever (n=2). Although not 
classical CNTD, acute rheumatic fever and RA were included in this group, as these 
diseases may have similar presentations to SLE with regards to constitutional 
symptoms and involvement of the joints and pericardium. The two patients with acute 
rheumatic fever were 13 and 15 years old, respectively, while the male patient with 
RA was 64 years old.  
 
The mean age (SD) at presentation for this group was 32.6 (14.8) years and the 
mortality was 33.3%. None of the deaths (three patients with SLE and one with RA) 
was clearly attributable to the pericardial disease per se.   
 
iv) Septic pericarditis 
Only five of the 233 patients (2.1%) were diagnosed with septic pericarditis, four of 
whom were immunocompromised: two were infected with HIV, one had underlying 
B-cell lymphoma and the fourth patient was a known diabetic with a history of 
chronic alcohol abuse. In three of these cases, the diagnosis was based on positive 
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cultures: Staphylococcus aureus (n=2) and Group B salmonella species (n=1). The 
remaining two cases had negative cultures, probably attributable to the fact that both 
were receiving treatment with broad-spectrum antibiotics. The mean (SD) age of this 
diagnostic group was 43.0 (25.6) years. The one-year mortality rate for this group was 
80.0%, and 100.0% in those infected with HIV. 
 
v) Uraemic pericarditis 
Twelve patients were classified as having uraemic pericarditis; one of them was HIV 
positive and had no evidence of opportunistic infection or TB. The mortality in this 
group was high (42.0%), and all the deaths occurred in males of mixed racial 
ancestry. The mean age (SD) at death was 50.2 (13.7) years.  
 
vi) Miscellaneous group  
In seven patients, large effusions followed cardiac trauma or pericardiotomy, 
including sustained blunt trauma secondary to motor vehicle accidents (n=2), previous 
stab wounds to the chest (n=3), post-aortic valve replacement surgery (n=1) and 
coronary artery bypass grafting (n=1). Five additional patients had large pericardial 
effusions that appeared to be idiopathic in nature. 
 
DISCUSSION 
Pericardial effusions can result from a number of disease processes. The clinical 
presentation can be variable, ranging from asymptomatic effusions discovered 
incidentally by chest X-ray to life-threatening emergencies associated with cardiac 
tamponade (Corey et al, 1993). Numerous studies have reported on the aetiologies of 
pericardial effusions (Krikorian and Hancock, 1978; Permanyer-Miralda et al, 1985; 
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Corey et al, 1993); however, the majority are retrospective reviews undertaken in first 
world countries.  
 
The incidence of the various types of pericardial effusions at Tygerberg Hospital 
differs significantly from developed countries. TB, which accounts for less than 4% of 
all cases in first world countries (Fowler, 1991), was the most prevalent cause in this 
study accounting for 69.5% of all pericardial effusions. It was especially significant 
amongst blacks and patients of mixed racial ancestry, accounting for 90.1% and 
52.5% of all effusions, respectively. TB was diagnosed in only one Caucasian patient. 
Conversely, pericardial effusions of non-tuberculous origin were seen more frequently 
in Caucasians (90.9% of effusions) and to a lesser extent in those of mixed racial 
ancestry. These data confirm previous reports indicating significant ethnic differences 
in the incidence and prevalence of TB in South Africa (Styblo, 1976; Wulfsohn and 
Küstner, 1985). There are, however, no data indicating that certain ethnic groups have 
increased genetic susceptibility to activation of latent tuberculous infection. A study 
performed in Puerto Rico, which involved the follow up of a large number of persons 
in a BCG vaccination trial, showed no major differences in the incidence of TB 
between black and white tuberculin reactors (Comstock et al, 1974).  
 
Although not excluding the possibility of genetic factors, this present study 
demonstrates clearly that socio-economic factors contribute significantly to the racial 
distribution observed. TB is more prevalent in poor nations, especially affecting 
individuals living in poverty. In the present study only 5.8% of African blacks had an 
individual income in excess of R6868 (≈USD 1000) per annum. Although total 
household income was not specified, the impression was that this would not have 
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been much higher. In keeping with these results and according to data contained in the 
income and expenditure survey, black households are the poorest in the Western Cape 
Province (South African Communication Service, 1995; Hirschowitz and Orkin, 
1996). Other indicators of deprivation, such as access to drinking water and 
sanitation, also suggest a relationship between race and socio-economic status. In the 
Western Cape, 37.0% of black households, compared to 77.0% of mixed and 99.0% 
of white households, have running tap water inside their dwelling; flush toilets are 
found in almost all white (99.0%) households, but in only 68.0% of mixed and 30.0% 
of black households (South African Communication Service, 1995; Hirschowitz and 
Orkin, 1996). The correlation between poverty and TB is probably based on the two 
most important elements of tuberculous disease; firstly the risk of becoming infected, 
and secondly the inactivity of the cellular immune system associated with poor 
nutrition, alcohol abuse and the feeling of hopelessness, which are all prevalent in 
impoverished communities. The high risk of infection is due to the late diagnosis of 
smear positive individuals (source), and the proximity and frequency of exposure 
related to the sharing of sleeping areas in overcrowded households (Rieder et al, 
1989). 
 
The risk of TB is now confounded by HIV co-infection (Narain et al, 1992; Cegielski 
et al, 1994; Maher and Harries, 1997). In this study 36.1% of the study population 
was HIV positive, whereas the seroprevalence amongst those with TB was 50.0% 
(p<0.05). Of the 84 HIV positive individuals in the study, 94.6% presented with 
tuberculous pericarditis and only 5.4% with other pericardial disease. This finding of 
dual infection is a major problem in sub-Saharan Africa. The World Health 
Organization (WHO) estimated that of the 9.4 million people with dual infection of 
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TB and HIV, 6.6 million (70.0%) live in sub-Saharan Africa (Department of Health, 
2000; World Health Organisation, 2003). In South Africa, the incidence rate of TB is 
686 per 100 000 per year, of which 52.5% are estimated to be coinfected with HIV 
(Weyer and Fourie, 2001). In the Western Cape, the TB incidence is estimated to be 
932 per 100 000 per year, but the HIV prevalence (36.5%) amongst TB patients is 
significantly lower than the national average (Weyer and Fourie, 2001).  
 
HIV, due to its ability to destroy the immune system, has frequently been implicated 
as a principal cause for the recent resurgence of TB worldwide. Furthermore, in many 
developing countries, TB has now emerged as the most common opportunistic disease 
associated with HIV infection (Narain et al, 1992). In our study group, 50.0% of all 
patients presenting with tuberculous pericardial effusions were HIV positive. The 
difference in age between the HIV positive and HIV negative TB groups was 
statistically significant (p <0.01), the mean (SD) ages of the two groups being 31.9 
(8.4) years and 39.7 (15.9) years, respectively. In this study, the highest prevalence of 
HIV was found in those that are most severely socio-economically deprived, namely 
African black females. 
 
In addition to an association between ethnicity and HIV infection, this study revealed 
a statistically significant association between unemployment and HIV infection. The 
overwhelming majority of those who were unemployed had never been employed; the 
high level of unemployment was thus not due to the effects of HIV disease. Overall, 
the level of unemployment observed in our study population was significantly higher 
than the official 19.0% unemployment level for this province (Hirschowitz and Orkin, 
1996). Differences with regards to both population group and gender have been 
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described in Western Cape unemployment patterns. In 1995, 45.0% of black women 
were unemployed compared to 23.0% of black men; in comparison, 14.0% of white 
females and only 3.0% of white men were unemployed, respectively (South African 
Communication Service, 1995). In keeping with previous studies, the majority of 
unemployed individuals were in the 15-34 years age groups (Hirschowitz and Orkin, 
1996). It is, however, important to note that although blacks are most severely 
affected by poverty (and dual infection), it should not distract from the high degree of 
unemployment and poverty experienced by people of mixed racial background. 
 
A previous experience of TB according to the history did not contribute significantly 
to the development of tuberculous pericarditis in patients with HIV. This finding 
could be interpreted to mean that previous infection had indeed occurred less 
frequently in those with HIV co-infection and that tuberculous pericardial disease 
occurs in these patients as part of rapidly progressive primary disease. Alternatively, it 
could mean that the diagnosis of TB was made less frequently in the HIV positive 
group of which the majority were blacks - many of whom who had grown up in the 
Eastern Cape with poor access to health services. In this group, the pericardial 
effusion could have occurred as a result of reactivation of previously undiagnosed 
disease. Patients with HIV co-infection were also significantly younger than the HIV 
negative patients and extrapulmonary TB is more likely to occur during a first 
(potentially diagnosable) episode of tuberculous disease in those infected with HIV.  
 
Tobacco smoking and alcohol abuse were not encountered more frequently in patients 
with tuberculous compared to non-tuberculous effusions. This data must, however, be 
reviewed cautiously because data were not collected from a matched group of 
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controls. A study performed in Shanghai found the incidence of TB higher (relative 
risk 2.2) among smokers than non-smokers after adjustment for age, sex, type of 
work, history of contact, and area of housing (Yu and Peng, 1989). The high level of 
alcohol abuse is particularly disturbing. A case-control study conducted in Mamre in 
the Western Cape found an association between alcohol problems in the household 
and TB with an odds ratio adjusted for employment status of 2.2 (Coetzee et al, 
1988). It is thus not sufficient to state that TB is caused by M. tuberculosis. The 
association between poverty and TB has long been recognised, both locally and 
internationally (Dormer and Wiles, 1946; Hinman et al, 1976).  
 
CONCLUSION 
The multifactorial conditions resulting in tuberculous disease involve an interaction 
between agent, host and environment. There are risk factors associated with becoming 
infected, and others that determine the breach in the cellular immunity that allows 
infection to progress to disease. South African statistics have for many years indicated 
major ethnic differences in the prevalence of TB infection, and similar differences are 
seen in the incidence (notification rate) of TB, suggesting that the latter are due 
mainly to differences in the risk of infection. In this study, 50% of all the tuberculous 
pericarditis patients studied were found to be HIV positive, compared to only 4.2% of 
patients presenting with non-tuberculous aetiology. HIV-infected tuberculous 
pericarditis patients were significantly younger than the HIV negative TB patients, 
and the highest prevalence of HIV and TB co-infection was found in the socio-
economically most deprived group, namely African females. The steady rise in the 
number of HIV and TB co-infected patients observed in this study may reflect 
progressively increasing numbers of new cases of HIV infection, however, it may also 
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demonstrate how the maturation of the HIV epidemic results in more cases of 
clinically ill individuals. After initial infection, the human immune system becomes 
increasingly destroyed and the longer the epidemic lasts, the more clinical cases of 
HIV associated disease will be seen. This has ominous social, medical and economic 
implications for the country and in particular, the Western Cape, and places 
considerable pressure on the existing fragile and overstretched health services in sub-
Saharan Africa where more than 70.0% of the world’s co-infection with HIV and TB 
occurs.  
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Chapter 4 
THE ROLE OF HISTOPATHOLOGY IN DIAGNOSING 
TUBERCULOUS PERICARDITIS  
 
Tuberculosis (TB) is the leading cause of pericarditis in South Africa and other 
developing countries (Fowler, 1991; Cegielski et al, 1994; Hakim et al, 2000). This is 
in stark contrast to first world countries where TB accounts for less than 4% of 
pericardial disease (Permanyer-Miralda et al, 1985). The incidence of tuberculous 
pericarditis in sub-Saharan Africa is increasing as a result of the human 
immunodeficiency virus (HIV) endemic, and this trend is likely to occur in other parts 
of the world where the spread of HIV is leading to a resurgence of TB (Cegielski et 
al, 1990; Cegielski et al, 1994; Maher and Harries, 1997). Tuberculous pericarditis 
accounts for up to 100% of HIV positive patients presenting with pericardial effusions 
in African countries (Cegielski et al, 1994; Pozniak et al, 1994), but for only 0-15% 
of corresponding patients in the USA (Eisenberg et al, 1992; Reynolds et al, 1992; 
Kwan et al, 1993; Hsia and Ross, 1994).  
 
A definitive diagnosis of tuberculous pericarditis is made by isolating the tubercle 
bacillus from the pericardial fluid and/or pericardial biopsy, yet pericardial TB is 
often not identified because of the difficulty in isolating the organism (Fowler, 1991; 
Zayas et al, 1995). Histological features of granulomatous inflammation and caseous 
necrosis are highly suggestive of TB. In the absence of demonstrable tubercle bacilli, 
these findings may also be present in chronic pericardial disease secondary to fungal 
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infections and rheumatoid arthritis (RA; Kumar and Robbins, 1997; Underwood, 
2000).   
 
Although the influence of HIV with regards to the epidemiology of extrapulmonary 
TB is well documented (Cegielski et al, 1990; Narain et al, 1992; Cegielski et al, 
1994; Pozniak et al, 1994; Maher and Harries, 1997), little is known about the effects 
of HIV on the pathogenesis, histomorphology and likelihood of establishing a definite 
diagnosis in an HIV positive individual with tuberculous pericarditis. The purpose of 
this study was thus to establish the influence of HIV on the histomorphological 
features of patients presenting with tuberculous pericardial effusions and to determine 
the diagnostic efficiency of pericardial histology compared to other diagnostic tests.  
 
PATIENTS AND METHODS 
A prospective study was carried out at Tygerberg Academic Hospital. During the 
period from February 1995 to June 2001, all patients presenting to the Cardiology 
Unit with large pericardial effusions (defined as epi-pericardial separation of more 
than 10 mm) and having open pericardial biopsies under general anaesthesia were 
included in this study. Each patient underwent a comprehensive diagnostic work-up as 
described in Chapter 2.  One sample of each pericardial biopsy specimen was fixed 
with 10% solution of buffered formalin, processed, paraffin-embedded and sectioned 
using routine technology. Samples were stained with haematoxylin-eosin (H&E) and 
Ziehl-Neelsen (ZN) before being examined independently by two histopathologists. 
The predetermined diagnostic criteria are summarised in Chapter 2. The utility of 
various diagnostic tests to confirm tuberculous pericarditis were evaluated by 
calculating sensitivity, specificity, positive predictive value (PPV), negative 
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predictive value (NPV) and diagnostic efficiency expressed as a percentage as 
described in Chapter 2.  
 
RESULTS 
During the period from February 1995 to June 2001, a total of 233 patients presented 
to the Cardiology Unit with large pericardial effusions; however, open pericardial 
biopsies under general anaesthesia were performed in only 36 patients. Of these, 25 
patients had pericardial biopsies for diagnostic purposes and 11 required surgical 
pericardial fenestration for therapeutic reasons. Based on predetermined criteria, 
tuberculous pericarditis was identified in 25 patients, five of whom were HIV-
positive. The eleven cases of non-tuberculous effusions included one patient with 
septic pericarditis who was HIV-positive. The other cases included uraemia (n=2), 
rheumatoid arthritis (n=1), T-cell lymphoma (n=1), adenocarcinoma (n=1) and 
idiopathic or “indeterminate” pericarditis (n=5). All of these patients tested negative 
for HIV. The histopathological patterns identified for pericarditis are summarised in 
Table 4.1.  
 
Tuberculous pericarditis 
The histopathological features in tuberculous pericardial effusions included non-
necrotising granulomatous pericarditis (Figure 4.1.a), necrotising granulomatous 
pericarditis (Figure 4.1.b), purulent pericarditis (Figure 4.1.c), fibrotic pericarditis 
(Figure 4.1.d), fibrinous pericarditis and serous pericarditis, respectively. Twelve 
biopsies (48% of tuberculous effusions) demonstrated necrotising granulomatous 
inflammation; four of these were ZN positive. Three other specimens showed 
granulomatous inflammation without any evidence of necrosis (ZN negative). 
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Table 4.1. Histopathological findings in patients with large pericardial 
effusions 
 
Tuberculosis (n=25) 
Culture (+) TB Culture (-) TB 
 
Histopathological 
finding HIV- HIV+ HIV- HIV+ 
Total 
TB 
Non-TB 
(n=11) 
Granulomatous, 
necrotising; ZN+ 
 
3 
  
1 
  
4 
  
Granulomatous, 
necrotising; ZN- 
 
4 
 
1 
 
3 
  
8 
  
Purulent; ZN+ 
  
1 
   
1 
  
Granulomatous, no 
necrosis; ZN- 
 
2 
   
1 
 
3 
  
Fibrotic 
 
1 
  
1 
  
2 
 
1 
 
Serofibrinous 
 
2 
  
3 
 
1 
 6 
5 
 
Serous 
    
1 
 
1 
 2 
Purulent; ZN- 
      
1 
 
Neoplastic deposits 
      
2 
 
 
ZN = Ziehl-Neelsen 
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Figure 4.1. Variety of histopathological findings in tuberculous pericarditis 
Panel demonstrates variety of histopathological findings in tuberculous pericarditis, 
including (1a) Non-necrotising granulomatous pericarditis with a Langhans giant cell 
(thin arrow), epithelioid macrophages (arrowhead) and small lymphocytes (thick 
arrow); (1b) Granulomatous pericarditis showing granulomata with central necrosis 
(arrow) against a background of granulation tissue; Insert demonstrates strongly 
positive ZN stain for acid-fast bacilli; (1c) Purulent pericarditis showing severe acute 
inflammatory cell infiltrate (arrow); (1d) Healed pericarditis showing dense 
fibrocollagenous tissue (arrow).  
 
Unless indicated otherwise haematoxylin and eosin stain; 40 x magnification. 
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Figure 4.1.   Variety of histopathological findings in tuberculous pericarditis 
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A further biopsy (taken from an HIV-positive individual with a CD4+ lymphocyte 
count of 39 cells/μL) showed an infiltrate of acute inflammatory cells suggestive of 
purulent pericarditis, the histology in this case was ZN positive. The pericardial fluid 
culture was positive for M. tuberculosis and negative for other bacterial or fungal 
growth. Other histopathological findings included fibrotic pericarditis (n=2), 
serofibrinous pericarditis (n=6) and serous pericarditis (n=1), respectively. Fibrotic 
pericarditis was characterised by plaque-like fibrinous thickening of the serosal 
membranes and multiple layers of fibrocollagenous tissue in the absence of any 
calcifications. 
 
Influence of HIV on tuberculous pericarditis  
Thirteen of the 20 HIV negative tuberculous effusions (65%) demonstrated 
granulomatous lesions compared to two of the five HIV positive cases (40%). In 11 
out of the 13 HIV negative cases (85%), the granulomatous inflammation was 
accompanied by central necrosis, whereas necrosis was present in only one (50%) of 
the two HIV positive cases with granulomatous inflammation. Serofibrinous 
pericarditis was demonstrated in five HIV negative patients (25%) and in one HIV 
positive patient (20%), respectively. In the HIV positive patients, all cases of 
granulomatous inflammation (n=2) and serofibrinous pericarditis (n=1) were 
associated with CD4+ lymphocyte cell counts >200 cells/μl, whereas the 
histopathological features of serous pericarditis (n=1) and purulent pericarditis (n=1) 
were restricted to patients with CD4+ lymphocyte cell counts of 44 and 39 cells/μl, 
respectively. Fibrotic pericarditis was not seen in HIV-positive individuals.  
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Non-tuberculous pericarditis 
In the non-tuberculous pericardial effusions the histopathological classes included 
serofibrinous pericarditis (Figure 4.2.a), serous pericarditis (Figure 4.2.b), neoplastic 
pericarditis (Figures 4.2.c and 4.2.d), purulent pericarditis and fibrotic pericarditis. 
The histopathological descriptions of the non-tuberculous pericarditis cases are 
presented in Table 4.2. Serofibrinous pericarditis was the most common 
histopathological class and was present in uraemic pericarditis (n=2), rheumatoid 
arthritis (RA) (n=1) and idiopathic pericarditis (n=2), respectively, whereas 
granulomatous inflammation was not seen in non-tuberculous pericardial effusions.  
 
The diagnostic utility of pericardial biopsy 
Various histopathological criteria were tested for the diagnosis of TB; the presence of 
granulomatous inflammation (with or without necrosis) and/or ZN positivity was 
found to yield the best results. This corresponded to a sensitivity, specificity, PPV, 
NPV, and diagnostic efficiency of 64%, 100%, 100%, 55%, and 75%, respectively. 
There were nine false negative but no false positive results.  
 
DISCUSSION  
In the current study, only six out of 36 (16.7%) patients were HIV positive; in five 
cases, the effusion was secondary to TB and in the remaining case, septic pericarditis 
was diagnosed. This finding is not representative of the population; HIV-associated 
pericardial effusions are present in 50% of patients presenting with large pericardial 
effusions in this population (Chapter 3). Pericardial biopsies were performed for (a) 
diagnostic purposes if no diagnosis was made within one week and (b) for therapeutic 
purposes when surgical fenestration was required. The low rate of HIV positive  
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Figure 4.2.  Variety of histopathological findings in non-tuberculous 
pericarditis 
Panel demonstrates variety of histopathological findings in non-tuberculous 
pericarditis, including (2a) Fibrinous pericarditis showing a fibrinous exudate (arrow) 
with underlying organisation against an inflammatory background (arrowhead); (2b) 
Serous pericarditis with chronic inflammatory cells and dilated blood vessels; (2c) 
Pericardial infiltration by T-cell lymphoma showing an infiltrate of small blue tumour 
cells; insert demonstrates uptake for immunohistochemical stain for CD3 (T-cell 
marker);  and (2d) Metastatic adenocarcinoma of the pericardium. 
Unless indicated otherwise haematoxylin and eosin stain; 40 x magnification. 
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Figure 4.2.   Variety of histopathological findings in non-tuberculous pericarditis   
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Table 4.2. Histopathological description of cases of non-tuberculous 
pericarditis 
 
 
Histological 
finding 
 
Septic 
(n=1) 
Uraemic 
(n=2) 
Neoplastic 
(n=2) 
RA 
(n=1) 
Other 
(n=5) 
Total 
(n=11) 
Purulent, ZN - 1     1 
Neoplastic deposits   2   2 
Healed     1 1 
Serofibrinous  2  1 2 5 
Serous     2 2 
 
RA = rheumatoid arthritis 
ZN - = Ziehl-Neelsen negative 
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patients being referred for pericardial biopsies in this setting can probably be 
attributable to (a) tendency for treating physicians to diagnose and treat tuberculous 
pericarditis more readily in HIV positive than in HIV negative patients in this setting 
and (b) an unwillingness of surgeons to perform these procedures in HIV positive 
patients unless truly indicated. Pericardial effusions are recognised as one of the early 
presenting features of HIV infection in sub-Saharan Africa (Cegielski et al, 1990; 
Taelman et al, 1990). In developed countries, large pericardial effusions in HIV 
positive patients are often idiopathic (Heidenreich et al, 1995), while in sub-Saharan 
Africa, the disease is caused by TB in as many as 100% of cases (Cegielski et al, 
1994; Longo-Mbenza et al, 1997).   
 
The diagnosis of TB as the aetiological cause is important. Without specific treatment, 
the average survival was 3.7 months and only 20% were alive at six months (Desai, 
1979). On the other hand, the prognosis is excellent with appropriate medical 
treatment (Long et al, 1989; Cherian et al, 2003a). A definitive diagnosis of 
tuberculous pericarditis is made by isolation of the tubercle bacillus from the 
pericardial fluid and/or pericardial biopsy, yet pericardial TB is often not identified 
because of the difficulty in isolating the causative organism (Fowler, 1991; Zayas et 
al, 1995). Culture of tubercle bacilli from pericardial fluid can range from 30% to 
75%, depending on the culture medium (Rooney et al, 1970; Gooi and Smith, 1978; 
Strang et al, 1991), while pericardial tissue established the diagnosis in up to 83% of 
cases (Rooney et al, 1970; Quale et al, 1987). These studies were performed in 
populations that did not have a high incidence of TB. In the current study, 
histopathological examination led to a definitive diagnosis of tuberculous pericarditis 
(caseating granulomata or tubercle bacilli on biopsy sample) in only 11 of the 20 
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HIV-negative tuberculous pericardial effusions (55%) and two of the five HIV-
positive patients (40%). Histological analysis played an important role in diagnosing 
malignant and septic pericarditis, respectively (100% for each group). In spite of its 
relatively poor sensitivity in diagnosing tuberculous pericarditis (58%), histology 
nevertheless had a better diagnostic efficiency (71%) than pericardial effusion culture 
(sensitivity 52%, diagnostic efficiency 69%). By including all cases of granulomatous 
inflammation as being diagnostic of tuberculous pericarditis, the sensitivity and 
diagnostic efficiency improved to 64% and 75%, respectively. This may be of 
importance in areas where HIV/TB co-infection is endemic. Our study revealed that 
HIV does not only exert its impact on the presence of caseating necrosis, but also on 
the presence of granuloma formation.  
 
We observed histological features in tuberculous pericarditis that have not, to our 
knowledge, previously been described. This included a ZN positive case resembling 
purulent pericarditis in a patient with a CD4+ lymphocyte cell count of 39 cells/μL, 
and a case of serous pericarditis in an individual with a CD4+ lymphocyte cell count 
of 44 cells/μL, respectively. The cases that demonstrated granulomatous inflammation 
and the case of serofibrinous pericarditis were associated with CD4+ lymphocyte cell 
counts >200 cells/μL. CD4+ lymphocytes are of particular importance in 
orchestrating the delayed hypersensitivity response that results in granuloma 
formation observed in TB (Sanchez et al, 1994), but which was in the present study 
absent in 60% of HIV positive patients. Although these effects of HIV have not 
previously been described for tuberculous pericarditis, our finding is consistent with 
observations that when atypical clinical, laboratory, and radiographic manifestations 
of TB do occur in HIV-infected persons, it usually implies that the degree of HIV-
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induced immunosuppression is severe; i.e. CD4+ lymphocyte cell counts <200 
cells/μL (Saks and Posner, 1992; Jones et al, 1993; Mlika-Cabanne et al, 1995a; 
Mlika-Cabanne et al, 1995b). Our findings demonstrated that depletion of CD4+ 
lymphocyte cells results in an altered immune response, which leads to diminished 
granuloma formation. It is likely that this affects the containment of bacillary spread 
and is thus responsible for the high frequency of extrapulmonary TB in 
immunodeficient individuals (Narain et al, 1992; Barnes et al, 1993). HIV prevalence 
rates are significantly higher among patients with extrapulmonary TB than among 
those with pulmonary TB (Narain et al, 1992).   
 
The major disadvantage of pericardial biopsy is the need for general anaesthesia, the 
discomfort caused by the surgical procedure and the potentially longer duration of 
hospitalisation recorded in the present study. The greatest utility of pericardial 
histology is its high level of specificity, and by using the new techniques of 
pericardioscopy and optically guided pericardial biopsy, better tissue can be sampled 
while avoiding general anaesthesia and surgery (Little and Ferguson, 1986; Wurtz et 
al, 1992; Maisch, 1994). Although pericardioscopy offers new approaches for 
obtaining diagnostic information in patients with suspected malignant or infectious 
pericardial disease (Maisch, 1994; Endrys et al, 1988), these techniques have mainly 
been used in countries where only the minority of effusions are caused by TB, and the 
usefulness of this diagnostic procedure still needs to be evaluated in larger number of 
patients with tuberculous pericarditis.   
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Chapter 5 
OPTIMISING THE DIAGNOSTIC PROTOCOL IN 
SUSPECTED TUBERCULOUS PERICARDITIS  
 
The prompt treatment of tuberculous pericarditis saves lives (Strang, 1984). Effective 
treatment requires a rapid and accurate diagnosis of pericardial fluid tuberculosis 
(TB), but this is often difficult (Koh et al, 1994). Ziehl-Neelsen (ZN) stained smears 
of pericardial have poor sensitivity for the detection of Mycobacterium tuberculosis 
(M. tuberculosis), while culture is too slow and insensitive to aid clinical decision-
making (Strang, 1984; Koh et al, 1994; Cherian, 2004). Pericardial biopsy, which is 
invasive and requires technical skills, is often also not diagnostic (Sagrista-Sauleda et 
al, 1988; Fowler, 1991; Koh et al, 1994). Clinicians thus have to rely heavily on 
clinical features of pericardial TB to initiate anti-tuberculous therapy (Cegielski et al, 
1994; Pozniak et al, 1994; Maher and Harries, 1997). The potential for toxic effects 
and the duration of anti-tuberculous chemotherapy mandate diagnostic specificity. It 
is thus important to identify which clinical and basic laboratory features should be 
used to predict tuberculous aetiology. A diagnostic algorithm or scoring system based 
on these predictors might improve the diagnostic accuracy. Multivariate logistic 
regression has been used to model the clinical predictors of tuberculous meningitis in 
251 adults  (Thwaites et al, 2002). The researchers developed a simple diagnostic rule 
that resulted in 86% sensitivity and 79% specificity for the diagnosis of tuberculous 
meningitis (Thwaites et al, 2002).  
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When diagnostic infrastructure and resources are less problematic, suspected cases of 
tuberculous pericarditis may be diagnosed with the aid of polymerase chain reaction 
(PCR) analysis for M. tuberculosis (Cegielski et al, 1997; Lee et al, 2002), adenosine 
deaminase (ADA) activity (Koh et al, 1994; Komsuoglu et al, 1995; Burgess et al, 
2002b) and pericardial interferon-gamma (IFN-γ) levels  (Burgess et al, 2002b). The 
effect of human immunodeficiency virus (HIV) infection on ADA levels in patients 
with TB is controversial (Hsu et al, 1993; Burgess et al, 2002b), and the impact of 
HIV infection on the production of IFN-γ has not been evaluated. Cytology has been 
used for the diagnosis of pleural TB (Spriggs and Boddington, 1960; Yam, 1967, 
Gresham, 1989), and although it has been shown to be useful for the diagnosis of 
pericardial malignancy (Reyes et al, 1982; Pozniak et al, 1986; Di Bonito et al, 1990; 
Wiener et al, 1991; Nugue et al, 1996), the utility of cytology for the diagnosis of 
pericardial TB has not been studied. We aimed to develop a strategy that would 
optimise the diagnostic efficiency of available diagnostic tests and test these 
prospectively in a population with a high prevalence of HIV.  
 
PATIENTS AND METHODS 
The general diagnostic work-up and management of patients are summarised in 
Chapter 2. ADA activity (U/L) was determined in all pericardial fluid specimens 
according to the method described by Giusti (1974). This is a calorimetric method 
based on measurement of the formation of ammonia by Berthelot’s reaction, which is 
produced when ADA acts on excess adenosine. One unit of ADA is defined as the 
amount of enzyme required to release one μmol of ammonia per minute from 
adenosine at standard assay conditions. The enzyme is stable for at least 24 hours at 
25°C, seven days at 4°C and three months at -20°C (Ellis and Goldberg, 1970; Heinz, 
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1984). For cytopathological analyses pericardial fluid specimens (5-10 mL) were 
fixed by adding an equal amount of 50% ethanol. Smears were prepared from 
sediments by routine methods and stained according to the Papanicolaou method. 
Aliquots of pericardial fluid were collected on ice, frozen within 30 minutes and 
stored at –700C for the analysis of IFN-γ and the diagnostic application of polymerase 
chain reaction (PCR) technology. A commercially available PCR assay (Roche 
AmplicorTM PCR for M. tuberculosis) was used for the detection of the IS6110 
sequence of M. tuberculosis in pericardial fluid specimens applying standard 
techniques and procedures. IFN-γ concentration was determined by enzyme-linked 
immunosorbent assay (ELISA) as described in Chapter 2.  
 
The methodology used for the statistical analyses is summarised in Chapter 2. In 
addition, we developed a TB prediction model as a diagnostic aid by means of a 
statistical approach called “classification and regression tree” (CART) analysis. The 
classification trees were developed by consideration of all the variables separately. 
The range of each variable was divided into two groups to obtain the best separation 
between patients with tuberculous pericarditis and those with non-tuberculous 
pericarditis. The division corresponding to the best separation was selected. The 
resulting subsets of cases were then partitioned independently in turn. The process 
was done recursively, until a stopping condition was satisfied. Node deviance, which 
measures node heterogeneity was set to 0.1 to stop the tree growing process, and 
subsets smaller than 10 were not partitioned further. The sample was randomly 
divided into a training set (101 patients) and a test set (63 patients).  The prediction 
model was then derived from the training set, and used on the test set to determine 
sensitivity and specificity values. The optimum cut-off for the total diagnostic index 
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(by which to classify a patient has having tuberculous pericarditis) was found by use 
of receiver operating characteristic (ROC) curves (Beck and Schultz, 1986).  
 
RESULTS 
During the study period, 233 patients presented to Tygerberg Hospital with large 
pericardial effusions requiring pericardiocentesis. These included 101 (43.0%) 
females and 132 (67.0%) males. Tuberculous pericarditis accounted for 162 effusions 
(69.5%), malignant effusions for 22 (9.4%), effusions associated with connective 
tissue diseases for 12 (5.2%), septic pericarditis for 5 (2.1%), and “other” effusions 
for 32 (13.7%). In total, 84 patients were HIV positive, including 81 patients who had 
pericardial TB (50.0% of TB patients). The epidemiology of these effusions has been 
described in Chapter 3. Eleven of the 162 tuberculous patients had been on anti-
tuberculous therapy for more than 48 hours at the time of pericardial aspiration; all of 
these were HIV negative.  
 
Microbiological/histopathological diagnosis of pericardial TB 
“Definite” TB (histological and/or microbiological evidence for TB) was diagnosed 
in 118 (73%) of 162 patients classified as having tuberculous pericarditis. These 
included three patients with a positive pericardial fluid Ziehl-Neelsen (ZN) smear, 91 
patients with a positive pericardial effusion TB culture, 16 patients with a pericardial 
biopsy that was diagnostic of TB, 32 patients with a positive ZN smear and/or 
culture, and 16 patients with a positive TB culture and/or histology in one or more 
extracardiac site. Positive TB cultures were obtained from pleural fluid (n=8), 
peritoneal fluid (n=2), blood (n=3), lymph node aspirate (n=3) and skin biopsies 
(n=2). Twenty-three patients had TB demonstrated in more than one site. Thirty-six 
 79
pericardial biopsy specimens were evaluated histologically. Of these, 15 biopsies 
demonstrated granulomatous inflammation; 12 accompanied by caseating necrosis. A 
biopsy specimen from an HIV positive patient resembled acute purulent pericarditis; 
a diagnosis of pericardial TB was based on the presence of numerous acid-fast bacilli 
(AFB).  Of the remaining 20 biopsies, 17 biopsies were non-diagnostic (non-specific 
features) and three biopsies were diagnostic for non-tuberculous disease, including 
septic pericarditis, T cell lymphoblastic lymphoma and pericardial adenocarcinoma 
 
Clinical and echocardiographic features 
Patients who presented with tuberculous pericarditis were significantly younger than 
patients who presented with non-tuberculous pericardial disease. The clinical features 
as observed at the time of admission are summarised in Table 5.1. Significant 
differences (p<0.05) between patients with tuberculous and patients with non-
tuberculous effusions were observed with regards to the presence of fever, night 
sweats, weight loss, cough, dyspnoea, and lymphadenopathy. Univariate analysis 
comparing HIV positive with HIV negative patients demonstrated an increased 
frequency of fever (p=0.02), weight loss (p<0.00001), and lymphadenopathy 
(p=0.00015) in the HIV positive TB group compared to HIV negative pericardial TB 
patients (Table 5.1.). In addition, oral candidiasis was significantly more frequent in 
the HIV positive TB group than in the HIV negative TB patients (16 versus 2 cases; 
p=0.004). The echocardiographic features are summarised in Table 5.2.  
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Table 5.1. Univariate analysis comparing clinical features as observed at 
admission 
 
 
 
TB/HIV- 
n=81 
TB/HIV+ 
n=81 
 
p 
TB 
n=162 
Non-TB 
n=71 
 
p 
Fever  65% 85% 0.02 75% 52% 0.0006 
Night sweats  56% 68% 0.16 62% 30% <0.0001
Weight loss  64% 94% <0.0001 79% 44% <0.0001
Cough  87% 93% 0.32 90% 69% 0.0002 
Dyspnoea  80% 93% 0.25 86% 73% 0.03 
Orthopnoea  44% 32% 0.08 38% 41%% 0.71 
Chest pain 30% 23% 0.22 27% 51% 0.001 
Lymphadenopathy 22% 51% <0.001 36% 20% 0.009 
Pleural effusion 42% 34% 0.25 38% 41% 0.71 
Tachycardia 72% 76% 0.91 74% 54% 0.003 
Soft heart sounds 75% 74% 0.99 75% 55% 0.003 
↑ JVP ≥4cm  80% 76% 0.17 78% 70% 0.20 
Pulsus paradoxus  24% 30% 0.34 27% 16% 0.15 
Hypotension 5% 7% 0.25 6% 6% 0.92 
Hepatomegaly  63% 60% 0.78 62% 45% 0.02 
Ankle oedema  42% 34% 0.32 38% 47% 0.24 
 
↑ JVP = elevated jugular venous pressure  
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Table 5.2. Univariate analysis of echocardiography findings at admission 
 
 
 
TB/HIV-
n=81 
TB/HIV+ 
n=81 
 
p 
TB 
n=162 
Non-TB 
n=71 
 
p 
Tamponade  90% 90% 1.0 90% 78% 0.04 
Pericardium >5mm  63% 72% 0.34 67% 46% 0.02 
Fibrin strands  60% 68% 0.44 65% 46% 0.02 
 
TB = tuberculosis 
HIV- = human immunodeficiency virus negative  
HIV+ = human immunodeficiency virus positive 
Non-TB = non-tuberculous  
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Significant differences were noted between the echocardiographic features of 
tuberculous pericarditis compared to non-tuberculous pericardial effusions regarding 
the presence of tamponade (p=0.03), pericardial thickness ≥5mm (p=0.02), and the 
presence of fibrinous strands in the pericardial space (p=0.02). Seven patients were 
diagnosed with effusive-constrictictive pericarditis, including five patients with 
tuberculous pericarditis (one of them HIV positive).   
 
Macroscopically, pericardial aspirates could be classified into pus, haemorrhagic or 
straw-coloured effusions. Tuberculous effusions were more frequently haemorrhagic 
than non-tuberculous effusions (72% versus 59%; p=0.04). Thirteen pericardial 
effusions resembled pus, including cases of septic pericarditis (n=4), tuberculous 
pericarditis (n=8) and one case of systemic lupus erythematosus (SLE).  
 
Biochemistry and haematology results 
The biochemistry results have been summarised in Table 5.3. Application of Light’s 
criteria (Light et al, 1972) classified all tuberculous pericardial aspirates as exudates. 
Patients who presented with tuberculous pericarditis had significantly higher serum 
protein, serum globulin and pericardial protein levels than patients who presented 
with non-tuberculous pericarditis (p<0.001 for each of these variables). Using a serum 
globulin concentration >40 g/L as a cut-off level for the diagnosis of tuberculous 
pericarditis resulted in an odds ratio of 15.1 (p<0.001), whereas a pericardial total 
protein level >39 g/L resulted in an odds ratio of 3.42 (p=0.005). Serum protein, 
serum globulin and pericardial fluid protein levels were significantly higher in HIV 
positive patients who presented with pericardial TB than HIV negative tuberculous 
pericarditis patients (p<0.01 for each of these variables). Peripheral blood and 
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pericardial fluid haematology results are summarised in Table 5.4. Peripheral blood 
total leukocyte counts, neutrophil, lymphocyte and monocytes numbers were 
significantly lower in patients diagnosed with tuberculous aetiology compared with 
patients who presented with non-tuberculous pericarditis (p<0.01 for each variable), 
and significant differences were demonstrated between HIV positive and HIV 
negative pericardial TB patients for each of these variables (p<0.05).  Using a 
peripheral blood total leukocyte count <10x109 cells/L as a cut-off level for the 
diagnosis of pericardial TB resulted in the respective odds ratio of 12.6 (p<0.01). 
Pericardial fluid total leukocyte counts and pericardial fluid neutrophil counts were 
significantly higher in non-tuberculous effusions than in tuberculous exudates, which 
were in turn characterised by significantly higher lymphocyte counts than those found 
in non-tuberculous cases. Various pericardial lymphocyte/neutrophil (pc-L/N) ratios, 
were evaluated as cut-off level for the diagnosis of pericardial TB and, based on ROC 
curves, the best results were obtained at a pericardial fluid L/N ratio ≥1.0, resulting in 
the corresponding sensitivity, specificity, PPV, NPV and diagnostic efficiency of 
73%, 78%, 86%, 61%, and 75%, respectively. 
 
Clinical prediction model for TB diagnosis 
The sample set used for deriving the prediction model consisted of 164 patients, who 
had valid test results, including 110 patients with definite TB (67%) and 54 patients 
with non-tuberculous pericarditis (33%). Five admission variables were identified that 
were independently predictive for tuberculous pericarditis and a diagnostic index was 
calculated for each of these as presented in Table 5.5. 
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Table 5.3. Comparison of biochemistry results  
 
 TB/HIV- 
n=64 
TB/HIV+ 
n=78 
 
p 
TB 
n=142 
Non-TB 
n=61 
 
p 
S-protein (g/L) 72 (9.8) 78 (8.6) <0.001 75 (9.0) 65 (11.4) <0.001 
S-globulin (g/L) 43 (7.7) 51 (6.4) <0.001 47 (7.1) 35 (8.2) <0.001 
S-albumin (g/L) 30 (2.1) 27 (2.2) 0.46 28 (2.2)  30 (2.4) 0.09 
S-albumin/S-
globulin  
0.67 (0.25) 0.48 (0.21) <0.001 0.56 (0.23) 0.83 (0.29) <0.001 
Pc-protein (g/L) 52.1 (11.9) 60.2 (14.9) 0.001 56.2 (8.0) 47.2 (17.9) <0.001 
Pc-protein/S-protein  0.72 (0.16) 0.79 (0.15) 0.08 0.76 (0.15) 0.73 (0.18) 0.27 
Pc-LDH/S-LDH  3.86 (5.06) 2.40 (1.62) 0.01 3.2 (3.31)  4.0 (6.2) 0.26 
CRP (mg/L) 109 (84.9) 121 (79.0) 0.46 115 (82) 90 (85.7) 0.04 
 
Results expressed as mean (standard deviation)  
S = serum 
Pc = pericardial fluid 
LDH = lactate dehydrogenase 
CRP = C-reactive protein 
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Table 5.4. Comparison of haematology results 
 
 TB/HIV- 
n=64 
TB/HIV+ 
n=78 
 
p 
TB 
n=142 
Non-TB 
n=61 
 
p 
PB-leukocytesa  7.9 (3.37) 6.7 (4.15) 0.01 7.33 (3.76) 12.6 (4.8) <0.001 
PB-neutrophils  5.68 (1.34) 4.92 (0.91) 0.01 5.38 (1.31) 8.87 (1.56) <0.001 
PB-lymphocytes  1.33 (0.61) 0.93 (0.53) 0.03 1.13 (0.57) 2.01 (2.23) <0.001 
PB monocytes   0.55 (0.19) 0.24 (0.12) 0.01 0.40 (0.16) 0.69 (0.25) 0.001 
Pc- leukocytes  2.69 (2.33) 1.85 (1.52) 0.03 2.27(1.92) 4.62 (3.81) 0.001 
Pc  % neutrophils 28.4 (22.5) 35.9 (25.5) 0.05 32.2 (24.0) 55.8 (24.6) 0.01 
Pc  % lymphocytes 52.1 (25.5) 39.4 (22.5) 0.03 45.5 (25.2)  25.6 (22.4) 0.01 
 
Results expressed as mean (standard deviation) 
a  cells x109/L 
PB = peripheral blood 
Pc = pericardial fluid 
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Table 5.5. Odds ratios and weighted diagnostic index for admission 
variables  
 
Admission variable Odds ratio Weight Diagnostic index 
 Weight loss 6.15 0.13 1 
 Night sweats 4.16 0.09 1 
 Fever 7.71 0.16 2 
 Serum globulin >40 g/L 15.09 0.31 3 
Leukocyte count <10x109/L 12.76 0.26 3 
 
 
 87
The first three variables are yes/no variables, whereas the remaining two (serum 
globulin and peripheral blood leukocyte count) are measurements for which optimal 
threshold values were derived using classification tree analysis. For each of these five 
factors the odds ratio for having TB (when the factor is present) was calculated and 
these odds ratios were used to calculate the respective weight and the diagnostic index 
(DI) for each variable in the following manner: 
 
odds ratioweight
sum of all odds ratios
=      and     DI = weight x 10 
 
The total diagnostic index was calculated for each patient according to the formula: 
DI (weight loss) + DI (night sweats) + DI (fever) + DI (serum globulin) + DI 
(peripheral blood leukocyte count). The optimum cut-off for the total diagnostic index 
was found by use of an ROC curve (Figure 5.1.).  
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Figure 5.1. Receiver operating characteristic (ROC) curve determining the 
optimal total diagnostic index for diagnosing pericardial TB  
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The prediction model was derived from the training set (n=101), and predictions made 
for the test set (n=63) to determine sensitivity and specificity. The best diagnostic 
efficiency for diagnosing TB corresponded in the training and in the test set to a total 
DI of 6 (point on graph closest to top left hand corner). Results for the prediction 
model applied to the training data demonstrated 86% sensitivity and 87% specificity 
for the diagnosis of TB, whereas application to the test set resulted in 82% sensitivity 
and 76% specificity. Our suggested diagnostic rule was therefore: if the patient has a 
total diagnostic index score of 6 or more, he or she has tuberculous pericarditis, and if 
the patient has a score of less than 6 he or she has non-tuberculous pericarditis. 
 
Pericardial fluid adenosine deaminase activity 
The corresponding median (range) adenosine deaminase (ADA) activity for patients 
with tuberculous (HIV negative), tuberculous (HIV positive), malignancy, septic 
pericarditis, connective tissue disease and other non-tuberculous pericardial effusions 
are presented in Table 5.6. Various levels of pericardial fluid ADA activity were 
evaluated as a cut-off level for the diagnosis of pericardial TB and, based on ROC 
curves (Beck and Schultz, 1986), the best results were obtained at a cut-off level of 40 
U/L. 
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Table 5.6. Pericardial ADA activity in various diagnostic groups of 
pericarditis 
 
Adenosine deaminase activity 
(U/L) 
Diagnostic groups  
n 
Mean  95% Confidence 
Intervals 
 
p 
Tuberculous pericarditis  
   HIV negative  
   HIV positive  
Malignant pericardial effusion 
Uraemic pericarditis 
Septic pericarditis 
Connective tissue disease  
Other pericardial effusions 
 
75 
76 
20 
9 
4 
8 
20 
 
79.6 
76.3 
39.3 
21.1 
102.3 
31.1 
30.0 
 
69.7 – 89.5 
66.6 – 86.0 
20.0 – 58.6 
-7.7 – 49.8 
59.2 – 145.4 
0.6 – 61.6  
10.7 – 49.3 
 
 
1.00 
0.007 
0.004 
1.00 
0.06 
0.0002 
 
*p-value established by Bonferroni test, notifying difference between diagnostic 
groups from HIV negative tuberculous pericarditis. 
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In total, 13 (out of 71) patients with non-tuberculous effusions had levels of ADA 
activity exceeding 40 U/L. These false positives included patients with septic 
pericarditis (n=4; corresponding ADA activities of 49.1, 55.6, 138.6 and 165.8 U/L, 
respectively), one case of systemic lupus erythematosus (SLE; corresponding ADA 
49 U/L), rheumatoid arthritis (n=1; corresponding ADA 65.3 U/L), post-traumatic 
pericarditis (n=1; corresponding ADA 47.5 U/L), pericarditis of unknown origin 
(n=1; corresponding ADA 50.4 U/L), non-haematological malignancies (n=3); and 
haematological malignancies (n=2). The malignancies included pericardial 
adenocarcinoma (ADA 47.5 U/L), squamous cell carcinoma (ADA 46.0 U/L), 
undifferentiated carcinoma (ADA 50.9 U/L), lymphoblastic T cell lymphoma (ADA 
166.0 U/L) and chronic myelomonocytic leukaemia (ADA 102.5 U/L). Using the cut-
off level of 40 U/L resulted in 22 false negative pericardial effusions, 12 of these 
occurred in HIV negative and ten in HIV positive patients, respectively. Nine of the 
12 HIV negative patients were on anti-tuberculous therapy at the time of 
pericardiocentesis, whereas no HIV positive patient was on active anti-tuberculous 
therapy at the time of pericardial aspiration. An additional two HIV negative patients 
were also on anti-tuberculous medication; in these two the corresponding pericardial 
ADA activity levels were 75.0 U/L and 81.0 U/L, respectively. The corresponding 
median (range) ADA activity for HIV negative TB patients on anti-tuberculous 
therapy, HIV negative TB patients not on anti-tuberculous therapy, HIV positive TB 
patients and patients with non-tuberculous pericardial effusions is presented in Table 
5.7. In three patients with tuberculous pericarditis no specific cause could be 
identified for the low pericardial ADA activity; the corresponding ADA activity for 
these three cases was 22 U/L, 24 U/L and 34 U/L, respectively.  
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After exclusion of all patients on anti-tuberculous therapy and all those patients 
categorized as pericarditis of unknown cause, an ADA activity cut-off level of 40 U/L 
resulted in the corresponding sensitivity, specificity, PPV, NPV and diagnostic 
efficiency of 90%, 74%, 90%, 76% and 86%, respectively.  
 
Pericardial fluid gamma-interferon concentration 
The corresponding mean (SD) IFN-γ concentrations for HIV negative tuberculous, 
HIV positive tuberculous and non-tuberculous effusions were 787 (115) pg/mL, 624 
(103) pg/mL, and 27 (19) pg/mL, respectively. The difference in IFN-γ concentration 
between tuberculous exudates and non-tuberculous effusions was highly significant 
(p<0.0001), whereas no difference was seen between HIV positive and HIV negative 
tuberculous groups (p=0.89). IFN-γ levels were detectable in only three of the non-
tuberculous effusions, including a case of staphylococcal sepsis (corresponding IFN-γ 
concentration of 28.9 pg/mL), a case of metastatic adenocarcinoma (42.9 pg/mL), and 
the remaining case was caused by diffuse large cell lymphoma (39.4 pg/mL). Various 
levels of pericardial fluid IFN-γ concentration were evaluated as a cut-off level for the 
diagnosis of pericardial TB and, based on ROC curves, best results were obtained at a 
cut-off level of 50 pg/mL.  Using a cut-off level of 50 pg/mL as being diagnostic for 
tuberculous pericarditis resulted in 92% sensitivity, 100% specificity and a positive 
predictive value of 100% for pericardial TB.   
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Table 5.7. Pericardial ADA activity in tuberculous and non-tuberculous 
pericarditis 
 
ADA activity (U/L)  
Diagnostic groups 
 
n Mean 95% Confidence 
intervals 
 
p 
Tuberculous pericarditis  
   HIV negative (not on ATC)   
   HIV negative (on ATC)  
   HIV positive 
Non-tuberculous pericarditis  
 
64 
11 
76 
61 
 
88.9 
24.9 
76.3 
36.6 
 
78.5 – 99.3 
0.1 - 50.1 
66.6 – 86.0 
25.9 – 47.3 
 
 
0.000004
0.48 
0.001 
 
ADA = adenosine deaminase activity 
ATC anti-tuberculous chemotherapy 
*p-value established by Bonferroni test, notifying difference between diagnostic 
groups from HIV negative tuberculous pericarditis not on ATC 
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Polymerase chain reaction for Mycobacterium tuberculosis 
In this study PCR for M. tuberculosis was used on pericardial fluid samples of 48 
consecutive patients, including 33 patients with tuberculous pericarditis and 15 
patients with non-tuberculous effusions. Positive PCR results were obtained for four 
“definite” tuberculous effusions and for six “probable” tuberculous effusions, but for 
none of the non-tuberculous effusions. Inclusion of the “probable” TB cases in the 
evaluation of the diagnostic utility of PCR resulted in the corresponding sensitivity, 
specificity, PPV, NPV and diagnostic efficiency of 30%, 100%, 100%, 31%, and 
52%, respectively. 
 
Cytopathology 
Cytopathology results were available for 202 patients, including 146 patients who 
were diagnosed with pericardial TB and 56 patients who presented with non-
tuberculous pericarditis. Ten out of 146 TB patients were using anti-tuberculous 
chemotherapy at the time of the pericardiocentesis and were excluded from further 
analyses. Each pericardial fluid specimen (n=192) was classified into one specific 
cytopathological category on the basis of cytodiagnostic criteria (Spriggs and 
Boddington, 1960; Yam, 1967; Pettersson, 1982; Gibas et al, 1986; Gresham, 1989) 
as summarised in Table 5.8.   
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Table 5.8. Cytopathological classification for various diagnostic groups  
 
Diagnosis n Benign Purulent Non-purulent Tuberculous Malignant
Tuberculous  136 7 (5%) 10 (8%) 108 (79%) 11 (8%)  
   HIV negative 
   HIV positive 
61 
75 
3 (5%) 
4 (5%) 
4 (7%) 
6 (8%) 
48 (79%) 
60 (80%) 
6 (10%) 
5 (7%) 
 
Non-tuberculous 56 11 (20%) 6 (11%) 25 (45%) 2 (4%) 12 (21%) 
   Malignant 
   CNTD  
   Uraemia 
   Septic 
   Traumatic 
   Idiopathic 
   Other 
19 
9 
8 
4 
7 
5 
4 
1 (5%) 
3 (33%) 
2 (25%) 
 
1 (14%) 
2 (40%) 
2 (50%) 
 
1 (11%)
 
4 (100%)
 
 
1 (25%)
5 (26%) 
4 (44%) 
6 (75%) 
 
6 (86%) 
3 (60%) 
1 (25%) 
1 (5%) 
1 (11%) 
 
 
 
 
 
12 (63%) 
 
 
 
 
 
 
 
CNTD = connective tissue disease 
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Three of the 192 effusions were ZN positive, including one purulent and two non-
purulent inflammatory effusions; all three were found in HIV positive individuals and 
results were verified by positive TB culture. None of these effusions fulfilled the 
cytodiagnostic criteria for the category “tuberculous” effusion. In the 136 tuberculous 
pericarditis patients (diagnosed according to predetermined criteria; Chapter 2), the 
most common cytopathological diagnosis was “non-purulent inflammatory effusion”, 
which was demonstrated in 79% of TB patients. Pericardial fluid 
lymphocyte/neutrophil (L/N) ratios >3:1 were demonstrated in 53% of HIV negative 
pericardial effusions and in 20% of HIV positive tuberculous effusions, and 
significant numbers of mesothelial cells were present in the majority of pericardial 
aspirates obtained from pericardial TB patients. The pericardial aspirates of 13 
patients were classified as “tuberculous” cytology (Figure 5.2.a), including 11 patients 
with a diagnosis of pericardial TB (according to predetermined criteria; Chapter 2), 
one case of SLE, and one case of histologically confirmed lymphoblastic T cell 
lymphoma. Cytopathological review of the lymphoma patient’s aspirate revealed 
cytological features suggestive of a haematological malignancy (Figure 5.2.b). Thirty-
six pericardial biopsy samples were available for comparative analysis between 
histopathological diagnosis and cytopathological diagnosis. Fifteen of the 36 biopsies 
demonstrated granulomatous inflammation. The cytological classification in these 15 
cases included “non-purulent inflammatory” effusion (n=13) and “tuberculous” 
effusion (n=2).  Two cases of serofibrinous pericarditis and one case of pericardial 
lymphoma corresponded to the cytological category “tuberculous” effusion. Using the 
cytodiagnostic category “tuberculous” effusion as measure of diagnosing pericardial 
TB resulted in 11% sensitivity and 85% specificity.  
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Figure 5.2.   Cytopathology smears of patients with large pericardial effusions    
 
 
2a 2b 
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Tuberculin skin testing 
Tuberculin skin testing was performed in 52 consecutive patients, including 36 
patients with tuberculous pericarditis (12 HIV positive) and 16 patients with non-
tuberculous pericarditis. The aetiological causes for the non-tuberculous pericarditis 
group included malignancy (n=6), septic pericarditis (n=2), uraemic pericarditis 
(n=2), post-traumatic pericarditis (n=2), rheumatoid arthritis (n=1), scleroderma (n=1) 
and systemic lupus erythematosus (n=1). Different cut-off levels for diameter of skin 
induration were tested and the best diagnostic efficiency for diagnosing TB (including 
HIV positive patients) was obtained at a diameter ≥10 mm. At this cut-off level, 
tuberculin skin tests were positive in 32 out of 36 tuberculous pericarditis patients 
(89% “true positive”) and in seven out of 16 patients with non-tuberculous effusions 
(44% “false positive”) resulting in the corresponding sensitivity, specificity, PPV, 
NPV and diagnostic efficiency of 89%, 56%, 82%, 69%, and 79%, respectively. At a 
cut-off level (diameter) ≥15 mm of skin induration, the respective sensitivity, 
specificity, PPV, NPV and DE was 43%, 93%, 93%, 38%, and 57%. 
 
Diagnostic classification tree   
Based on the predictive sensitivity and specificity for the diagnosis of TB, we 
identified four parameters that form the basis of the diagnostic classification tree that 
we developed as an aid for the diagnosis of pericardial TB (Figure 5.3.). Application 
of the patient data set resulted in 96% sensitivity and 97% specificity for the diagnosis 
of pericardial TB (Table 5.9.).  The utility of various tests for the diagnosis of TB, 
including pericardial effusion culture, pericardial histology, PCR, IFN-γ and ADA 
activity were evaluated and the results are summarised in Table 5.9. 
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Table 5.9. Utility of various diagnostic tests  
 
 
 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
DE 
(%) 
Pericardial effusion culture 
positive 
52 100 100 48 56 
Histopathology 
(granulomatous and/or ZN+) 
64 100 100 55 75 
Pericardial ADA activity 
≥40 U/L 
87 89 95 72 88 
Pericardial lymphocyte/ 
neutrophil ratio ≥1 
73 79 86 61 75 
Interferon-γ ≥50 pg/mL 92  100 100 85 94  
PCR for M. tuberculosis 
positive 
30 100 100 31 52 
Diagnostic classification tree  
(excluding “probable” TB 
patients) 
96 97 98 94 96 
Diagnostic classification tree  
(including “probable” TB 
patients) 
96 97 98 92 96 
 
PPV = positive predictive value 
NPV = negative predictive value 
DE = diagnostic efficiency 
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Pc-ADA activity
>40 U/L
HIV serology
positive
Yes
YesNo
Non-tuberculous 
pericarditis
Pc L/N ratio
>1
No Yes
Tuberculous
pericarditis
PB-WCC
<10X109/L
Yes
No
No
 
 
Figure 5.3. Classification tree developed for the diagnosis of pericardial TB 
 
Pc-ADA = pericardial adenosine deaminase 
PB-WCC = peripheral blood white cell count 
Pc L/N ratio = pericardial lymphocyte / neutrophil ratio  
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DISCUSSION 
The diagnosis of tuberculous pericarditis is important, because without specific 
treatment, the average survival is 3.7 months and the mortality approaches 85% at six 
months (Desai, 1979). Our study confirmed the insensitivity of the traditional 
diagnostic tools used for diagnosing pericardial TB. Pericardial biopsy specimens 
taken from the tuberculous group demonstrated caseating granulomatous 
inflammation in about 50% of biopsy samples and non-specific histopathological 
findings were common, even when M. tuberculosis was found in the pericardial fluid. 
Although mycobacterial culture was much more sensitive than fluid smear, it yielded 
positive results in only 56% of patients diagnosed with pericardial TB. In our study 
the microbiological diagnosis was significantly augmented by culturing M. 
tuberculosis from extracardiac sites, including sputum (n=32), pleural fluid (n=8) and 
lymph node aspirate (n=3).  Pleural TB and peripheral tuberculous lymphadenitis are 
the two most common forms of extra-pulmonary TB (Light, 1994), and both are 
commonly seen in patients with pericardial TB. In one series, 50% of patients with 
tuberculous pericarditis had necropsy evidence of pleural effusion due to tuberculous 
pleuritis (Rooney et al, 1979), and peripheral lymphadenopathy affecting the cervical 
glands has been reported in 13%–28% with tuberculous pericarditis (Desai, 1979; 
Cherian, 2004). Persistent generalised lymphadenopathy is a common manifestation 
of HIV positive patients (Jacobson et al, 1991; Pantaleo et al, 1994), however, when 
the enlarged lymph nodes are >1cm in diameter and their distribution not 
symmetrical, disseminated TB needs to be considered. Tuberculous lymphadenopathy 
is characterised by caseation and "matting" on palpation, and the adenopathy clears or 
regresses on specific therapy (Cherian et al, 2003b). The diagnostic workup of 
patients with suspected pericardial TB should thus include sputum smears in patients 
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with a productive cough and lymph node aspiration when possible. However, culture 
results take long and rarely influence decision-making.  
 
We documented high levels of ADA in tuberculous pericardial effusions. In HIV 
negative TB patients the most notable cause for low pericardial ADA levels was the 
concomitant use of anti-tuberculous chemotherapy at the time of pericardiocentesis, 
suggesting that anti-tuberculous therapy influences ADA activity by one or more of 
the following mechanisms: (i) it effects the cell turnover of pericardial macrophages 
and T lymphocytes, thereby reducing ADA levels, and/or (ii) it increases the 
metabolic breakdown of ADA (possibly by rifampicin’s enzyme inducing effect on 
hepatic metabolism), and/or (iii) anti-tuberculous therapy suppresses ADA activity 
directly. 
 
Pericardial lymphocyte counts were higher and pericardial neutrophil counts 
significantly lower in patients with tuberculous effusions compared to patients who 
presented with non-tuberculous effusions, whereas median ADA activity was 
significantly higher in tuberculous than in non-tuberculous exudates. This implies that 
in tuberculous effusions lymphocytes (and possibly macrophages) play the major role 
in the production and release of ADA as has been demonstrated in the case of 
tuberculous pleural exudates (Valdes et al, 1996). ADA is a polymorphic enzyme that 
is involved in purine metabolism and metabolises the deamination of adenosine to 
inosine and ammonium (Van der Weyden and Kelley, 1976). There are two principal 
isoenzymes of ADA, namely ADA1 and ADA2. ADA1 is found in all cells, with the 
highest activity in lymphocytes and monocytes (Ungerer et al, 1992), whereas ADA2 
exists only in monocytes (Ungerer et al, 1992; Gakis, 1996). The elevated ADA levels 
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found in tuberculous exudates are thought to result from cell-mediated immunity 
(Blake and Berman, 1982), and HIV infection has been implicated as a cause for low 
ADA levels in patients with TB (Hsu et al, 1993). In our study ADA activity was 
significantly more elevated in tuberculous than in non-tuberculous pericardial 
effusions. Pericardial ADA levels were not affected by HIV infection, and contrary to 
a previous report (Hsu et al, 1993), the diagnostic utility measuring ADA activity was 
not diminished by underlying HIV. Based on ROC curves (Beck and Schultz, 1986), 
the best diagnostic results were obtained at a pericardial ADA cut-off level of 40 U/L, 
which corresponded to a sensitivity, specificity, PPV, NPV, and diagnostic efficiency 
of 90%, 74%, 90%, 76% and 86%, respectively.  
 
The use of pericardial ADA levels in a patient with suggestive clinical features 
provides a rapid and accurate means of diagnosing tuberculous pericarditis, especially 
in high-prevalence areas. If a high ADA level is found, septic pericarditis and 
haematological neoplastic diseases need to be excluded by differential white blood 
cell, direct microscopy, Gram stain, bacterial culture, and cytological analysis, all of 
which should be performed routinely on patients with large pericardial effusions. If 
these tests are negative, the diagnosis will in all likelihood be TB, especially in 
countries where this infection is endemic or in those infected with HIV. If a low level 
of ADA is found, non-tuberculous causes are likely, and further tests such as cytology 
or pericardial biopsy are indicated to determine the cause.  
 
The cytopathological analysis of tuberculous pericardial exudates demonstrated two 
distinct differences between pericardial and pleural tuberculous exudates. First, 
mesothelial cells were present in the majority of tuberculous pericardial aspirates, and 
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second, almost 30% of tuberculous pericardial exudates displayed neutrophilic 
dominance, whereas tuberculous pleural exudates are characterised by prominent 
lymphocytosis and virtually complete absence of mesothelial cells (Spriggs and 
Boddington, 1960; Yam, 1967, Gresham, 1989). Consequently, strict applicarionof 
the cytodiagnostic criteria that had been developed for the diagnosis of pleural TB 
resulted in a low diagnostic yield for pericardial TB. However, the finding of 
pericardial lymphocytosis was nevertheless 73% sensitive and 79% specific for a 
diagnosis of pericardial TB. The literature is vague about pericardial lymphocytosis; it 
is mentioned but has to the best of our knowledge not been quantified (Harvey and 
Whitehill, 1937; Hopewell, 1994; Cherian et al, 2004). Our study illustrated the useful 
role of pericardial cytology for the diagnosis of malignant effusions (Reyes et al, 
1982; Pozniak et al, 1986; Di Bonito et al, 1990), and as a screening tool for septic 
pericarditis. Finding a purulent exudate does however not exclude TB, and has also 
been described for SLE, rheumatoid arthritis, and various fungal infections (Gresham, 
1989, Meyers et al, 1997). Further investigations such as Gram stain, bacterial culture 
and TB culture are necessary. If possible, determining IFN-γ levels would be the ideal 
investigation. Significantly elevated levels of IFN-γ were demonstrated in tuberculous 
pericarditis compared to non-tuberculous pericardial effusions (p<0.00005), and 
importantly, concentrations never exceeded 50 pg/mL in any of the non-tuberculous 
effusions. Using a cut-off level of 50 pg/mL as being diagnostic for tuberculous 
pericarditis resulted in 92% sensitivity, 100% specificity and a diagnostic efficiency 
of 94% and the diagnostic usefulness was not influenced by HIV infection. The 
underlying immunological principle has resulted in the development of the highly 
sensitive and accurate enzyme-linked immunospot (ELISPOT) test that detects IFN-γ 
producing T-cells specific for M. tuberculosis antigen (Ewer et al, 2003; Liebeschuetz 
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et al, 2004). The ELISPOT test is very useful to detect tuberculous infection, but it 
does not differentiate between latent infection and active disease, which is a major 
problem for use in TB endemic areas. The diagnostic utility of currently available 
IFN-γ assays is unfortunately seriously limited by technical and financial constraints. 
 
Less sensitive, but related to the ELISPOT test is tuberculin skin testing where a T 
cell mediated immune response to an intradermally injected dose of purified protein 
derivative (PPD) is quantified by measuring the diameter of skin induration 48-72 
hours after injection. Our study confirmed lack of specificity for the diagnosis of 
active TB. At a cut-off level of 10 mm skin induration we observed 89% sensitivity 
and 56% specificity for correct diagnostic classification. The high proportion of “false 
positive” tests (44% of patients with non-tuberculous effusions) is similar to 
previously reported rates of 30–40% (Fowler, 1991). A strongly positive tuberculin 
skin test increases the suspicion of pericardial TB, but it is important to realise that a 
negative result (11% of TB patients in our study) does not exclude tuberculous 
disease, and the response to tuberculin may be affected by HIV infection, malnutrition 
and the time of presentation (Fowler and Manitas, 1973; Rooney et al, 1970; Pozniak 
et al, 1994; Trautner and Darouiche, 2001).  
 
The use of PCR for the detection of M. tuberculosis provides a test with high 
specificity for the diagnosis of pericardial TB; however, we observed a low diagnostic 
sensitivity of 32%. This surprisingly poor sensitivity has also been reported in 
tuberculous pleural effusion (Vlaspolder et al, 1995) and pericardial effusion studies 
(Cegielski et al, 1997), where corresponding sensitivity ranged between 15-20% and 
specificity between 96-100%, respectively. Explanations for the poor sensitivity of 
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PCR in tuberculous exudates include poor specimen preparation, the presence of 
inhibitors such as fibrin, haemoglobin, as well as low numbers of tubercle bacilli or 
their DNA in the specimens (Kox et al, 1994; Ferrer, 1997). Sensitivity is much better 
when pericardial tissue is used for analysis by PCR analysis (Cegielski et al, 1997; 
Rana et al, 1999). Recently, concerns have been raised about false positive results 
with PCR (Lee et al, 2002). Overall, PCR has not provided the answers to the quest 
for a sensitive, specific and cost-effective tool for the diagnosis of TB.  
 
For 2003, the WHO reported 8.8 million new cases of TB and an estimated 1.7 
million TB deaths, including 229 000 coinfected with HIV (WHO report, 2005). The 
majority of TB cases come from of South East Asia, however most cases of HIV and 
TB co-infection were reported in sub-Saharan Africa (WHO report 2005). These 
regions are characterised by serious lack of financial resources and almost complete 
absence of diagnostic infrastructure (Cegielski et al, 1994; Maher and Harries, 1997; 
Thwaites et al, 2002). Our study demonstrates the potential usefulness of a basic 
diagnostic rule that assists clinical decision-making and could be applied in resource 
poor settings. We developed this diagnostic aid by identifying independently 
predictive clinical features and basic laboratory tests. In our study, the features of 
pericardial effusion and cardiac compression (jugular distension, soft heart sounds, 
pulsus paradoxus, Kussmauls’s sign, ankle oedema, hypotension) were similarly 
distributed among tuberculous patients and non-tuberculous patients; this concurs 
with previous reports in the literature (Schepers, 1962; Hageman et al, 1964; Rooney 
et al, 1970; Fowler and Manitas, 1973; Gooi and Smith 1978; Ortbals and Avioli, 
1979; Desai, 1979; Fowler, 1991).  
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Univariate analysis of the admission variables suggested a set of potentially 
discriminative clinical features, including cough, fever, night sweats, weight loss and 
lymphadenopathy. In addition, patients with tuberculous pericarditis have higher 
serum globulin levels than non-tuberculous patients, and will usually not present with 
peripheral blood leukocytosis. Multivariate logistical regression and CART analyses 
identified five of these features that were independently predictive of distinction 
between tuberculous and non-tubercuous pericarditis, namely fever, night sweats, 
weight loss, globulin level and peripheral leukocyte count  (Table 5.5). Based on the 
respective odds ratio for each of these five variables, we developed a weighted score 
or diagnostic index that if added together would amount to a potential maximum score 
of 10 (Table 5.5). By using a ROC curves we demonstrated the best diagnostic 
efficiency for the training and the test set at a total score of 6. Results for the 
prediction model applied to the training data demonstrated 86% sensitivity and 87% 
specificity for the diagnosis of TB, whereas application to the test set resulted in 84% 
sensitivity and 78% specificity. Our suggested diagnostic rule was therefore: if the 
patient has a total diagnostic index score of 6 or more, he or she has tuberculous 
pericarditis, and if the patient has a score of less than 6 he or she has non-tuberculous 
pericarditis. In spite of the simplicity of the rule, the diagnostic results are similar or 
better than those reported for culture or pericardial histology (Strang 1984; Fowler, 
1991; Zayas et al, 1995). Major advantages of this proposed diagnostic rule include 
the non-invasiveness, availability, cost-effectiveness and the rapidity of the laboratory 
tests. However, the predictive value of this diagnostic rule may be influenced by the 
prevalence of HIV and TB. In a setting with a substantially different TB and HIV 
prevalence than that of the Western Cape, these predictors should not be used without 
prospective evaluation in those settings.  
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The strength of association between HIV infection and tuberculous pericarditis cannot 
be overemphasised. Pericardial effusion is recognised as one of the early presenting 
features of HIV infection in sub-Saharan Africa (Cegielski et al, 1990; Taelman et al, 
1990; Cegielski et al, 1994), and the disease has been ascribed to TB in as many as 
100% of cases (Cegielski et al, 1994; Longo-Mbenza et al, 1997). In our series, TB 
caused 94% of cases, and only three out of 84 HIV positive patients were diagnosed 
with non-tuberculous aetiology, including two cases of septic pericarditis. Univariate 
analysis demonstrated significantly higher frequency of lymphadenopathy, weight 
loss, and oral candidiasis in HIV positive TB patients compared with the HIV 
negative group. The differential diagnosis of pericarditis in HIV positive individuals 
includes other opportunistic infections (bacterial, fungal, protozoal or viral), Kaposi’s 
sarcoma, lymphoma, uraemia, and idiopathic pericarditis (Acierno, 1990; Reynolds et 
al, 1992; Kwan et al, 1993).  In our experience septic pericarditis was the most likely 
non-tuberculous cause, and it was characterised by a pericardial fluid 
lymphocyte/neutrophil ratio <0.5, peripheral blood leukocyte counts >10x109/L, 
peripheral blood neutrophil counts >7x109/L and pericardial leukocyte count 
>2x109/L.  
 
By combining the predictive attributes of four widely available laboratory tests into a 
diagnostic classification tree (Figure 5.3.) we achieved our aim of developing a tool 
that is sensitive, specific, rapid and relatively inexpensive. HIV serology, pericardial 
ADA activity, peripheral blood leukocyte count and pericardial differential leukocyte 
do not require sophisticated technology and can be performed in rural hospitals. ADA 
is an enzyme that is stable for at least 24 hours at 25°C, 7 days at 4°C and 3 months at 
-20°C (Ellis and Goldberg, 1970; Heinz, 1984). The major advantage of determining 
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ADA activity lies in the fact that it can be determined within hours by a simple hand-
method requiring only a spectrophotometer (Burgess et al, 2002b). It is thus possible 
to perform this analysis in basic peripheral and rural laboratories. Application of the 
entire patient data set to the classification tree resulted in a sensitivity of 96%, a 
specificity of 97%, and a diagnostic efficiency of 96%, and the diagnostic utility was 
not influenced by inclusion or exclusion of the patients with “probable TB”. In 
settings where it is not possible to measure ADA activity and whenever 
pericardiocentesis cannot be done we suggest the use of the diagnostic rule, using a 
score of 6 or more as a predictor of pericardial TB. The likelihood of TB increases 
with an increase in the total diagnostic index. The predictive value of characteristic 
clinical features and diagnostic tests used for the determination of tuberculous 
aetiology is influenced by the prevalence of HIV and TB infection in the population 
studied. In areas of substantially different HIV and TB prevalence to those of 
Southern Africa the diagnostic classification tree and the diagnostic rule should not be 
used until prospectively assessed for diagnostic accuracy in such an area.  
 
When available, IFN-γ is the diagnostic tool of choice and should be used to aid in the 
rapid diagnosis of pericardial TB. It can be used effectively in combination with ADA 
and pericardial cytology to confirm or exclude contentious cases. The diagnostic 
utility of currently available IFN-γ assays is however, seriously limited by technical 
and financial constraints.  
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Chapter 6 
THE ROLE OF ELECTROCARDIOGRAPHY AND 
RADIOGRAPHY IN PERICARDIAL DISEASE 
 
Echocardiography is the most useful test for the diagnosis of pericardial disease, but 
where not available, electrocardiography and chest radiography (CXR) have to be 
alternatives. Several studies have found the 12-lead electrocardiogram (ECG) to be 
helpful in the diagnosis of pericarditis. Electrocardiographic changes have been 
described in 50-70% of patients presenting with pericarditis (Fowler, 1992). The 
presence of micro-voltage has been reported to correlate with a large effusion size and 
the presence of electrical alternans and PR segment depression was found to be 
specific for the presence of cardiac tamponade (Eisenberg et al, 1996; Spodick, 1997). 
The majority of studies have been conducted in patients with characteristics that differ 
from our population. In published studies, tuberculous pericarditis was rare, whereas 
the majority of pericardial effusions in our hospital are attributable to TB. The 
classical finding on chest X-ray (CXR) is an enlarged globular cardiac shadow with a 
clear margin due to impaired movement of the distended pericardium (Commerford 
and Strang, 1991). It is not clear how the CXR assists in diagnosing the underlying 
cause for large pericardial effusions. According to the literature, less than one third of 
patients with tuberculous pericardial effusions have any evidence of active pulmonary 
tuberculosis (TB) on CXR (Strang et al, 1988; Lorell, 1997).   
 
The aim of this study was thus to evaluate the usefulness of electrocardiography and 
chest radiography in patients presenting with large pericardial effusions. 
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PATIENTS AND METHODS 
All new patients that were referred between February 1995 and June 1999 and had 
echocardiographically confirmed large pericardial effusions, with an epi-pericardial 
separation of more then 10 mm, underwent the following diagnostic work up: history, 
physical examination, 12-lead surface ECG (MAC, Marquett Electronics, Inc; 
Milwakee, Wisconsin; paper speed 25 mm/sec), CXR with postero-anterior and lateral 
views, and two dimensional echocardiographic studies (Hewlett Packard, Sonos 2000 
Phased Array Imaging System). The location (anterior, apical, posterior, inferior, 
circumferential), measured epi-pericardial distance (mm), presence and amount of 
epicardial thickening  (mm), presence of fibrin strands, signs of tamponade (at least 
30% of the right atrial wall inverted during late diastole/early systole, inward motion 
of the right ventricular wall in early diastole persisting after mitral valve opening), 
and presence and localization of constriction were determined, followed by 
pericardiocentesis and drainage by an indwelling pig-tail catheter. The amount of 
drained effusion was measured. Four groups of patients were identified according to 
the amount that was drained, namely < 499 mL, 500-999 mL, 1000-1499 mL, > 1500 
mL, respectively.  
 
The admission CXR was studied in detail by a radiologist and two physicians, all of 
whom were blinded to the clinical diagnosis. The following radiological parameters 
were noted: the cardio-thoracic ratio (CTR), presence of pericardial or pleural 
calcifications, presence of pleural effusions, mediastinal lymphadenopathy, 
pulmonary mass lesion, features of disseminated TB, alveolar infiltrates and evidence 
of cavitatory lesions.  The admission ECG was evaluated by two physicians with 
regards to various parameters, including rate, rhythm, and presence of micro-voltage, 
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electrical alternans, PR segment abnormalities, J-ST segment abnormalities, and T 
wave abnormalities. Micro-voltage was diagnosed when all limb lead complexes were 
<5 mm, and or all precordial leads complexes <10 mm.  
 
RESULTS 
Poor quality radiographs and those of patients with “probable” TB were excluded. A 
radiologist and two physicians who were not aware of the aetiological diagnosis 
evaluated 129 radiographs, including the radiographs of 90 patients with tuberculous 
pericardial effusions and 39 individuals with non-tuberculous pericardial effusions. 
The aetiology of these non-tuberculous effusions included malignancy (n=17), septic 
pericarditis (n=3), uraemic pericarditis (n=6), systemic lupus erythematosus (n=5), 
rheumatoid arthritis (n=1), scleroderma (n=1), post-traumatic pericarditis (n=4), and 
idiopathic pericarditis (n=2). Forty-three of the subjects were HIV positive, including 
41 patients who presented with tuberculous pericarditis and two patients who were 
diagnosed with pericardial sepsis. The median (range) CD4+ lymphocyte count of the 
HIV positive patients was 266 (34–1006) cells/μL. The echocardiographic data are 
presented in Table 6.1. There was no significant difference between the HIV positive 
and HIV negative patients with regards to the amount of pericardial fluid drained or 
the echocardiographic findings. All 129 radiographs revealed enlarged cardiac 
silhouettes (cardio-thoracic ratio >0.55). The radiographic findings are summarised in 
Table 6.2. In ten tuberculous pericarditis patients, the CTR was >0.75. Eighteen 
patients who presented with non-tuberculous pericarditis (46%) and 45 of the 
pericardial TB patients (50%) had radiological evidence of pleural effusions, with no 
significant difference between HIV positive and negative individuals. In the 
tuberculous  group 12  patients  presented  with bilateral  effusions compared  to 15  
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Table 6.1. Echocardiographic data of patients presenting with pericarditis 
 
   
Parameter 
TB/HIV+  
(n=41) 
TB/HIV–  
(n=49) 
Non-TB  
(n=39) 
Presence of tamponade 37 (90%) 44   (90%) 30   (78%) 
Presence of fibrin strands 26   (63%) 32   (65%) 16   (41%) 
Effusive constriction 2   (5%) 3   (6%) 2   (5%) 
Pericardial thickness (mm) 6.7 6.8 6.3 
Volume of aspirate (mL) *  
[Median (range)] 
816 (250 – 1 800) 832 (250 – 2 700) 678 (80-1450) 
 
* Volumes not available for 7 patients (HIV+: n=1, HIV-: n=2, non-TB: n=4)  
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Table 6.2. Summary of CXR findings of patients presenting with pericarditis 
   
 
Variable 
TB/HIV+  
(n=41) 
TB/HIV–  
(n=49) 
Non-TB  
(n=39) 
CTR > 0.55 and ≤ 0.75 39   (95%) 41   (84%) 39   (100%) 
CTR > 0.75 2   (5%) 8   (16%) 0 (0%) 
Pleural effusion 20   (49%) 25   (51%) 18   (46%) 
Left-sided pleural effusion 
Right-sided pleural effusion 
Bilateral pleural effusion 
7   (17%) 
8   (20%) 
5   (12%) 
8   (16%) 
10   (20%) 
7   (14%) 
6   (15%) 
7   (18%) 
5 (13%) 
Mediastinal lymphadenopathy 5   (12%) 2   (4%) 2  (5%) 
Disseminated TB 2   (5%) 2   (4%) 0   (0%) 
Alveolar infiltrates with cavitation 2   (5%) 5   (10%) 0   (0%) 
Alveolar infiltrates without cavitation 2   (5%) 2   (4%) 1   (3%)  
Bronchopneumonia 1   (2%) 2   (4%) 2   (5%) 
Consolidation pneumonia 2   (5%) 0   (0%) 1    (3%) 
Pulmonary mass lesion 0   (0%)  0   (0%)  2   (5%)  
 
CTR = cardio-thoracic ratio 
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patients with left-sided and 18 with right-sided pleural effusions. In HIV positive TB 
patients, the median (range) CD4+ lymphocyte count was significantly higher in 
patients with pleural effusions than in those without pleural effusions [312 (34–1006) 
cells/μL versus 144 (39–445) cells/μL, respectively; p< 0.05]. 
 
It was generally difficult to evaluate the hilar region, especially on the left side, due to 
the cardiac enlargement and displacement of anatomical structures. Two patients who 
presented with malignant pericardial effusions demonstrated radiographic evidence 
for mediastinal lymphadenopathy. Among the tuberculous patients, four were 
identified with right-sided mediastinal lymphadenopathy and three had bilateral 
mediastinal node enlargement; five of these seven patients were HIV positive. Seven 
patients had radiographic evidence of cavitatory disease and six of these were found 
to be sputum smear positive for M. tuberculosis. A total of 27 patients (30%) 
presented with radiographic features suggestive of active pulmonary TB, and a further 
six individuals diagnosed with tuberculous pericardial effusions had radiological 
features of pulmonary fibrosis suggestive of previous TB (6.7%). Four TB patients 
had calcified nodules suggestive of a healed Ghon focus (4.4%). 
 
The amount of pericardial fluid drained at initial pericardiocentesis correlated with the 
radiographic finding of cardiac enlargement, as summarised in Table 6.3. In patients 
displaying a CTR between 0.55 and 0.75, the median (range) amount of fluid drained 
by pericardiocentesis was 795 (250–1800) mL, whereas in those with a CTR > 0.75, it 
amounted to 1605 (1400–2700) mL. Two of the HIV-infected TB patients had a CTR 
> 0.75 compared with eight TB patients who were HIV negative. No pericardial 
calcifications were noted on CXR. 
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Table 6.3. Cardio-thoracic ratio and amount of pericardial aspirate in 
patients presenting with pericardial effusion (n=122) 
 
Amount of pericardial aspirate (mL) 
Range Mean (SD) 
Mean (SD) cardio-
thoracic ratio 
n* 
<500 398.8 (82.6) 0.68 (0.12) 32 
500 – 999 703.6 (124.8) 0.69 (0.17) 55 
1 000 – 1 499 1 223.1 (96.7) 0.72 (0.16) 26 
>1 500 1 770.0 (226.4) 0.77 (0.18) 9 
 
* Volumes not available for seven patients (HIV+: n=1, HIV-: n=2; non-TB: n=4) 
 
 117
Electrocardiography 
We evaluated the 12-lead surface ECG of 88 patients who presented with tuberculous 
pericarditis patients. Thirty-nine of these 88 patients were HIV positive patients 
(44%), and there were no significant differences in the amount of drained effusions, 
the ECG or echocardiographic findings between the HIV positive or and the HIV 
negative TB patients. The majority presented with a sinus tachycardia (73%), and 
there was no correlation between the size of the effusion and the rate or rhythm. 
Thirty-three patients (38%) had micro-voltage in the extremity and/or precordial leads 
and were found to have significant larger effusions than patients without micro-
voltage (918 mL versus 740 mL; Table 6.4.). 
 
Seventy-four patients (84%) presented with ECG changes of chronic pericarditis 
characterised by iso-electric PR segments and T-wave flattening/inversion compared 
to 14 patients who demonstrated ECG changes compatible with acute or subacute 
pericarditis (iso-electric or depressed PR segment with or without ST segment 
elevation; Spodick, 1997).  Patients who presented with the ECG changes of chronic 
pericarditis were more likely to have larger effusions than those presenting with acute 
or subacute ECG changes.   
 
The presence of micro-voltage (<5mm) in the extremity leads was 45% sensitive and 
75% specific for the presence of cardiac tamponade compared with a sensitivity of 
25% and a specificity of 69% when micro-voltage (<10mm) was present in the 
precordial leads alone. 
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Table 6.4. ECG parameters in correlation to amount of pericardial aspirate  
 
ECG parameter Amount aspirated (mL) Number of patients 
Micro-voltage in extremity leads 874 20 (23%) 
Micro-voltage in precordial leads 1175 4 (5%) 
Micro-voltage in both 903 9 (10%) 
No micro-voltage  740 55 (63%) 
PR-segment depression 654  24 (27%) 
Electrical alternans 827  43 (49%) 
Tachycardia 825 69 (78%) 
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DISCUSSION 
In many TB endemic areas clinicians do not have access to echocardiography, but 
when available, the sonographic detection of intrapericardial fibrinous strands and the 
presence of prominent pericardial thickening is suggestive of tuberculous aetiology. 
Liu et al (2001) went as far as describing these features diagnostic of pericardial TB. 
In our series, fibrinous strands and pericardial thickening were generally more 
prominent and occurred more frequently in tuberculous disease, but were also 
demonstrated in cases of septic, malignant and post-traumatic pericardial effusion. 
However, when echocardiography is not available, the diagnosis of pericardial 
effusion needs to be based on clinical features, chest radiography and in some cases 
electrocardiography.  
 
Enlargement of the cardiac silhouette on CXR does not usually occur until ≥250 mL 
of fluid have accumulated in the pericardial space (Lorell, 1997). Classically, the 
presence of a pericardial effusion is suspected when a rapid increase in the size of the 
cardiac silhouette is seen in the presence of clear lung fields. In some cases, the heart 
may assume a globular or “water bottle” shape, blurring the contours along the left 
cardiac border and obscuring the hilar vessels (Strang, 1984; Lorell, 1997). The 
parietal pericardial and epicardial fat layers are normally 1-2 mm apart. The presence 
of an effusion may result in more marked separation of the pericardial fat lines, 
apparent on high-quality frontal or lateral chest films in about 25% of patients with 
pericardial effusions (Carsky et al, 1980). The fact that all our patients had enlarged 
cardiac silhouettes confirms that there is a good correlation between the 
sonographically confirmed diagnosis of large pericardial effusions and CXR. A study 
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conducted in Harare, Zimbabwe also found that 100% of patients with tuberculous 
pericarditis had a CTR > 55% (Hakim et al, 2000).  
 
The 50% proportion of tuberculous patients in this study with radiological evidence of 
pleural effusions is higher than the 30% previously reported (Strang et al, 1988), but 
in keeping with necropsy data. Rooney et al (1970) found that 50% of patients with 
tuberculous pericarditis had necropsy evidence of pleural effusion due to tuberculous 
pleuritis. In our study, right-sided pleural effusions occurred slightly more frequently 
than left-sided effusions. These results differ from previous studies in which it was 
found that pericarditis is more strongly associated with left-sided pleural effusions 
(Spodick, 1973; Weiss and Spodick, 1983). These studies were, however, not 
performed in TB endemic areas. The effusions seen in the present study could have 
developed either as a result of congestion or as part of a pleural immune response 
against tubercular antigens (Ferrer, 1997). In our study, mycobacteria were cultured 
from the pleural fluid of six individuals. 
 
Median CD4+ lymphocyte counts were found to be higher in those HIV positive 
patients who presented with pleural effusions (median CD4+ lymphocyte count of 
312 cells/μL) than those that did not have pleural effusions (median CD4+ 
lymphocyte count of 144 cells/μL). In a similar study, the prevalence of pleural 
effusion in tuberculous HIV patients with CD4+ lymphocyte counts greater than 200 
cells/μL was 27%, while it was only 10% in HIV patients with TB and CD4+ 
lymphocyte counts of less than 200 cells/μL (Jones et al, 1993). It is possible that a 
more vigorous immune response seen in patients with higher CD4+ lymphocyte cell 
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counts is responsible for pleural effusions that are larger and more easily detectable 
by chest radiograph.  
 
The radiological evidence of active pulmonary TB in 30% of our patients confirms 
previous results (Strang et al, 1988). Although this finding emphasises the importance 
of chest radiography in the search for supportive evidence for tuberculous aetiology, it 
also demonstrates the relative insensitivity theory. The correlation between cavitatory 
TB and smear positivity is well documented (Beyers, 1991). Four of the six patients 
with mediastinal lymphadenopathy were HIV positive. Generalised lymphadenopathy 
was noted in more than half of the HIV positive patients in the current study and is 
related to B cell and CD8+ lymphocyte cell hyperactivity caused by HIV (Jacobson et 
al, 1991). Individuals with dual infection of TB and HIV are particularly prone to 
significant mediastinal lymphadenopathy (Chaisson et al, 1987; Barnes et al, 1991; 
Saks and Posner, 1992; Barnes et al, 1993; Jones et al, 1993). Mediastinal 
lymphadenopathy is much better visualised by chest CT (computerised tomography) 
than by chest radiograph, and detects enlarged mediastinal lymph nodes in virtually 
100% of patients with pericardial TB (Cherian et al, 2003b). Enlarged nodes 
disappeared or regressed with specific anti-tuberculous therapy (Cherian et al, 2003b).  
 
The presenting ECG in patients diagnosed with tuberculous pericarditis is generally 
considered to show non-specific changes, usually T wave inversion (Rooney et al, 
1970; Strang, 1984; Cegielski et al, 1994). Changes of acute pericarditis have been 
reported in 9% of patients, while micro-voltage was found in 34% (Rooney et al, 
1970). In our study, most patients (84%) presented with ECG changes of chronic 
pericarditis, and 38% of our patients had micro-voltage in either the extremity, or the 
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precordial or both leads. Five patients (6%) presented with atrial fibrillation, 
confirming previous reports (Meyers et al, 1993; Spodick, 1997). Uncomplicated 
acute pericarditis does not produce significant rhythm disturbances unless there is 
underlying cardiac disease, either pre-existing or myocarditis.  
 
In our study, the presence of micro-voltage in the extremity leads was 45% sensitive 
and 75% specific for the presence of cardiac tamponade and presence of micro-
voltage in extremity leads corresponded to a sensitivity of 25% and a specificity of 
69%, which supports published data. Eisenberg et al (1996) reviewed the 
electrocardiograms of 136 patients with echocardiographically diagnosed pericardial 
effusions and found that low voltage was associated with moderate and large 
effusions and the presence of tamponade, whereas Meyers et al (1993) demonstrated a 
weak correlation between QRS voltage and effusion size. In our study, cardiac 
tamponade was less likely in the absence of micro-voltage than when it was present.  
 
CONCLUSION 
In developing countries, where TB is usually more prevalent than in industrialized 
nations, CXR plays an important role in the identification of large pericardial 
effusions. The degree of radiographic cardiomegaly correlates well with the amount 
of pericardial fluid aspirated at the time of pericardiocentesis, and a chest radiograph 
may contribute to the diagnosis of coexistent pulmonary TB. Radiographic evidence 
of mediastinal lymphadenopathy is suggestive of co-infection with HIV. The presence 
of micro-voltage on ECG points towards the presence of a large pericardial effusion. 
Importantly, in the absence of micro-voltage, it is unlikely that the patient suffers 
from cardiac tamponade. Our study demonstrates that CXR and electrocardiography 
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can be useful screening tools for the diagnosis of pericardial effusion and aid patient 
management. 
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Chapter 7 
THE USE OF ADJUNCTIVE CORTICOSTEROIDS IN 
THE MANAGEMENT OF TUBERCULOUS 
PERICARDIAL EFFUSIONS 
 
Pericardial disease accounts for about 10% of all patients who are hospitalised for 
cardiac impairment in developing countries (Maharaj, 1991), the most common cause 
being tuberculosis (TB). Before the introduction of anti-tuberculous drugs and 
improved anaesthetic and surgical techniques, tuberculous pericarditis was usually 
fatal (Harvey and Whitehill, 1937). The mortality has since decreased to between 17% 
and 40% (Rooney et al, 1970; Desai, 1979; Bhan, 1980).  
 
Tuberculous pericarditis is routinely treated with pericardiocentesis (Harvey and 
Whitehill, 1937) and chemotherapeutic agents (including isoniazid, pyrazinamide, 
rifampicin and ethambutol; Department of Health, 1996). Although national 
guidelines recommend six months of intensive therapy (Department of Health, 1996), 
some experts recommend longer regimens ranging from nine (Sagrista-Sauleda et al, 
1988; Fowler, 1991) to 12 months (Koh et al, 1994). Uncertainty exists as to whether 
the treatment duration should be altered in human immunodeficiency virus (HIV) 
positive individuals. Higher rates of side effects from standard treatment regimens and 
higher relapse rates have been described in these patients (Harries, 1990), although 
this finding has not been consistent (Harries, 1990; de Cock et al, 1992). 
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The use of adjunctive corticosteroid therapy, together with anti-tuberculous drugs 
administered as standardized directly observed short-course treatment (DOTS), 
remains topical in the treatment of tuberculous pericarditis. Rapid improvement of 
symptoms and reduced mortality has been suggested following the use of oral 
adjunctive corticosteroids (Rooney et al, 1970; Bhan, 1980; Strang et al, 1987; Strang 
et al, 1988; Spodick, 1994). However, their use in HIV positive individuals may 
increase the risk of bacterial and viral infections (Gill et al, 1989; Eliott et al, 1992; 
Clifford et al, 1993). The risk of systemic infection may be reduced by the delivery of 
steroids directly into the epicardial space. Quigg et al (1985) successfully treated 
patients with uraemic pericardial effusions by pericardiocentesis with an indwelling 
catheter followed by a stat instillation of a nonresorbable steroid, triamcinolone 
hexacetonide, into the pericardial space. This procedure has not previously been 
tested in patients presenting with tuberculous pericarditis.  
 
The aims of this study were: (i) To assess the role of adjunctive corticosteroid therapy 
with regards to mortality and the prevention of constrictive pericarditis; (ii) To 
compare the administration of conventional oral corticosteroid therapy with 
intrapericardial triamcinolone hexacetonide; and (iii) To assess the impact of HIV co-
infection on the clinical course of patients with tuberculous pericardial effusions, as 
well as the effects of therapy in these patients. 
 
PATIENTS AND METHODS 
Patients presenting to the Cardiology Unit of Tygerberg Academic Hospital, Western 
Cape, South Africa with large tuberculous pericardial effusions requiring diagnostic 
and/or therapeutic pericardiocentesis from February 1997 to June 2000 were screened 
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for possible enrolment into this randomised trial. The study was approved by  the 
Ethics Committee of Stellenbosch University and was conducted in accordance with 
the Declaration of Helsinki. All patients gave written informed consent and received 
counselling for HIV antibody testing. Baseline demographic, clinical, 
echocardiographic and electrocardiographic data were also obtained. 
 
Patient selection and management 
All patients met the following inclusion criteria: (a) age 13-75 years; (b) large 
pericardial effusion on echocardiography (epi-pericardial distance >10 mm); (c) 
pericardial aspirate with protein content >30 g/L and (d) pericardial fluid adenosine 
deaminase (ADA) activity >35 U/L.   
 
Exclusion criteria are summarised in Table 7.1. Patients with CD4+ lymphocyte 
counts <200 cells/μL were excluded due to uncertainty as to what the effects of 
corticosteroids would be on immunocompromised patients with TB with regards to 
risk for disseminated disease. In addition, patients presenting with signs of 
constrictive pericarditis or requiring pericardial surgery within the first five days of 
admission were excluded. 
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Table 7.1. Summary of ineligible patients who presented with tuberculous 
pericarditis (n=38) 
 
 
Exclusion criteria 
Number of 
patients 
(n=38) 
Baseline 
constriction 
(n=6) 
Deaths
 
(n=16) 
 
CD4+ lymphocyte cell count <200 cells/μL 
Lymphocyte count <0.8 x 109/L 
DTB / lymphocyte count <0.8 x 109/L 
Early death/lymphocyte count <0.8 x 109/L 
Early pericardial surgery 
Blocked drainage tube 
Left ventricular ejection fraction <35% 
Severe fibrotic lung disease 
21 
4 
1 
1 
5 
1 
2 
3 
3 
0 
0 
0 
2 
0 
1 
0 
 
4 
3 
1 
1 
1 
1 
2 
3 
 
 
DTB = disseminated tuberculosis 
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The pericardial effusion was drained by echocardiographically guided aspiration via 
an indwelling pigtail catheter (Louw et al, 2002; Reuter and Doubell, 2002); the 
intention of this procedure was complete pericardial drainage. Chest radiography 
(CXR) was performed thereafter to exclude a pneumothorax and to evaluate the lung 
fields. The patient was then admitted into a general medical ward. The catheter was 
kept in situ to allow daily intermittent drainage and was removed when the daily 
aspirate was <100 mL, when it became blocked, or when there was evidence of 
localised skin infection. During hospitalisation, patients were examined twice daily 
for fever, change in haemodynamic status, and clinical evidence of localised skin 
and/or pericardial infection.  
 
A standard short course anti-tuberculous regimen was initiated according to national 
guidelines, namely a combination of rifampicin, isoniazid, pyrazinamide and 
ethambutol for two months, followed by rifampicin and isoniazid for a further four 
months (Department of Health, 1996). An unblinded, independent physician then 
randomised patients to one of the following groups: (i) Triamcinolone group: 200 mg 
(5 mL) intrapericardial triamcinolone hexacetonide (n=17); (ii) Prednisone group: 
Oral prednisone plus intrapericardial placebo (5 mL 0.9% saline solution; n=16). Oral 
prednisone was started at 60 mg/day for four weeks, followed by 30 mg/day for four 
weeks, 15 mg/day for two weeks and 5 mg/day for one week; (iii) Placebo group: 5 
mL intrapericardial 0.9% saline (n=24).  
 
Triamcinolone was injected directly into the pericardium just prior to the removal of 
the indwelling catheter. Due to limited resources, an oral placebo was not used in 
conjunction with the intrapericardial triamcinolone.  
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Patients were discharged on anti-tuberculous therapy and pyridoxine, with or without 
adjunctive prednisone. HIV positive patients also received daily oral cotrimoxazole 
and multivitamin supplement; due to the prevailing national policy at the time of this 
study, none of these patients received antiretroviral therapy. The diagnostic protocol 
and methodology of the laboratory investigations have been described in Chapter 2.  
 
Follow-up assessment 
Patients were assessed one month after discharge and thereafter at three-monthly 
intervals for a minimum of one year. At follow-up visits, patients were assessed 
clinically for features of ongoing TB, immunodeficiency, pericardial disease 
(effusion, tamponade and constriction), side-effects of medication (anti-tuberculous 
drugs and prednisone), general sense of well-being and functional capacity. 
Therapeutic response was assessed as: (i) absence, improvement or worsening of 
exercise tolerance, dyspnoea, cough, ankle swelling, abdominal discomfort, chest 
pain, fever, night sweats and/or weight loss; (ii) absence, improvement or worsening 
of oedema, ascites, hepatomegaly, pleural effusion, raised jugular venous pressure 
(JVP), tachycardia, hypotension, pulsus paradoxus, Kussmaul’s sign, pericardial rub 
and/or pericardial knock; (iii) evidence of infection at the puncture site and/or the 
pericardial space; and  (iv) echocardiographic evidence of persisting or reaccumulated 
pericardial fluid or pericardial constriction and the subsequent need for 
pericardiectomy. Echocardiography was performed at baseline, at the first follow-up, 
and thereafter as clinically indicated.  
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Outcome measures 
The primary end point was all cause mortality. Secondary endpoints included: (i) 
death attributed to pericarditis; (ii) disability related to pericardial disease at one year 
follow-up visit, where disability is defined as a history of restricted physical activity 
(using New York Heart Association [NYHA] functional class), (iii) development of 
effusive constriction, and (iv) development of fibrous constrictive pericarditis 
requiring pericardiectomy. The diagnosis of constrictive pericarditis was made on the 
basis of a combination of clinical and echocardiographic features (Strang, 1984; 
Feigenbaum, 1986). The collected data was analysed by statistical methods described 
in Chapter 2.   
 
RESULTS 
A total of 134 patients were admitted to Tygerberg Academic Hospital with large 
pericardial effusions requiring pericardiocentesis between February 1997 and June 
2000. Ninety-five individuals (70.9%) were diagnosed with pericardial TB, 47 of 
whom tested HIV positive (49.5%). Based on pre-determined eligibility criteria, 57 
patients (60.0%) were enrolled into the study. The age of study subjects ranged from 
17 to 66 years, and included 23 females and 34 males. Reasons for patient ineligibility 
are shown in Table 7.1. The mean (SD) follow up period was 14.2 (2.3) months.  
 
Forty of the 57 patients (70.0%) had microbiological and/or histological evidence of 
TB; the remaining 17 patients (30.0%) were diagnosed by clinical and supportive 
laboratory data. Twenty-one of these patients (37.0%) were HIV positive. Baseline 
demographic, radiographic, electrocardiographic and echocardiographic findings were 
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similar between the three treatment groups, as were baseline diagnostic and other 
laboratory findings (including Adenosine deaminase [ADA] results). 
 
Clinical endpoints and complications   
Complications and observations of trial patients at follow-up are presented in Table 
7.2. All patients had a good clinical response to initial  pericardiocentesis. The 
duration of hospitalisation ranged from four to 30 days; although the hospitalisation 
duration was slightly lower in the two steroid groups compared to the placebo group, 
the difference was not statistically significant. There were no significant differences in 
the number of patients in each group that experienced minor complications such as 
localised pain, leakage at wound site and local skin infection. Two patients developed 
transient jaundice but still completed six months of anti-tuberculous therapy. Thirteen 
cases of infection were recorded during the follow-up period, including oral 
candidiasis (n=5), local skin infection (n=4), herpes labialis (n=2) and varicella zoster 
(n=2). These events occurred more frequently in the combined corticosteroid group 
(n=9; 27.2%) than in the placebo arm (n=4; 16.7%;  p=0.07). 
 
Two male patients (both HIV negative) developed effusive-constrictive pericarditis, 
which was diagnosed clinically and confirmed echocardiographically at the first 
follow up. Both patients were over 40 years of age with a positive smoking history. In 
addition, both patients had evidence of pulmonary infiltrates on CXR and had been 
investigated for pulmonary TB in the month preceding pericardial aspiration, 
suggesting the possibility of a more chronic form of pericardial TB. One patient 
(prednisone group) underwent surgical pericardial fenestration at six weeks, followed 
by total pericardiectomy at four months, and was entirely well at his one-year follow-
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up. The other patient (triamcinolone group) had relatively mild features and refused 
surgery. He was managed conservatively, and the features of constriction improved 
progressively and had subsided by the one-year follow-up. Echocardiography 
demonstrated pericardial thickening, which was still present at the two-year follow-
up, but not accompanied by features of constriction.  
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Table 7.2.   Complications and observations of trial patients at follow-up (n=57) 
 
 Prednisone 
(n=16) 
Triamcinolone 
(n=17) 
Placebo 
(n=24) 
Complications in hospital 
     Local pain 
     Repeat pericardiocentesis 
     Leakage at skin insertion 
     Local skin infection 
 
3 
1 
1 
0 
 
3 
0 
1 
1 
 
4 
1 
2 
1 
Duration of hospitalisation 
     Mean (SD) days 
     Range in days 
 
9.9 (5.1) 
4-21 
 
10.5 (4.4) 
4-19 
 
11.2 (5.3) 
4-30 
Complications as out-patient 
     Herpes labialis 
     Varicella zoster 
     Local skin infection 
     Effusive constriction 
     Fibrous constriction 
     Left ventricular aneurysm 
 
1 
1 
1 
1 
1 
0 
 
0 
1 
1 
1 
0 
1 
 
1 
0 
0 
0 
0 
0 
Surgical intervention 
     Pericardial fenestration 
     Total pericardiectomy 
 
1 
1 
 
0 
0 
 
0 
0 
Status at 1-year follow-up 
     Reduced level of activity 
     Raised JVP 
     Hepatomegaly 
     Failure to attend follow-up visit 
 
2 
1 
0 
4 
 
2 
1 
1 
1 
 
3 
2 
0 
4 
 
JVP =  jugular venous pressure 
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Seven patients (12.0%) complained of reduced levels of activity at their one-year 
follow up. Three of these patients (42.9%; all HIV positive) had no cardiac 
abnormalities and tests for disseminated TB and other opportunistic infections were 
negative. The other four patients (57.1%; of which one was HIV positive) were found 
to have an increased jugular venous pressure. Echocardiography confirmed cardiac 
abnormalities: two had pericardial thickening but no definitive evidence of 
constriction; the other two had left ventricular impairment with mild to moderate 
mitral and tricuspid regurgitation. The distribution of complications was similar 
between the three treatment arms (Table 7.2). No deaths were recorded for the study 
population, but nine patients (16.0%) failed to attend their follow-up appointments at 
six and 12 months.  None of these patients were admitted to Tygerberg Academic 
Hospital or any other public hospitals in the region for a period of two years after 
enrolment and all efforts to trace them failed. In addition, their names did not appear 
on the National Death Registry. The age distribution of these “non-attendees” ranged 
from 17 to 58 years. Four of the nine patients were HIV positive with baseline CD4+ 
lymphocyte counts of 392, 214, 256, and 243 cells/μL, respectively.  
 
An analysis of the outcomes of the 38 TB patients that were excluded from the 
randomised trial is presented in Table 7.1. All of these patients were treated by closed 
pericardiocentesis and concurrent early initiation of anti-tuberculous therapy. Patients 
with effusive constrictive pericarditis were treated by pericardial fenestration and 
adjunctive oral prednisone based on published recommendations (Strang et al, 1987; 
Strang et al, 1988). 
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DISCUSSION 
The present study suggests that echocardiographically guided closed 
pericardiocentesis with intermittent daily aspiration in combination with early 
initiation of anti-tuberculous therapy results in excellent outcomes in patients with 
effusive pericardial TB, irrespective of HIV status. Only two cases of effusive 
constrictive pericarditis developed during the first six months after enrolment. Both 
patients did well; one required total pericardiectomy due to symptomatic constriction, 
whereas the other improved without surgical intervention. The study was, 
unfortunately, underpowered to detect significant effects of adjunctive corticosteroids 
and a multi-centered study is required to assess larger number of patients in order to 
evaluate the potential benefit of adjunctive corticosteroids. 
 
The study also demonstrated that secondary skin infection occurs rarely when an 
aseptic technique is applied and no differences in the frequency of skin sepsis were 
noted between the various treatment groups. The incidence of systemic infections or 
HIV-associated complications such as opportunistic infections or malignancies was 
also similar in the three treatment categories. The use of adjunctive corticosteroids led 
to shortened hospitalisation with a mean (SD) duration of days in hospital for the 
prednisone, triamcinolone and placebo groups of 9.9 (5.1), 10.5 (4.4) and 11.2 (5.3), 
respectively. Differences between the two adjunctive corticosteroid and the placebo 
groups were statistically insignificant.  
 
The results of this study support the use of routine anti-tuberculous therapy for six 
months in both HIV positive and negative patients. There were no associated cases of 
multi-drug resistance, reactivation or dissemination of TB. HIV infected patients had 
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very similar outcomes to those that were HIV negative and based on our results, there 
is no reason to support prolonged treatment duration in individuals who have CD4+ 
lymphocyte counts > 200 cells/μL.   
 
Contrary to a number of other reports (Strang et al, 1987; Strang et al, 1988; Alzeer 
and Fitzgerald, 1993; Senderovitz and Viskum, 1994), the use of adjunctive steroids 
did not result in improved clinical outcome in patients with effusive tuberculous 
pericarditis. Our findings are in accordance with a systematic review concluding that 
prednisone has no clear beneficial effect in patients with tuberculous pericarditis 
(Mayosi et al, 2002). Effusive-constrictive pericarditis was an exclusion criterion in 
the present study, whereas other studies have described features suggestive of 
established or threatening effusive-constrictive pericarditis (Strang et al, 1987; Strang 
et al, 1988). In the Transkei, effusive constriction was considered to be a more 
common clinical variety than pericardial effusion or classical fibrous constrictive 
pericarditis (Commerford and Strang, 1991). It is thus necessary to recognize that 
different interventions may be required for specific clinical phases of the same 
disease. In an observational study, patients who had only 80-100 mL of fluid aspirated 
before treatment with high doses of oral prednisolone (including four weeks of 120 
mg daily) and where standard TB therapy was initiated, had rapid resolution of their 
effusions (Strang, 1994). A potential place for adjunctive corticosteroids may thus be 
for those patients who present relatively late and have features of effusive-constrictive 
disease at presentation (Strang et al, 1987; Strang et al, 1988), or those in whom 
pericardiocentesis is unsuccessful (Lorell, 1997). It has also been suggested that 
corticosteroids should be reserved for critically ill patients with recurrent large 
effusions who do not respond to pericardial drainage and anti-tuberculous drugs 
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alone. In view of the results of our study, no benefit was observed by using 
intrapericardial triamcinolone and we would thus recommend the use of oral 
corticosteroids in these cases.   
 
The present study also suggests that the mortality of HIV infected individuals (CD4+ 
lymphocyte counts >200 cells/μL) does not differ significantly from those who are 
HIV negative. This contradicts earlier reports suggesting a significantly higher 
mortality due to the increased likelihood of disseminated TB (Pozniak et al, 1994). In 
the present study, adjunctive steroids resulted in a tendency towards a higher number 
of minor infections; however, none of the patients developed oesophageal candidiasis, 
cryptococcal meningitis or other more serious opportunistic infections, malignancies, 
septicaemia, or pneumonia.  
 
Other researchers have found potentially harmful side effects related to the use of 
steroids in HIV infected individuals, including a higher incidence of bacterial 
infections, herpes simplex and herpes zoster reactivation, and potentially the 
development of Kaposi’s sarcoma (Schulhafer et al, 1987; Gill et al, 1989; Eliott et 
al, 1992). In a non-randomised study of TB in HIV positive patients, Elliott and 
colleagues (1992) reported increased risk for herpes zoster and Kaposi’s sarcoma in 
patients treated with prednisone, but in the study of Hakim and colleagues (2000), 
Kaposi’s sarcoma occurred only in patients who were not on steroids. None of the 
HIV patients in the present study developed constriction and it has been postulated 
that the rate of constriction is reduced by HIV infection (Hakim et al, 2000). Hakim 
and colleagues (2000) observed a trend towards improved survival but no reduction in 
the occurrence of constriction in the adjunctive steroid group. In keeping with our 
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results, the latest version of the Cochrane systematic review (which includes Hakim’s 
study) revealed that the results of all published studies are still inconclusive and that 
there is uncertainty regarding the effectiveness of steroids in patients with tuberculous 
pericarditis (Mayosi et al, 2002; Ntsekhe et al, 2003).  
 
Our study has a number of weaknesses, most notably the fact that 16.0% of patients 
did not attend their 6-month and/or one-year follow-up visits and that data on 
mortality and constriction may therefore be incomplete. The poor follow-up rate 
probably reflects the impact of migratory lifestyles on health care in poorer socio-
economic regions of South Africa. It could also be argued that an oral placebo should 
have been used in combination with the intrapericardial placebo. At the time of study 
planning, the role of corticosteroids in HIV infected patients was unclear and it was 
decided to expose only those with CD4+ lymphocyte counts >200 cells/μL. Twenty-
one potential patients were not enrolled due to this reason. An analysis of these 
patients confirmed an increased rate of morbidity and mortality due to non-cardiac 
complications. There was a dramatically increased mortality in patients that had been 
excluded from the randomised trial on the basis of low CD4+ and/or total lymphocyte 
counts. Retrospectively it could be argued that these patients should have been 
included in the study.  
 
CONCLUSION 
Intrapericardial and systemic corticosteroids were well tolerated, but did not improve 
the outcome in these selected patients. The standard six-month treatment regimen was 
effective regardless of HIV infection. Unfortunately, this study was underpowered to 
detect significant effects of adjunctive corticosteroids. Further placebo-controlled 
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trials are warranted but should be conducted at several centres using the same 
protocol, as single centre studies are unlikely to answer these questions. Patients with 
effusive constrictive disease should be included, as well as those with CD4+ 
lymphocyte counts <200 cells/μL. At present, corticosteroids should be reserved for 
critically ill patients with recurrent large effusions who do not respond to pericardial 
drainage and anti-tuberculous drugs alone (Lorell, 1997).   
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Chapter 8 
THE MANAGEMENT OF PATIENTS WITH LARGE 
PERICARDIAL EFFUSIONS 
 
Tuberculous pericarditis is a life-threatening form of extrapulmonary tuberculosis 
(TB) and presents either as pericardial effusion or as constrictive pericarditis (Strang, 
1984, Strang et al, 2004). Recently, a rapid rise in the incidence of tuberculous 
pericarditis has been observed in countries with a high prevalence of human 
immunodeficiency virus (HIV) infection (Cegielski, 1994; Maher and Harries, 1997). 
The first goal in the treatment of large pericardial effusions is effective drainage of the 
pericardial space to decrease compression of the cardiac chambers. This needs to be 
followed by specific therapy directed at the underlying aetiological cause of the 
pericardial disease. In the case of tuberculous pericarditis, anti-tuberculous therapy 
has reduced the mortality of TB from about 85% (Harvey and Whitehill, 1937) to 
between 17% and 40% (Rooney et al, 1970; Desai, 1979; Bhan, 1980). The use of 
adjuvant corticosteroids for the prevention of constriction and TB-related death 
remains controversial (Strang et al, 1988; Alzeer and Fitzgerald, 1993; Senderovitz 
and Viskum, 1994; Hakim et al, 2000; Mayosi et al, 2002; Strang et al, 2004). If 
constriction develops, pericardiectomy is usually indicated (Maisch et al, 2004).  
 
Standard management for pericardial effusion includes pericardiocentesis, ideally 
under guidance by echocardiography or fluoroscopy (Tsang et al, 1998; Tsang et al, 
1999; Tsang et al, 2002a; Tsang et al, 2002b; Strang et al, 2004). Echocardiography 
identifies the safest route where the pericardium can be entered intercostally or 
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subcostally (Tsang et al, 2002b). The most serious complications of pericardiocentesis 
include laceration and perforation of the myocardium and the coronary vessels, air 
embolism, pneumothorax, arrhythmias (usually vasovagal bradycardia), and puncture 
of the peritoneal cavity or abdominal viscera (Seferovi  et al, 2000).  
 
We have reported on our experience of pericardiocentesis with extended intermittent 
pericardial drainage in 170 patients, including 116 patients who presented with 
tuberculous pericardial effusion (Louw et al, 2002). Contrary to the perception that 
the HIV positive patients would suffer more infective complications, no cases of local 
skin or pericardial sepsis were encountered in any of the 54 HIV-infected patients 
studied (Louw et al, 2002). We are now reporting the thirty-day and one-year 
outcomes of 233 patients who presented with large pericardial effusions, focusing on 
the 162 patients who presented with pericardial TB.  
 
METHODS AND PATIENTS 
All 233 pericarditis patients described in Chapter 3 are included in this review. The 
predetermined diagnostic criteria, the diagnostic work-up and standardised 
management protocol have been described in Chapter 2. Patients were assessed one 
month after discharge and thereafter at three-monthly intervals for a minimum of one 
year. Therapeutic response was assessed regarding improvement or worsening of 
admission clinical features, evidence of infection at the puncture site and/or the 
pericardial space, and evidence of persisting effusion or pericardial constriction. 
Echocardiography was performed at baseline, at first follow-up, and thereafter as 
clinically indicated. Echocardiographic diagnosis of cardiac tamponade was made 
when, in the presence of pericardial effusion, the following were noted: inversion of 
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≥30% of the right atrial wall during late diastole/early systole, and/or inward motion 
of the right ventricular wall in early diastole that persisted after mitral valve opening 
(Gubermann et al, 1981). The methods used for statistical analysis are summarised in 
Chapter 2.   
 
RESULTS 
Altogether, 233 patients were treated by echo-guided pericardiocentesis. Of these, 162 
patients (100 males and 62 females) were diagnosed with pericardial TB; “definite” 
TB was diagnosed in 118 patients, whereas 44 presented with “probable” TB. Eleven 
patients were on anti-tuberculous treatment at the time of pericardiocentesis; these 
patients are included in this review. Eighty-four patients were HIV positive, including 
81 patients with tuberculous pericarditis, two patients with pericardial sepsis and one 
patient with uraemic pericarditis. The mean (SD) age at presentation differed 
significantly between HIV positive and HIV negative patients with pericardial TB 
[31.9 (8.4) years versus 39.7 (15.9) years; (p<0.05)]. The mean (SD) CD4+  
lymphocyte count for HIV positive patients was 215 (202) cells/μL. 
Echocardiographic evidence of tamponade was found in 197 cases (87%). Chest wall 
puncture site was chosen in 204 of the 233 patients (88%), and the subcostal approach 
in the remaining 29 patients (12%). The median (range) volume of pericardial fluid 
drained at initial pericardiocentesis was 791 (80-2770 mL). The majority of 
pericardial effusions had a haemorrhagic macroscopic appearance (66.1%), 25% of 
effusions were straw-coloured and 3% resembled pus. A pigtail catheter was left in 
situ for intermittent daily drainage. The pericardiocentesis related complications are 
summarised in Table 8.1.  
 
 143
Table 8.1.   Complications in 233 pericardiocenteses   
 
 TB / HIV+ 
n=81  
TB / HIV- 
n=81 
Non-TB 
n=71 
Minor complications 
  Local pain 
  Catheter removed inadvertently 
  Repeat pericardiocentesis 
  Catheter blockage 
  Leakage at skin insertion 
  Local skin infection 
  Local bleeding 
  Disconnection of system 
 
15 (19%) 
2 
3 
3 
3 
3 
1 
1 
 
12 (15%) 
3 
4 
3  
4  
1 
1 
2 
 
15 (21%) 
2  
1 
2 
2 
 
 
1 
Major complications 
  Tamponade post-tap (non-fatal) 
  Intrapericardial sepsis 
  Thrombus left ventricle 
  Pneumothorax 
 
 
1  
 
 
 
1  
1  
1  
1  
 
1 
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The most common minor complication (n=42) was local pain at the site of catheter 
insertion.  In four (2.4%) patients local skin infection necessitated removal of the 
catheter; three of them were HIV positive and had CD4+ lymphocyte counts <200 
cells/μL. No patient developed a pneumothorax during catheter insertion, but one 
patient developed a pneumothorax during catheter removal, which was managed by 
intercostal under-water tube drainage. Although the 30-day mortality rate was 11.6%, 
no death was attributable to the pericardiocentesis procedure.  
 
Anti-tuberculous treatment was initiated in hospital and continued at the TB clinic 
closest to a patient’s home. TB treatment was tolerated well and the six months 
course was adequate for both HIV positive and HIV negative patients; there were no 
relapses or need for prolonged treatment in any of the patients. Three patients 
presented with liver toxicity resulting in brief interruption and successful staggered 
reintroduction of treatment. HIV positive patients also received daily oral 
cotrimoxazole. Nine patients with complicated pericardial effusions (namely 
recurrent pericardial effusions, loculated pericardial effusions and/or constrictive 
pericarditis) received oral prednisone according to published guidelines (Strang et al, 
1987; Strang et al, 1988; Lorell, 1997). In addition, 33 patients received 
corticosteroids as part of a randomised trial, as reported in Chapter 7. Non-
tuberculous effusions were treated according to underlying cause. Septic pericarditis 
was treated with broad-spectrum antibiotics until the causative organism was 
identified by culture. Two patients with septic pericarditis underwent pericardial 
fenestration.  
 
 145
Thirty-six patients underwent pericardial surgery; 19 of these had diagnostic 
pericardial biopsies, 17 patients underwent therapeutic pericardial fenestration; one of 
them had a total pericardiectomy after developing fibrous constrictive pericarditis. 
The indications for the therapeutic biopsies are summarised in Table 8.2. Two 
tuberculous pericarditis patients died postoperatively while still in theatre. Both of 
them had echocardiographic evidence of poor left ventricular function; one of them 
was HIV positive. The mean (SD) duration of hospitalisation was 18.7 (4-57) days for 
surgically treated patients compared to 10.6 (4.9) days for the “pericardiocentesis-
only” group (p<0.01). One patient underwent total pericardiectomy for constrictive 
pericarditis performed after two months of anti-tuberculous therapy; he was well at 
one-year follow-up. 
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Table 8.2.   Therapeutic indications for pericardial surgery 
      
 Tuberculous 
pericarditis 
n=11  
Non-tuberculous 
pericarditis 
n=6 
Recurrent effusion 3 1 
Effusive constriction 4 2 
Loculated effusion 1 2 
Daily drainage >100 mL  2 0 
Obstructed tube  1 1 
Fibrous constriction* 1 0 
 
* One patient had pericardial fenestration and total pericardiectomy was 
performed after 2 months of anti-tuberculous therapy 
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The 30-day all-cause mortality was higher in patients with non-tuberculous pericardial 
disease than in patients with pericardial TB (20% versus 8.0%; p<0.01). The causes of 
30-day mortality in the pericardial TB group are presented in Table 8.3. The one-year 
all-cause mortality data are summarised in Table 8.4. The one-year all-cause mortality 
was significantly higher in patients who presented with non-tuberculous pericardial 
effusions than in the tuberculous pericarditis patients, namely 60.0% versus 17.3% 
(p<0.001), and in the tuberculous pericarditis group it was higher for HIV positive 
(22.2%) than for HIV negative patients (12.3%; p=0.04). The causes of the one-year 
mortality observed in pericardial TB patients are summarised in Table 8.5. 
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Table 8.3. Causes of 30-day mortality in patients presenting with pericardial 
TB  
 Case 
No. 
Age 
(years) 
HIV Cause of death 
<24 hours 85 25 + Drug abuse, pneumonia, septicaemia and respiratory 
failure (day 1) 
74 43 - Disseminated TB, sudden hypotensive episode 
followed by cardiac arrest (day 5) 
97 40 + Loculated pericardial effusion with tamponade and 
constrictive features, died pre-operatively due to 
massive gastrointestinal haemorrhage (day 4) 
143 36 + Unexpected sudden cardiac arrest, echo showed no 
constriction or loculated effusion (day 4) 
181 28 + Cerebral toxoplasmosis, status epilepticus, 
septicaemia, uraemia, progressive deterioration, no 
pericardial cause noted on repeat echo (day 5)  
188 54 - Disseminated TB, sudden deterioration in spite of 
daily pericardial drainage (day 4) 
24 hours to 
7 days 
203 31 + Underlying muscular dystrophy, cardiac arrest (day 
2)  
83 53 - Post TB bronchiectasis, cor pulmonale, reactivation 
of TB, cardio-respiratory failure (day 20) 
126 30 - Chronic pulmonary fibrosis, cavitation, smear 
positive pulmonary TB, cardio-respiratory failure 
(day 10) 
138 53 - Large residual effusion with tamponade and features 
of constriction – died due acute peri-operative 
cardiac insufficiency (day 16) 
157 35 + Underlying cardiomyopathy, removal of obstructed 
catheter on day 2. Cardiac arrest 9 days later (day 11)
173 47 + CD4+ lymphocyte count 43 cells/μL, severe 
diarrhoea, vomiting, tender abdomen, dysentery, 
septicaemia (day 17) 
7 to 30 
days 
181 29 + CD4+ lymphocyte count 9 cells/μL, severe pain in 
left flank, delirious, diarrhoea, septicaemia (day 9)  
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Table 8.4. Mortality according to diagnostic groups 
 
 30-day mortality One-year mortality 
 Tuberculosis (n=162) 
 Malignancy (n=22) 
 Uraemic (n=12) 
 Septic (n=5) 
  Other (n=32) 
13 (8%) 
5 (23%) 
3 (33%) 
3 (60%) 
3 (9%) 
28 (17%) 
20 (91%) 
5 (42%) 
4 (80%) 
13 (41%) 
 Total 27 (11.6%) 70   (30.0%) 
 
 
 
 
 
 150
Table 8.5. Causes of one-year mortality in tuberculous pericarditis patients 
 
   
n 
HIV negative 
(n=10) 
HIV positive 
 (n=18) 
Disseminated TB 3 1 2 
Effusive constriction / Tamponade 6 3 3 
Fibrotic pulmonary disease 3 3  
Systemic non-tuberculous infection 9 1 8 
Underlying cardiomyopathy 2 1 1 
Gastrointestinal haemorrhage 1  1 
Underlying muscular dystrophy 1  1 
Unknown  3 1 2 
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Three pericardial TB patients (two of which were HIV positive) died during the first 
60 days after pericardiocentesis as a result of disseminated TB; one of them had 
interrupted anti-tuberculous therapy. HIV-related non-tuberculous infectious 
complications that resulted in death included Pneumocystis carinii pneumonia (n=2), 
cerebral toxoplasmosis with status epilepticus (n=1), cryptococcal meningitis (n=1), 
abdominal sepsis (n=1) and septicaemia (n=3). Low CD4+ lymphocyte counts were 
associated with increased mortality risk; 75% of patients that died during the first year 
of follow-up had an admission CD4+ lymphocyte count <200 cells/μL, whereas 
admission CD4+ lymphocyte counts <200 cells/μL were observed in only 45% of 
“one-year survivors”. The corresponding mean (SD) CD4+ lymphocyte count for 
survivors was 237.2 (212.4) cells/μL compared to 155.1 (188.6) for non-survivors 
(p<0.01). 
 
DISCUSSION 
Large pericardial effusions are usually the manifestation of underlying disease, and 
the 60% mortality of the non-tuberculous group reflects the seriousness of the 
conditions that resulted in patients requiring therapeutic pericardiocentesis. Although 
the prognosis was significantly better for tuberculous pericardial disease, effective 
management of tuberculous pericarditis is nevertheless of utmost importance. 
Without specific treatment, the reported average survival was 3.7 months and only 
20% were alive at six months (Desai, 1979). In our experience the majority of 
patients who presented to the echocardiography department with suspected 
pericardial TB are critically ill and have large pericardial effusions; 90% of those 
enrolled into this study had echocardiographic evidence of tamponade. On average, 
more than 800 mL of fluid was drained at the initial drainage procedure. The 
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community based epidemiology and clinical presentation of pericardial TB may 
differ significantly from our observations in hospitalised patients in a tertiary referral 
centre. However, in our experience echo-guided pericardiocentesis with extended 
intermittent drainage resulted in effective relief of cardiac tamponade and over period 
of seven years in almost complete absence of fibrous constrictive pericarditis. Six 
patients (2.6%) had major complications related to the pericardiocentesis. We 
observed a very low incidence of recurrence and only nineteen were referred for 
therapeutic pericardial surgery indicating a pericardiocentesis success rate of 92%. 
Procedural success rates are high in most series, generally more than 90%, whereas 
complication rates are approximately 4% (Callahan et al, 1985; Kopecky et al, 1986; 
Tsang et al, 1998). In our study it was equally safe and effective in tuberculous 
pericardial effusions as in non-tuberculous pericardial effusions and our results are 
similar to series reported from settings where only the minority of patients have 
pericardial TB (Tsang et al, 2002a; Tsang et al, 2002b).  
 
Patients were referred for pericardial surgery, whenever pericardiocentesis failed to 
adequately drain loculated effusions or if echocardiography was suggestive of 
effusive-constrictive pericarditis. As was to be expected, the duration of 
hospitalisation was significantly longer for the surgically treated patients than for the 
pericardiocentesis group because it was reserved for critically ill patients and during 
the first 18 months of the study for those in whom a diagnosis could not be reached 
within the first seven days. Besides the 19 diagnostic biopsies, pericardial 
fenestration was performed on 17 patients for therapeutic indications. The post-
operative 30-day mortality for these 36 individuals was 5.6% in comparison to a 30-
day mortality for surgical drainage of malignant pericardial effusions of 19.4% 
 153
(Piehler et al, 1985). More specifically, complete pericardiectomy, partial 
pericardiectomy, and subxiphoid or anterior transthoracic window were associated 
with 30-day mortality rates of 37.5, 23.8, and 8.6%, respectively (Tsang et al, 1999). 
In the present series, two patients died while awaiting surgery. One of them had a 
massive upper gastrointestinal haemorrhage, whilst the other, a critically ill HIV 
positive patient died from tamponade which could not be adequately relieved by 
catheter drainage. Most patients can be adequately treated by pericardiocentesis. The 
technique is safe even in very sick and unstable patients, and does not usually need to 
be performed in theatre. In selected stable patients, it can even be performed on an 
outpatient basis (Drummond et al, 1998).  
  
Effusive-constrictive pericarditis preceded fibrous constriction in the two patients 
who developed this complication. One of them refused surgery. Fortunately, he 
improved over a period of two years and thus had transient constrictive pericarditis, 
which is a rare but important entity, since pericardiectomy is not indicated for these 
patients (Haley et al, 2004). Possibly, his favourable outcome was related to the 
installation of intrapericardial triamcinolone. The other constrictive pericarditis 
patient was treated successfully by total pericardiectomy; he was well at one-year 
follow-up. Pericardiectomy for constrictive pericarditis has a mortality rate of 6–25% 
(Culliford et al, 1980; Robertson and Mulder, 1984; Aagaard and Haraldsted, 1984; 
Siefert et al, 1985; Palatianos et al, 1985; McCaughlin et al, 1985; Cameron et al, 
1987; Bashi et al, 1988; Astrudillo and Ivert, 1989; Nataf et al, 1993; Tirilomis et al, 
1994; Ling et al, 1999; Ufuk et al, 2003). Major complications include acute peri-
operative cardiac insufficiency (low-output syndrome) and ventricular wall rupture 
(Sunday et al, 1999). The low-output syndrome occurs in 14–28% of patients in the 
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immediate postoperative period, and the major risk factors predictive of in-hospital 
mortality and low-output syndrome include presurgically unrecognised presence of 
myocardial atrophy or myocardial fibrosis (Reinmuller et al, 1993), the degree of 
preoperative disability (functional Class III or IV) and the severity of constriction as 
indicated by marked elevation of right atrial/right ventricular end-diastolic pressure 
(Tirilomis et al, 1994; McCaughlin et al, 1985, Siefert et al, 1985). In effusive-
constrictive pericarditis, pericardiocentesis usually fails to alleviate the features of 
haemodynamic compromise, and subtotal or complete pericardiectomy is not possible 
because the pericardium cannot be stripped from the epicardium. In our experience, 
patients with effusive-constrictive pericarditis required surgical fenestration to drain 
the fibrinous material from the pericardial space, and to break down pericardial 
adhesions. This did not, however, address the main problem, namely the presence of 
a stiffened epicardium which causes the constriction and cannot be removed at this 
stage of the disease, because a skin has not yet formed that would allow surgical 
stripping. Once the fibrous skin becomes echocardiographically evident, total 
pericardiectomy should be performed in symptomatic patients before pericardial 
calcifications have formed or the onset of cardiac cachexia (Lorell, 1997; Maisch et 
al, 2004).  
 
An unfortunate proportion of deaths is attributable to disseminated TB (Harvey and 
Whitehill, 1937; Gooi and Smith, 1978), and despite the availability of anti-
tuberculous chemotherapy, the mortality of disseminated TB is as high as 20-30% 
(Munt 1971; Vijayan, 2000). The HIV epidemic has considerably altered the 
frequency and descriptive epidemiology of disseminated TB (Narain et al, 1992; 
Barnes et al, 1993). Disseminated TB, which arises from the inadequacy in 
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containing tuberculous infection, occurs more frequently and may be more difficult to 
diagnose in HIV positive individuals (Chaisson et al, 1987; Barnes et al, 1993). 
Because of the multisystem involvement in disseminated TB, the clinical 
manifestations are protean. Presenting symptoms are dominated by systemic effects, 
particularly fever, weight loss, anorexia and weakness (Munt 1971; Grieco and 
Chmel, 1974 Sahn and Neff, 1974; Prout and Benatar, 1980; Vijayan, 2000). 
Approximately 25% of patients with tuberculous pericarditis have evidence of other 
organ involvement at the time pericarditis is diagnosed, particularly pleuritis and 
lymphadenitis (Harvey and Whitehill, 1937; Gooi and Smith, 1978). The degree of 
immunodeficiency and risk for disseminated TB and other serious opportunistic 
infections and death correlates with CD4+ lymphocyte cell counts (Barnes et al, 
1993; Mellors et al, 1997). In our study, 75% of HIV positive patients who died 
during the first year of follow-up had admission CD4+ lymphocyte counts <200 
cells/μL compared to only 45% of the HIV positive one-year survivors, and the 
majority of deaths was caused by opportunistic infections, septicaemia and 
disseminated TB.  
 
The cornerstone of the treatment of HIV is highly active antiretroviral therapy 
(HAART), which has been shown to reduce the mortality and the morbidity of people 
living with advanced HIV disease, decreasing death rates in Europe by at least 
fivefold (Palella et al, 1998; Mocroft et al, 1998). The goal of HAART is maximal 
and durable viral suppression to enable preservation and restoration of the immune 
system (Mellors et al, 1997). During the course of our study, HAART was not 
available at Tygerberg Hospital. The recently improved accessibility of HAART will 
hopefully result in improved prognosis of the HIV-infected TB patients. The use of 
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HAART in the treatment of patients co-infected with TB and HIV may be 
problematic because there are potential complex drug interactions, overlapping 
adverse reactions, potential non-adherence due to the pill burden, and drug 
malabsorption (Burman and Jones, 2001). Despite these potential problems, HAART 
substantially reduces new acquired immunodeficiency syndrome (AIDS) events and 
death in co-infected patients (Badri et al, 2002; Dheda et al, 2004). Those with CD4+ 
lymphocyte counts <100 cells/μL have a high event risk during the intensive phase of 
anti-tuberculous treatment (Dheda et al, 2004). Paradoxical deterioration due to the 
immune reconstitution inflammatory syndrome (IRIS) has been reported to occur in 
11-36% of patients with TB who start HAART (Narita et al, 1998; Wendel et al, 
2001). Secondary preventive therapy with isoniazid reduces TB recurrence in HIV 
infected patients: the absolute impact seems to be greatest among individuals with 
low CD4+ lymphocyte cell counts. (Churchyard et al, 2003).  
 
CONCLUSION 
Before the advent of anti-tuberculous chemotherapy in 1945, tuberculous pericarditis 
was often rapidly fatal, with a mortality rate of 80-85% (Harvey and Whitehill, 1937; 
Desai, 1979). Our series of 162 consecutive patients demonstrates that the risk for 
constriction and cardiac death can be very effectively reduced by using echo-guided 
pericardiocentesis with extended intermittent drainage and early initiation of anti-
tuberculous therapy, and this drainage technique is safe and effective irrespective of 
the patient’s HIV status. The one-year all-cause mortality was higher in HIV positive 
patients than in HIV negative patients. The majority of deaths were caused by non-
cardiac disease and CD4+ lymphocyte counts <200 cells/μL predicted a poor 
prognosis. 
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Chapter 9 
THE INFLUENCE OF HIV INFECTION ON THE 
CYTOKINE PRODUCTION IN PATIENTS WITH 
TUBERCULOUS PERICARDITIS 
 
The human immune response eliminates microbial pathogens through an 
inflammatory response that may be harmful to host tissue. In tuberculosis (TB), tissue 
necrosis and pleural exudates are characteristic manifestations of the cytokine 
mediated inflammatory response (Barnes et al, 1991). A large number of TB related 
studies has focused on the T helper1/T helper2 (Th1/Th2) response and has shown 
that the Th1 cytokine profile is associated with successful elimination of tubercle 
bacilli (Collins and Kaufmann, 2001; Barnes and Wizel, 2000; Jo et al, 2003). 
Cytokines produced by Th1 and Th2 subsets reciprocally regulate the functions of 
each other. Interferon-gamma (IFN-γ) inhibits the proliferation of Th2 cells, but not of 
Th1 cells (Gajewski and Fitch, 1988). Within the complex immunoregulatory 
response to mycobacterial infection, IFN-γ and tumour necrosis factor-alpha (TNF-α) 
are of particular importance because of their potential anti-mycobacterial effects.  
 
In 2002 we reported on the cytokine production in 30 pericardial effusions (Burgess et 
al, 2002c). Various pericardial fluid cytokine concentrations were measured, 
including IFN-γ, TNF-α, interleukin-1 (IL-1), IL-2, IL-4, IL-6, and IL-10. Our results 
indicated a Th1 dominant immune response in the tuberculous pericarditis group and 
we concluded that tuberculous pericardial effusions result from a delayed 
 158
hypersensitivity reaction that is orchestrated by Th1 lymphocytes in collaboration 
with activated macrophages. Activated T lymphocytes produce a number of 
cytokines, including IFN-γ, IL-2 and IL-10. Of these, IFN-γ plays the leading role in 
the anti-mycobacterial response. However, both IFN-γ and IL-2 enhance the 
recruitment and activation of monocytes-macrophages in the pericardial space, which 
results in the production of IL-1 and TNF-α (Burgess et al, 2002c). This first phase of 
our study included only four HIV positive tuberculous pericarditis patients. To 
determine the influence of HIV infection on the cytokine production in patients with 
tuberculous pericarditis we have subsequently evaluated the cytokine production in a 
further 26 patients, including an additional 18 HIV positive patients with tuberculous 
pericardial effusion. 
 
 
PATIENTS AND METHODS 
At the time of pericardiocentesis, an aliquot of pericardial fluid was collected on ice 
and frozen within 30 minutes at -70°C for the analysis of cytokines. Fifty-six 
pericardial specimens, ten serum samples and five pericardial fluid samples from 
normal controls were included in this sub-study. Control patients were evaluated by 
obtaining pericardial fluid during routine open-heart surgery by open pericardial 
aspiration. The following cytokines were measured: IL-4, IL-10, TNF-α and IFN-γ by 
using an enzyme-linked immunosorbent assay (ELISA) according to manufacturer’s 
instructions (Amersham Pharmacia Biotech, UK; Chapter 2). The laboratory and 
statistical methods are presented in Chapter 2.  
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RESULTS 
The concentrations of various cytokines were determined in 56 pericardial effusions. 
The diagnostic causes of these pericardial effusions included TB (n=43), malignancy 
(n=6), septic pericarditis (n=5) and systemic lupus erythematosus (SLE; n=2). The 
malignant group included two patients with metastatic adenocarcinoma, one with 
undifferentiated bronchus carcinoma, one with small cell carcinoma, one with 
lymphoma and one with neuroblastoma. Twenty-four patients were HIV positive, 
including 22 who presented with tuberculous pericarditis and two who presented with 
septic pericarditis. The mean (SD) CD4+ lymphocyte count for these HIV positive 
patients was 214 (200) cells/μL. The cytokine concentrations found in the 56 
pericardial effusions are summarised in Table 9.1. In the five normal controls, the 
concentrations of all cytokines tested were below the detectable minimum range.  
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Table 9.1. Cytokine concentrations in various pericardial effusions  
 
 TB / HIV+ 
(n=22) 
TB / HIV- 
(n=21) 
Non-tuberculous 
(n=13) 
Interleukin-4 0.4 (n=1) * * 
Interleukin-10 85.0 (30.3) 176.3 (31.9) 152.0 (33.9) 
Tumour necrosis factor-α 2.4 (1.9) 8.7 (2.0) 5.3 (2.3) 
Interferon-γ 623.6 (103.3) 786.7 (115.4) 27.0 (18.9) 
 
Results expressed as mean (SD) pg/mL 
*  Concentration below minimum detectable range 
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The concentration of IFN-γ was significantly higher in the tuberculous pericardial 
effusions than in non-tuberculous effusions (p <0.00001; Figure 9.1.). IFN-γ levels 
were detectable in only three of the 13 non-tuberculous effusions, including two 
malignant effusions and one septic pericardial effusion; in each of these effusions the 
IFN-γ concentration was <50 pg/mL. The concentration of TNF-α was elevated in all 
diagnostic categories; TNF-α levels tended to be lower in HIV positive TB patients 
than in HIV negative patients with pericardial TB (p=0.09; Figure 9.2.). Elevated 
levels of IL-10 were found in all three groups; the differences in IL-10 concentrations 
were not statistically significant (p=0.11; Figure 9.3.). With the exception of one HIV 
positive TB patient (corresponding IL-4 concentration, 0.4 pg/mL), the concentration 
of IL-4 was below the minimum range in all other patients. Fourteen of the 56 patients 
underwent pericardial biopsy, including nine HIV negative TB patients, three HIV 
positive TB patients, one HIV positive patient with septic pericarditis and one patient 
who had adenocarcinoma involving the pericardium. The comparison between 
histological findings and cytokine concentrations are summarized in Table 9.2. Nine 
of the 12 tuberculous effusions were associated with histological evidence of 
necrotising granulomatous inflammation; the other three biopsies showed non-
necrotising granulomata. The histology of the case of septic pericarditis demonstrated 
an acute inflammatory cellular infiltrate, whereas the pericardial biopsy taken from 
the patient with the malignant effusion showed adeno-carcinomatous infiltration. IFN-
γ levels exceeded 700.0 pg/mL in ten out of the twelve TB cases, whereas in the cases 
of septic pericarditis and adenocarcinoma, the corresponding IFN-γ levels were 28.9 
pg/mL and 42.4 pg/mL, respectively. No significant difference in IFN-γ levels was 
noted regarding cases of granulomatous inflammation with or without necrosis 
(p=0.48). The concentration of IL-10 exceeded 600.0 pg/mL in one pericardial fluid 
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sample corresponding to granulomatous inflammation without tissue necrosis, 
whereas the lowest level (15.0 pg/mL) corresponded to extensive tissue necrosis. The 
corresponding mean (SD) IL-10 levels tended to be lower in effusions associated with 
necrosis than those without necrosis, at levels of 110.0 (116.2) pg/mL and 257.9 
(198.5) pg/mL, respectively (p=0.18). The corresponding mean (SD) TNF-α 
concentrations for tuberculous effusions associated with tissue necrosis and 
tuberculous effusions without tissue necrosis were 12.4 (4.4) pg/mL and 11.2 (7.1) 
pg/mL, respectively (p=0.89).  
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Table 9.2. Comparison between pericardial cytokine levels and histology 
 
 
Cytokine a 
Necrosis (+) 
n=8 
Necrosis (-) 
n=3 
Purulent  
n=1 
Malignant
n=1 
Interleukin-10 110.0 (116.2) 257.9 (198.5) 390.1 163.4 
Tumour necrosis factor-α 12.4 (4.4) 11.2 (7.1) 22.4 0.5 
Interferon-γ 966.0 (386) 775.7 (223.4) 28.9 42.4 
 
a Values expressed as mean (SD) pg/mL 
 
Necrosis (+) = necrotising granulomatous inflammation  
Necrosis (-) = non-necrotising granulomatous inflammation 
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Figure 9.1. Distribution of interferon-γ in pericardial effusions 
 
TB = tuberculosis  
HIV+ = human immunodeficiency virus positive  
HIV- = human immunodeficiency virus negative  
Non-TB = non-tuberculous  
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Figure 9.2. Distribution of tumour necrosis factor-α in pericardial effusions 
 
TB = tuberculosis  
HIV+ = human immunodeficiency virus positive  
HIV- = human immunodeficiency virus negative  
Non-TB = non-tuberculous 
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Figure 9.3. Distribution of interleukin-10 in pericardial effusions  
 
TB = tuberculosis  
HIV+ = human immunodeficiency virus positive  
HIV- = human immunodeficiency virus negative  
Non-TB = non-tuberculous 
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DISCUSSION 
The clinical outcome of infection with M. tuberculosis depends on the efficacy of 
cell-mediated immunity rather than humoral immunity. Persons with defective cell-
mediated immunity, such as those with HIV infection, are at markedly increased risk 
for TB (Barnes et al, 1991). The immune response to TB is, however, a double-edged 
sword that may contribute to both clearance of infection and tissue damage, or in the 
case of pericardial TB to cardiac tamponade or constrictive pericarditis. .  
 
In our study, a highly significant difference in the pericardial levels of IFN-γ was 
noted between tuberculous effusions and effusions caused by SLE, septic pericarditis 
or malignancy (p <0.00005). This finding emphasizes the importance of IFN-γ in the 
pathogenesis of tuberculous pericarditis and supports an important role in the 
protective immune response against infection with M. tuberculosis. No significant 
correlation could be demonstrated between pericardial lymphocyte counts and IFN-γ 
concentration. Interestingly, IFN-γ levels were not significantly affected by HIV 
infection. This indicates that the production of IFN-γ does not depend on the total 
number of lymphocytes, but rather on specific activated subpopulations. IFN-γ is 
encoded by a single gene and produced by a number of T lymphocytes, including 
CD8+ cells, γδ cells, Th1 and Th0 CD4+ lymphocyte cells, but not Th2 CD4+ 
lymphocytes (Barnes et al, 1992; Farrar and Schreiber, 1993). IFN-γ is a major role 
player in the differentiation and activation of monocytes and macrophages (Snapper 
and Paul, 1987; Farrar and Schreiber, 1993). It promotes their action by enhancing 
antigen-presenting activity, and by the production of hydrogen peroxide, which 
facilitates intracellular elimination of mycobacteria (Farrar and Schreiber, 1993). In 
addition to this direct promotion of cellular immunity and delayed hypersensitivity, 
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IFN-γ suppresses the production of IL-4 by Th2 cells, and it antagonises the actions of 
IL-4 on B cells (Finkelman et al, 1990). Under the influence of IFN-γ and IL-2, 
activated monocytes and macrophages produce TNF-α (Cuturi et al, 1987; Vassalli, 
1992).  
 
In our series, pericardial fluid TNF-α concentrations tended to be lower in HIV 
positive patients. Although the production of TNF-α depends primarily on activated 
monocytes and macrophages (Cuturi et al, 1987), it is, in part, also produced by B 
lymphocytes (Sung et al, 1988), T lymphocytes (Steffen et al, 1988), natural killer 
(NK) cells (Vassalli, 1992), mast cells, polymorphonuclear leukocytes, keratinocytes 
and tumour cells (Vassalli, 1992). TNF-α increases macrophage phagocytic capacity 
and enhances mycobacterial killing by human macrophages in vitro.  
 
Concentrations of IL-4 were indeterminably low in all but one HIV positive TB 
patient. In the presence of elevated levels of IFN-γ, this provides further evidence that 
tuberculous effusions result from a Th1 dominant cytokine response (Gajewski and 
Fitch, 1988; Mosman an Sad, 1996). Our data demonstrate that this Th1 dominant 
cellular response takes place irrespective of HIV status, even when peripheral blood 
CD4+ lymphocyte cell numbers are as significantly reduced as in the present study, 
where HIV positive tuberculous pericarditis patients were found to have a mean (SD) 
CD4+ lymphocyte cell count of 214 (200) cells/μL at admission. .  
 
The Th1-dominant immune response is essential for successful elimination of tubercle 
bacilli, but it may result in detrimental tissue damage (Barnes and Wizel, 2000; 
Collins and Kaufmann, 2001; Jo et al, 2003). In this regard the correlation of 
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pericardial histology and cytokine levels produced interesting results, although the 
significance of our observations is unclear due to the small number of pericardial 
biopsy specimens. We noted that IFN-γ levels exceeded 800 pg/mL in nine out of the 
12 specimens that demonstrated granulomatous lesions, and all of these were 
associated with elevated levels of TNF-α, ranging from between 8.4 to 36.8 pg/mL. 
These observations support the notion that in response to infection with M. 
tuberculosis an interaction between IFN-γ and TNF-α results in a delayed 
hypersensitivity reaction and the development of granulomatous lesions (Ando et al, 
1972; Nathan et al, 1983; Phillip and Epstein, 1986; Esparza et al, 1987; Kindler et al, 
1989). In addition to the association between granulomatous lesions and IFN-γ levels, 
we noted a tendency towards an inverse relationship between IL-10 levels and tissue 
damage seen on pericardial biopsy specimens. The highest IL-10 level (exceeding 600 
pg/mL) corresponded with a biopsy that demonstrated granulomatous inflammation 
without tissue necrosis, whereas the lowest IL-10 concentration (15 pg/mL) 
accompanied a biopsy revealing extensive tissue necrosis. The corresponding mean 
(SD) IL-10 levels for effusions with or without histological evidence of tissue 
necrosis were 110.0 (116.2) pg/mL and 257.9 (198.5) pg/mL, respectively (p=0.18). 
The small numbers in the present study preclude definitive conclusions; nevertheless, 
our findings are in keeping with reports that suggest a tissue protective 
immunoregulatory role for IL-10 (Novelli et al, 1991; Barnes et al, 1993; Othieno et 
al, 1999; Shaw et al, 2000). IL-10 down-regulates the Th1 immune response and 
thereby protects the TB-infected host against excessive tissue damage (Barnes et al, 
1993).  
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It has been suggested that a “switch” from a Th1 cytokine phenotype to a Th2 
phenotype is a critical step in the progression of HIV disease (Clerici and Shearer, 
1993; Maggi et al, 1994). Our data do not support this; our HIV infected patients 
demonstrated a classical Th1 cytokine response characterised by high IFN-γ levels 
and undetectable levels of IL-4, despite advanced HIV disease and significant CD4+ 
lymphocyte cell depletion.  
 
Although chemotherapy remains the mainstay of anti-tuberculous therapy, the use of 
adjunctive immunotherapeutic modalities is attractive, particularly in patients with 
drug-resistant TB or in those that are severely immunocompromised. Our data 
indicate that IFN-γ is of primary importance in the human defence mechanism against 
infection with M. tuberculosis and the administration of IFN-γ should enhance 
mycobacterial elimination. Administration of IFN-γ to lepromatous leprosy patients 
decreases the bacillary burden, but increases the frequency of erythema nodosum 
leprosum (Sampaio et al, 1992). Therapeutic use of recombinant cytokines is limited 
by high costs and by toxicity of the large parenteral doses required to attain effective 
tissue concentrations. The administration of thalidomide, which acts as a TNF-α 
antagonist has been used to treat erythema nodosum leprosum (Sampaio et al, 1992), 
and has experimentally been used in the management of tuberculous meningitis. 
Another immunomodulatory approach could involve administering neutralising 
antibodies to immunosuppressive cytokines such as IL-4. Further research is indicated 
to explore the potential use of immunomodulatory responses in patients who are co-
infected with TB and HIV. 
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Chapter 10 
ADENOSINE DEAMINASE – MORE THAN A 
DIAGNOSTIC TOOL 
 
In countries where tuberculosis (TB) is endemic, the increase in adenosine deaminase 
(ADA) activity observed in the pericardial fluid of patients with TB has been used to 
establish the diagnosis of tuberculous pericarditis (Telenti et al, 1991: Koh et al, 
1994; Komsuoglu et al, 1995). ADA is a polymorphic enzyme that is involved in 
purine metabolism. It catalyses the deamination of adenosine and deoxyadenosine to 
produce inosine and deoxyinosine, respectively (Van der Weyden and Kelley, 1976). 
ADA plays a role in the differentiation of lymphoid cells (Barton and Goldschneider, 
1979; Shore et al, 81), and the maturation of monocytes to macrophages (Fischer et 
al, 1976). The presence of ADA in pericardial and other body fluids reflects the 
activity of the cellular immune response in the respective compartment and, in 
particular, the activation of T lymphocytes and macrophages (Ocaña et al, 1983; 
Petterson et al, 1984).  
 
In order to improve the understanding of factors that influence the ADA activity in 
large pericardial effusions, we determined whether ADA activity levels correlated 
with pericardial fluid leukocyte counts, peripheral CD4+ lymphocyte counts, 
pericardial cytokine concentrations and/or histopathological features of tuberculous 
pericarditis.  
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PATIENTS AND METHODS 
ADA activity (U/L) was determined in all pericardial fluids specimens according to 
the method described in Chapter 2. Peripheral blood and pericardial fluid leukocyte 
counts were routinely done. Statistical analysis was done as summarised in Chapter 2. 
The correlation between two variables was plotted on a scatter plot and Spearman 
rank correlation coefficients were used to express the relationship.  The significance 
of the correlation was denoted by a p-value <0.05.  
 
RESULTS 
During the study period, 233 patients presented to Tygerberg Hospital with large 
pericardial effusions requiring pericardiocentesis, including 162 patients who were 
diagnosed with tuberculous pericarditis (Chapter 3). We documented high levels of 
ADA in tuberculous pericardial effusions (Chapter 5).  The most notable cause for 
low pericardial ADA levels in patients with tuberculosis pericarditis was the 
concomitant use of anti-tuberculous chemotherapy at the time of pericardiocentesis, 
and eleven patients who were taking anti-tuberculous therapy at the time of 
pericardiocentesis were excluded from analyses. The pericardial fluid ADA activity 
and peripheral blood differential leukocyte counts have been summarised in Table 
10.1. Pericardial ADA activity was significantly elevated in tuberculous pericardial 
effusions compared to other diagnostic classes (p<0.01). HIV infection did not have a 
significant influence on ADA levels in the tuberculous effusions (p=0.48; Table 10.1). 
In tuberculous pericardial effusions, lymphocytes dominated the inflammatory 
cellular infiltrate, and the corresponding median (range) pericardial 
lymphocyte/neutrophil ratios for tuberculous (HIV negative), tuberculous (HIV  
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Table 10.1. Summary of differential leukocyte counts and pericardial fluid 
ADA activity in patients presenting with pericardial effusion  
 
 TB / HIV- 
n=64 
TB / HIV+ 
n=76 
 
p 
TB 
n=140 
Non-TB 
n=61 
 
p 
PB leukocytesa  7.8 (3.4) 6.6 (4.2) 0.01 7.3 (3.8) 12.5 (4.8) <0.01 
PB neutrophils  5.6 (2.9) 4.8 (3.8) 0.01 5.3 (3.4) 8.9 (6.1) <0.01 
PB lymphocytes  1.1 (0.6) 0.9 (1.1) 0.03 1.0 (0.8) 1.8 (2.3) <0.01 
PB monocytes  0.55 (0.19) 0.24 (0.16) 0.01 0.40 (0.18) 0.69 (0.25) <0.01 
Pc- leukocytes  2.7 (2.3) 1.8 (1.5) 0.03 2.3(1.9) 4.6 (3.8) <0.01 
Pc % neutrophils b 28.4 (22.5) 35.9 (25.5) 0.05 32.2 (24.0) 55.8 (24.6) 0.01 
Pc neutrophils 1.0 (1.8) 0.8 (0.7) 0.88 0.9 (1.3) 2.6 (1.8) <0.01 
Pc % lymphocytes 52.1 (25.5) 39.4 (22.5) 0.03 45.5 (25.2)  25.6 (22.4) <0.01 
Pc lymphocytes 1.3 (0.9) 0.8 (0.6)  0.03 1.0 (0.8) 0.6 (0.6) 0.01 
Pc % macrophages  19.4 (20.3) 18.9 (13.7) 0.89 19.2 (17.0) 13.3 (12.8) 0.03 
Pc macrophages 0.38 (0.44) 0.34 (0.28) 0.60 0.36 (0.36) 0.48 (0.78) 0.06 
Pc-ADAc 89 (35) 76 (38) 0.48 82 (37) 36 (29) <0.01 
 
 
a Number of cells expressed as mean (SD) x 109 / L 
b Percentages expressed as mean (SD) % 
c Pericardial adenosine deaminase activity expressed as mean (SD) U/L  
PB = peripheral blood 
Pc = pericardial fluid 
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positive) and non-tuberculous pericardial effusion were 2.7 (0.2-74.0), 1.9 (0.1-7.5) 
and 0.4 (0.1-2.2), respectively.  
 
The corresponding Spearman rank correlation coefficient between pericardial ADA 
activity and pericardial total leukocyte, neutrophil, lymphocyte and macrophage 
counts were r = 0.30 (p = 0.07); r = 0.25 (p = 0.13); r = 0.31 (p = 0.07); and r = 0.14 
(p = 0.59), respectively. No significant correlation was demonstrable between ADA 
activity and peripheral blood leukocyte counts. However, a significant association was 
noted between high levels of ADA activity and high pericardial leukocyte, neutrophil 
and lymphocyte counts. In the tuberculous pericardial exudates, the corresponding 
median (range) pericardial fluid leukocyte, neutrophil and lymphocyte counts were 
significantly higher in effusions with ADA activity ≥40 U/L than in pericardial 
effusions with ADA levels <40 U/L (p<0.05 for each), whereas in non-tuberculous 
effusions only the total leukocyte and neutrophil counts were higher in high ADA 
(≥40 U/L) effusions than in low ADA (<40 U/L) effusions (Table 10.2.).   
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Table 10.2.  Relationship between pericardial fluid leukocytes numbers and 
pericardial fluid ADA activity 
 
Adenosine deaminase activity  
Subgroups ADA <40 U/L ADA ≥40 U/L 
 
p 
Tuberculous effusions 
Pericardial total leukocytesa  
Pericardial neutrophils 
Pericardial lymphocytes  
 
1220 (470-2210) 
53 (15-88) 
721 (180-1768) 
 
2580 (400-10260) 
918 (158-7377) 
1140 (99-2654) 
 
0.03 
0.02 
0.03 
Non-tuberculous effusions 
Pericardial total leukocytes  
Pericardial neutrophils 
Pericardial lymphocytes  
 
1655 (220-360) 
812 (103-1787) 
584 (51-1520) 
 
4341 (80-24140) 
2843 (24-19336) 
260 (56-1497) 
 
0.02 
0.04 
0.18 
 
 
a Results expressed as median (range) cells x 106/L 
 
p-value established by two-way ANOVA 
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Correlation between ADA and peripheral blood CD4+ lymphocyte cells 
No significant correlation between pericardial ADA activity and peripheral blood 
CD4+ lymphocyte cell counts could be demonstrated (r = 0.17; p = 0.20). However, at 
very low CD4+ lymphocyte cell counts there was a distinct tendency towards low 
levels of ADA activity. The corresponding median (range) CD4+ lymphocyte cell 
counts for patients with ADA activity <30 U/L, ADA activity <40 U/L and ADA 
activity ≥ 40 U/L were 59.0 (6.0-115.0) cells/μL, 183.0 (6.0-578.0) cells/μL and 219.0 
(25.0-1006.0) cells/μL, respectively.  
 
In the HIV negative tuberculous patients and the non-tuberculous patients the 
corresponding correlation between pericardial ADA activity and peripheral CD4+ 
lymphocyte cell counts was r = -0.89 (p = 0.04) and r = -0.42 (p = 0.57), respectively.   
 
Correlation between ADA and pericardial cytokines  
Various cytokine concentrations were evaluated in pericardial effusion patients (n=56; 
Chapter 9). Significant correlation was demonstrable between pericardial fluid ADA 
activity and pericardial TNF-α concentration of patients with tuberculous pericardial 
effusions (r=0.63; p=0.001; Figure 10.1). No significant correlation could be 
demonstrated between pericardial ADA activity and pericardial IFN-γ (r=0.33, 
p=0.13), nor a correlation between pericardial ADA and pericardial IL-10 
concentration (r=0.06, p=0.76). There was also no significant correlation between 
pericardial ADA levels and cytokines in the non-tuberculous pericardial effusion 
patients. 
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Figure 10.1.   Correlation between pericardial ADA activity and concentration of 
tumour necrosis factor-α in tuberculous pericarditis 
 
Pc-TNF = pericardial tumour necrosis factor-α (pg/mL) 
Pc-ADA = pericardial adenosine deaminase activity (U/L) 
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Correlation between ADA and pericardial histology 
A total of 25 tuberculous pericarditis patients underwent pericardial biopsy; five of 
these patients were HIV positive. Fifteen biopsies (60%) demonstrated granulomatous 
inflammation; 12 of these were accompanied by caseating necrosis. The remaining ten 
biopsies demonstrated no characteristic histomorphological features of TB. For 
patients with pericardial TB, the corresponding mean (SD) ADA level for 
granulomatous necrotising, granulomatous non-necrotising, and non-granulomatous 
pericarditis was 125 (77) U/L, 105 (56) U/L, and 95 (53) U/L, respectively (p=0.62). 
The lowest ADA activity was associated with serofibrinous pericarditis 
{corresponding mean (SD) of 67 (78) U/L}. 
 
 
DISCUSSION 
In South Africa, the majority of patients presenting with large pericardial effusions 
have pericardial TB (Desai, 1979; Strang, 1984. The present study confirms that 
pericardial TB is responsible for approximately 70% of the large pericardial effusions 
seen at Tygerberg Academic Hospital. We documented high levels of ADA in 
tuberculous pericardial effusions. The ADA activity was not significantly lower in 
HIV positive patients than in HIV negative TB patients and the correlation between 
peripheral CD4+ lymphocyte counts and pericardial ADA activity levels was non-
significant. However, a relationship between severe peripheral CD4+ lymphocyte cell 
depletion and low ADA levels was noted. Seven of the 10 HIV positive patients with 
low ADA tuberculous effusions (ADA activity <40 U/L) had corresponding CD4+ 
lymphocyte cell counts < 200 cells/μL. The difference between CD4+ lymphocyte 
cell counts associated with pericardial ADA activity < 40 U/L and pericardial ADA 
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activity ≥40 U/L was minimal [corresponding counts being 183.0 (6.0-578.0) cells/μL 
and 219.0 (25.0-1006.0) cells/μL, respectively (p=0.8)], whereas in the group of 
tuberculous patients with pericardial ADA activity < 30 U/L the corresponding 
median (range) CD4+ lymphocyte cell count being 59.0 (6.0-115.0) cells/μL, was 
significantly decreased (p=0.04). These results suggest that severe CD4+ lymphocyte 
cell depletion may result in low ADA activity levels, probably by impeding the CD4+ 
lymphocyte dependent cellular immune response against mycobacterial antigens in 
the pericardial space.  
 
Pericardial exudates with an ADA activity ≥40 U/L were associated with higher total 
leukocyte and higher neutrophil counts than pericardial effusions with ADA activity 
<40 U/L. In the group of patients with tuberculous pericarditis, pericardial exudates 
with ADA activity ≥40 U/L were also characterised by higher lymphocyte counts than 
tuberculous exudates with ADA activity <40 U/L. No specific correlation between 
ADA levels and macrophage counts could be demonstrated. The lack of correlation 
between pericardial ADA and the number of pericardial lymphocytes is in keeping 
with numerous studies that could not demonstrate any correlation or were 
inconclusive (Ocaña et al, 1983; Baganha et al, 1990; Bovornkitti et al, 1991). 
However, pericardial neutrophil counts were lower for tuberculous effusions than for 
non-tuberculous effusions, whereas median ADA activity was significantly higher in 
tuberculous than in non-tuberculous exudates, implying that lymphocytes (and 
possibly macrophages) play the major role in the production and release of ADA in 
tuberculous effusions; this supports data from tuberculous pleural exudates (Valdes et 
al, 1996). It has been demonstrated that lymphocytes and macrophages contain 
similar levels of ADA activity, and that this is much higher than in other cell types or 
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tissues (Ungerer et al, 1994). Our study does not add additional information on the 
potential contribution of macrophages to the ADA activity in tuberculous exudates. 
Tuberculous exudates with ADA activity <40 U/L were accompanied by significantly 
lower pericardial neutrophil counts than effusions with ADA activity ≥40 U/L, 
suggesting that neutrophils also contribute to ADA activity. In non-tuberculous 
effusions, neutrophils are probably the major source of ADA, although lymphocytes 
may also contribute (Ungerer et al, 1994). In our study, the contribution of neutrophils 
to ADA activity in non-tuberculous effusions was most notable in the case of septic 
pericarditis. However, significantly higher pericardial leukocyte counts are “required” 
to produce similar levels of ADA activity. 
 
Two molecular forms of ADA have been described, namely ADA1 and ADA2 
(Hischhorn and Ratech, 1980). Although ADA1 is found in all cells, its highest 
activity is in lymphocytes and macrophages, whereas the ADA2 isoenzyme appears to 
originate from monocytes and macrophages (Ungerer et al, 1992). ADA1 and ADA2 
seem to function together to ensure the homeostasis of adenosine and 2’deoxygenase 
in monocytes-macrophages, and a small proportional increase in ADA2 may result in 
a rapid increase in the levels of 2’deoxygenase in these monocytes-macrophages 
(Gakis, 1996). Seto et al (1986) demonstrated that 2’deoxygenase is deleterious for 
nucleic acid, and this has led to the postulation that ADA may play an important role 
in the defensive mechanisms of monocytes-macrophages against cellular micro-
organisms (Gakis, 1996). 
 
In the present study, ADA levels tended to be higher in cases that showed histological 
evidence of granulomatous inflammation than cases with serofibrinous pericarditis, 
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suggesting that the cells involved in the development and maintenance of 
granulomatous lesions (mainly activated macrophages and T lymphocytes) are also 
responsible for the elevated ADA activity in the pericardial fluid, as has been 
previously suggested (Ocaña et al, 1983; Petterson et al, 1984). The correlation noted 
between pericardial ADA activity and pericardial TNF- α suggests that there is an 
interaction between the locally produced cytokines and the demonstrable ADA 
activity. The question whether ADA production is influenced directly or indirectly by 
cytokines, and specifically by which cytokines, warrants further research.  
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Chapter 11 
THE EFFECT OF HIV ON LYMPHOCYTE 
SUBPOPULATIONS IN PERICARDIAL TB 
 
The protective immune response to active tuberculosis (TB) depends on the presence 
and activity of macrophages, as well as CD4+ lymphocyte cells and CD8+ T 
lymphocytes, which are responsible for the orchestrated production of cytokines (Cho 
et al, 2000; Rook and Zumla, 2001; Collins and Kaufmann, 2001; Boom et al, 2003). 
Pathologically, a number of stages are recognized in the development of tuberculous 
pericarditis. The early stage is characterised by a fibrinous serosal exudate that 
contains lymphocytes. The middle stage manifests granuloma formation, and the 
presence of viable acid-fast bacilli. This is followed by absorption of the effusion, 
pericardial thickening, and proliferation of granulomata often accompanied by 
caseating necrosis. At this stage, viable acid-fast bacilli are often no longer detected. 
In the late stage, fibrous pericarditis develops as the granulomatous reaction is 
replaced by fibrous tissue and collagen (Peel, 1948; Lorell, 1997; Nardell et al, 2004). 
These changes are followed by the accumulation of cholesterol crystals and the 
development of pericardial calcification (Lorell, 1997).  
 
In tuberculous pleural effusions lymphocytes are the predominant cell type, 
accounting for more than 70% of the total white cell count (Spriggs and Boddington, 
1960; Yam, 1967, Gresham, 1989), and these cells are mainly of the CD4+ 
lymphocyte phenotype (Bergroth et al, 1987; Tsukaguchi et al, 1999; Bergroth et al, 
1987). To the best of our knowledge, the composition of the phenotypically 
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heterogeneous inflammatory cellular infiltrate has not previously been described in 
tuberculous pericarditis. To improve our understanding of the protective immune 
response against M. tuberculosis and to assess the influence of HIV on the 
inflammatory cells that participate in the immune response that results in pericardial 
effusion, we evaluated the composition of the cellular infiltrate in patients with 
tuberculous pericarditis. 
 
PATIENTS AND METHODS 
To evaluate the phenotypic lymphocyte subpopulations, 24 pericardial fluid and 
corresponding peripheral blood specimens were evaluated by flow cytometry, as 
described in Chapter 2. The blood and pericardial fluid was collected at the time of 
initial pericardiocentesis. The diagnoses were made according to predetermined 
criteria. None of the patients was receiving anti-tuberculous therapy at the time of 
presentation. The methodology used for statistical analysis has been summarised in 
Chapter 2. 
 
RESULTS  
Phenotypic differentiation of lymphocyte subpopulations was performed on 24 
pericardial fluid and corresponding peripheral blood specimens. The diagnostic causes 
of the pericardial effusions (as per predetermined diagnostic criteria) included TB 
(n=18), malignancy (n=2), septic pericarditis (n=2), and systemic lupus erythematosus 
(SLE; n=2). Eleven patients were HIV positive; all presented with pericardial TB and 
none of them was previously known with HIV. The results of the phenotypic 
lymphocyte differentiation in peripheral blood and in pericardial fluid specimens are 
summarised in Table 11 .1. and Table 11.2., respectively. 
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Table 11.1. Phenotypic lymphocyte differentiation in peripheral blood samples 
of pericarditis patients   
  
 
 
TB / HIV+  
n=11 
TB / HIV- 
n=6 
Non-TB  
n=7 
 
p 
Leukocytesa   6.5 (4.1) 7.6 (3.2) 12.1 (4.6) <0.01 
Neutrophils 4.8 (3.4) 5.5 (2.7) 8.9 (6.1) <0.01 
Monocytes  0.22 (0.17) 0.54 (0.17) 0.72 (0.34) <0.01 
Lymphocytes  1.10 (1.34) 1.33 (0.60) 1.72 (1.40) 0.03 
% CD3+ lymphocytesb  79.2 (29.8) 74.5 (41.3) 75.0 (38.5) 0.16 
% CD4+ lymphocytes 25.1 (6.4) 36.8 (24.6) 42.7 (24.3) 0.01 
% CD8+ lymphocytes 56.1 (6.7) 39.2 (29.7) 26.7 (25.3) <0.01 
% CD19+ lymphocytes  11.6 (6.4) 7.3 (4.5) 12.9 (4.1) 0.25 
% CD16+/56+ cells  10.1 (2.9) 13.6 (2.8) 8.7 (2.6) 0.47 
CD4+/CD8+ cell ratio 0.41 (0.37) 1.12 (1.75) 2.50 (1.53) <0.01 
 
 
a Number of cells expressed as mean (SD) x 109/L 
b Percentages expressed as mean (SD) %  
P value established by Kruskall-Wallis One-Way ANOVA test on ranks  
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Table 11.2. Phenotypic lymphocyte differentiation in pericardial fluid samples 
of pericarditis patients   
 
 
 
TB / HIV+  
 
n=11 
TB / HIV- 
 
n=6 
Non-TB  
 
n=7 
 
 
p 
Leukocytesa   1.8 (1.5) 2.7 (2.3) 4.6 (3.8) <0.01 
Neutrophils 0.8 (0.7) 1.0 (1.8) 2.6 (1.8) <0.01 
Macrophages  0.34 (0.28) 0.38 (0.44) 0.48 (0.78) 0.07 
Lymphocytes  0.86 (0.56) 1.34 (0.91) 0.70 (0.85) 0.03 
% CD3+ lymphocytesb  91.8 (3.5) 86.7 (4.0) 80.0 (2.1) 0.05 
% CD4+ lymphocytes 25.3 (12.9) 50.2 (26.9) 58.0 (23.9) <0.01 
% CD8+ lymphocytes 61.0 (12.8) 37.3 (13.7) 19.5 (10.7) <0.01 
% CD19+ lymphocytes  1.3 (0.6) 5.7 (1.7) 4.3 (2.7) 0.02 
% CD16+/56+ cells  1.1 (0.4) 3.8 (6.5) 3.9 (4.5) 0.03 
CD4+/CD8+ cell ratio 0.46 (0.31) 1.66 (1.36) 4.46 (2.08) <0.01 
 
 
a Number of cells expressed as mean (SD) x 109/L 
b Percentages expressed as mean (SD) %  
P value established by Kruskall-Wallis One-Way ANOVA test on ranks  
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Peripheral blood 
The lymphocyte subpopulations differed significantly in patients presenting with 
pericardial TB compared with patients with non-tuberculous pericarditis. The 
percentage of CD4+ lymphocyte cells and the total number of natural killer (NK) cells 
was significantly lower in patients with tuberculous pericarditis than in patients with 
non-tuberculous effusions (p<0.01 for both variables), whereas the percentage of 
CD8+ lymphocyte cells was higher in patients with tuberculous effusions than in 
those with non-tuberculous aetiology (p<0.01).  
 
The distribution of lymphocyte phenotypes differed also significantly between the 
HIV positive TB group and the HIV negative tuberculous pericarditis patients, as 
indicated in Table 11 .1. The corresponding mean (SD) CD4+ lymphocyte cell counts 
for HIV positive TB, HIV negative TB and non-tuberculous effusions were 214.5 
(210.3) cells/μL, 635.4 (482.5) cells/μL, and 538.7 (264.9) cells/μL, respectively. In 
addition, the peripheral blood CD4+lymphocyte/CD8+ lymphocyte cell ratios were 
significantly higher in HIV positive TB patients than in both HIV negative TB 
patients and patients presenting with non-tuberculous effusions (p<0.01 for both 
groups; Figure 11.1.). 
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Figure 11.1. Distribution of peripheral blood CD4+ cell / CD8+ cell ratio  
 
TB = tuberculosis  
HIV+ = human immunodeficiency virus positive  
HIV- = human immunodeficiency virus negative  
Non-TB = non-tuberculous 
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Pericardial fluid 
Lymphocytes dominated the pericardial fluid cellular infiltrate in patients with 
tuberculous pericarditis in comparison to effusions caused by sepsis, malignancy or 
SLE, in which neutrophils were the dominant type of leukocyte. We also observed 
significant differences in the composition of lymphocyte subpopulations between 
patients with tuberculous pericarditis and patients who presented with non-
tuberculous pericarditis (Table 11.2).  
 
In comparison with HIV negative patients with tuberculous pericarditis, HIV positive 
TB patients were found to have a lower percentage of CD4+ lymphocyte cells 
(p<0.01; Figure 11.2.), a lower percentage of NK cells (CD16+/56+ cells; p=0.01; 
Figure 11.3.), a lower percentage of B lymphocyte cells (CD19+ cells; p=0.03; Figure 
11.4.), and a lower CD4+ cell/CD8+ cell ratio (p < 0.01), however, the percentage of 
CD8+ lymphocyte cells was higher in HIV positive TB patients than in the HIV 
negative TB group (p< 0.01; Figure 11.5). 
 
.  
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Figure 11.2. Distribution of pericardial CD4+ lymphocyte cells as percentage of 
pericardial lymphocytes 
 
TB = tuberculosis  
HIV+ = human immunodeficiency virus positive  
HIV- = human immunodeficiency virus negative  
Non-TB = non-tuberculous 
Pc = pericardial  
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Figure 11.3.  Distribution of pericardial CD16+/56+ cells as percentage of  
pericardial lymphocytes 
 
 
TB = tuberculosis  
HIV+ = human immunodeficiency virus positive  
HIV- = human immunodeficiency virus negative  
Non-TB = non-tuberculous 
Pc = pericardial  
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Figure 11.4. Distribution of pericardial CD19+ cells as percentage of 
pericardial lymphocytes 
 
TB = tuberculosis  
HIV+ = human immunodeficiency virus positive  
HIV- = human immunodeficiency virus negative  
Non-TB = non-tuberculous 
Pc = pericardial  
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Figure 11.5. Distribution of pericardial CD8+ cells as percentage of pericardial  
lymphocytes 
 
TB = tuberculosis  
HIV+ = human immunodeficiency virus positive  
HIV- = human immunodeficiency virus negative  
Non-TB = non-tuberculous 
Pc = pericardial  
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DISCUSSION 
The central immunological feature of HIV disease is the loss of lymphocytes. In 
infected individuals, the rate of CD4+ lymphocyte loss reflects the balance between 
ongoing cellular destruction and an inadequate repopulation from progenitor cells. 
Infected CD4+ lymphocytes may be depleted through direct cytopathic effects of the 
virus, by virus-specific cytotoxic lymphocytes, or by antibody-dependent cell 
mediated cytotoxicity (Fauci, 1988; Siliciano, 1996). However, impaired regeneration 
of mature CD4+ lymphocyte cells from the precursor cell pool also contributes to the 
ultimate depletion of these cells.  
 
In our study, significantly decreased numbers of peripheral blood CD4+ lymphocytes 
and monocytes were demonstrated in HIV positive TB patients compared to both HIV 
negative TB patients and patients with non-tuberculous disease. This was 
accompanied by significantly elevated CD8+ lymphocytes in the HIV infected 
individuals compared with those not infected with HIV.  The lymphocyte phenotypes 
in the pericardial fluid reflected the phenotypic distribution observed in the peripheral 
blood. The dominant features were severely diminished presence of CD4+ 
lymphocytes and a predominance of CD8+ cells in HIV positive tuberculous effusions 
in contrast to HIV negative tuberculous patients in whom CD4+ lymphocytes 
dominated the inflammatory cell infiltrate. Previous studies that did not include HIV 
positive patients described CD4+ lymphocyte cell dominance in pleural fluid of 
patients with tuberculous pleurisy (Bergroth et al, 1987; Rossi et al, 1987; Ribera et 
al, 1988; Fontes et al, 1990). CD8+ lymphocyte dominance in tuberculous pericardial 
exudates of HIV positive individuals has, to the best of our knowledge, not previously 
been described but is consistent with the dominance of CD8+ lymphocyte cells in the 
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peripheral circulation of HIV positive patients (Margolick et al, 1995), as well as in 
bronchoalveolar lavage samples of HIV-infected individuals (Venet et al, 1985; 
Young et al, 1985). As CD4+ lymphocyte cells are lost in HIV positive individuals, 
CD8+ lymphocyte cells increase in a seemingly compensatory fashion, resulting in a 
constant level of total CD3+ lymphocyte cells (Margolick et al, 1995). The depletion 
of NK cells in tuberculous exudates of HIV positive patients was consistent with the 
diminished number of NK cells found in the peripheral blood of HIV positive patients 
with tuberculous pericarditis in this present study.   
 
In spite of significant differences in the composition of the inflammatory cellular 
infiltrate, pericardial fluid cytokine levels were affected less markedly than expected. 
The difference in pericardial IFN-γ levels of HIV positive and HIV negative TB 
patients was negligible and no demonstrable correlation was found between 
pericardial lymphocyte counts and the corresponding IFN-γ levels in tuberculous 
effusions (Chapter 9). The contribution of CD4+ lymphocyte cells in the delayed 
hypersensitivity response and protection against TB is well described, including the 
interaction between IFN-γ secreting CD4+ lymphocyte cells and macrophages 
(Sanchez et al, 1994). In our study pericardial fluid CD4+ lymphocyte cell numbers 
were about fivefold higher in the HIV negative than the HIV positive TB group (mean 
[SD] 785.5 [166.9] cells/μL versus 145.5 [123.3] cells/μL); the negligible difference 
in IFN-γ level between the HIV positive and HIV negative tuberculous groups is thus 
unexpected. It is likely that a large proportion of the IFN-γ found in HIV positive 
patients originated from CD8+ lymphocyte cells, which dominated the cellular 
infiltrate, and in addition to cytolysis, contribute significantly to the host defence 
against TB by secreting protective cytokines such as IFN-γ and TNF-α (Cooper et al, 
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1997; Laochumroonvorapong et al, 1997; Sousa et al, 1999; Smith and Dockrell, 
2000). IFN-γ and other cytokines are, in part, produced by gammadelta (γδ) T 
lymphocytes and CD4 CD8 double negative T lymphocyte cells (Mosmann and 
Moore, 1991; Abehsira-Amar et al, 1992; Chehimi and Trinchieri, 1994; Boom, 1999; 
Tsukaguchi, 1999). Of these, γδ T-lymphocytes seem to play an important role in the 
human anti-tuberculous immune response (Barnes et al, 1992).  
 
In addition to the severe depletion of CD4+ lymphocyte cells HIV and TB co-infected 
individuals were characterised by decreased numbers of NK cells and B lymphocytes; 
only CD8+ lymphocyte cell numbers were maintained or elevated.  It is possible that 
the widespread cytopenia observed in this study in HIV positive patients who 
presented with pericardial TB resulted from a combination of depressed 
haematopoiesis caused by HIV infection of CD34+ progenitor cells (Folks et al, 1988; 
Terstappen and Loken, 1990) and disturbed maturation of pluripotent haematopoietic 
stem cells (Folks et al, 1988). In the present study, peripheral monocytes were 
significantly diminished in the HIV positive TB patients compared to HIV negative 
individuals with TB, whereas the number and proportion of pericardial macrophages 
was similar in HIV positive and HIV negative individuals with pericardial TB. 
Monocytes and tissue macrophages are both susceptible to HIV infection (Rich et al, 
1992), but due greater numbers of CD4+ lymphocyte molecules on peripheral blood 
monocytes than tissue macrophages these cells are more prone to be affected by HIV 
(Rich et al, 1992).  
 
In patients who were co-infected with HIV and TB, CD8+ T lymphocyte cell numbers 
were elevated in the peripheral blood and pericardial cellular infiltrate, whereas the 
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numbers of other lymphocyte phenotypes, neutrophils and monocytes were 
significantly reduced. The observed cytopenia probably results from infection of 
haematopoietic stem cells and the release of endogenous cytokines within the 
haematopoietic micro-environment that affect the proliferation and differentiation of 
haematopoietic cells in the bone marrow and thymus (Kunzi et al, 1995). In spite of 
the decreased number of CD4+ lymphocyte cells and other types of leukocytes, 
tuberculous effusions of HIV positive individuals nevertheless demonstrated a Th1 
dominant cytokine profile, characterised by indeterminably low levels of IL-4 and 
elevated levels of IFN-γ. 
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Chapter 12 
GENERAL CONCLUSIONS 
 
More than a hundred years after Robert Koch’s discovery of the tubercle bacillus, 
tuberculosis (TB) remains a major cause of morbidity and mortality, accounting for 
more deaths of adults than any other infectious agent. More than 8 million new cases 
of TB were reported to the World Health Organization in 2003 (WHO Report, 2005), 
and millions are co-infected with the human immunodeficiency virus (HIV) and 
Mycobacterium tuberculosis (M. tuberculosis; Dye et al, 1999; WHO Report, 2005). 
A rapid increase in TB cases coincident with the HIV epidemic has been reported for 
sub-Saharan Africa (WHO Report, 2005). The effects of HIV include a higher 
proportion of extrapulmonary TB (Narain et al, 1992, Barnes et al, 1993), including 
an increase in the incidence of tuberculous pericarditis (Cegielski et al, 1990; 
Cegielski et al, 1994; Magula and Mayosi, 2003). In our study, 50% of all the 
tuberculous pericarditis patients were HIV positive, compared to only 4.2% of 
patients presenting with non-tuberculous aetiology. The number of newly diagnosed 
HIV and TB co-infected individuals showed a year-to-year increase. HIV-infected 
tuberculous pericarditis patients were significantly younger than the HIV negative TB 
patients, and the highest prevalence of HIV and TB co-infection was found in the 
socio-economically most deprived group, namely African black females. The steady 
rise in the number of HIV and TB co-infected patients observed in this study reflects 
progressively increasing numbers of new cases of HIV infection, but it may also 
partly be due to maturation of the HIV epidemic resulting in more cases of clinically 
affected individuals.  
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The diagnosis of TB as the aetiological cause is important. Without specific treatment, 
the reported survival was 3.7 months and only 20% were alive at six months (Desai, 
1979). On the other hand, the prognosis is excellent with appropriate medical 
treatment. Echocardiography provides the most efficient way to determine the 
presence of pericardial effusion. However, in developing countries echocardiography 
is not always available. We demonstrated how chest radiography and 
electrocardiography (ECG) assist in the diagnostic process under such circumstances. 
Our findings indicate good correlation between the degree of radiographic 
cardiomegaly and the amount of pericardial fluid aspirated at the time of 
pericardiocentesis. In a substantial number of cases, radiography also contributes to 
the diagnosis of coexistent pulmonary TB, whereas radiographic evidence of 
mediastinal lymphadenopathy suggests co-infection with HIV. The presence of micro-
voltage on ECG points towards the presence of a large pericardial effusion, whereas 
absence of micro-voltage almost always excluded it.  
 
A definitive diagnosis of tuberculous pericarditis is made by isolation of the tubercle 
bacillus from the pericardial fluid and/or pericardial biopsy, yet pericardial TB is 
often not identified because of the difficulty in isolating the causative organism. In the 
present study pericardial effusion cultures were positive in 56% of cases, and culture 
results usually only became available after management decisions had already been 
taken. Histopathological examination led to a definitive diagnosis of tuberculous 
pericarditis (caseating granulomata or tubercle bacilli on biopsy sample) in only 11 of 
the 20 HIV-negative tuberculous pericardial effusions (55%) and two of the five HIV-
positive patients (40%). Pericardial biopsy is invasive, adds the risk of anaesthesia, 
requires technical skills and may result in longer hospitalisation. As a result of these 
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difficulties and the lack of other diagnostic resources it is important to utilise 
alternative strategies. The potential for toxic effects and the duration of anti-
tuberculous chemotherapy mandate diagnostic specificity. In addition, numerous other 
infectious and non-infectious causes present with similar clinical features, thus 
sensitive and accurate diagnostic tools are required.  
 
We evaluated a number of diagnostic strategies and used our results to develop tools 
to optimise the diagnostic efficiency of available tests. We propose a basic diagnostic 
rule that is simple and effective and can be applied in areas where TB and HIV co-
infection is endemic, and where access to pericardial biopsy, microbiologic studies 
and other diagnostic tests is difficult. In patients with large pericardial effusions five 
features were identified that are independently predictive of tuberculous pericarditis, 
namely fever, night sweats, weight loss, serum globulin >40 g/L and peripheral blood 
leukocyte count <10x109/L. Based on these variables, we developed a TB prediction 
model by means of a statistical approach called “classification and regression tree” 
(CART) analysis. A weighted diagnostic index was allocated to each of the five 
variables and by adding these up a total diagnostic index (score) was obtained, 
ranging between 0-10. The optimum cut-off for the total diagnostic index (by which 
to classify a patient has having tuberculous pericarditis) was found using receiver 
operating characteristic (ROC) curves (Beck and Schultz, 1986). The diagnostic rule’s 
best diagnostic efficiency for diagnosing TB corresponded in a training and in a test 
set to a total diagnostic index of 6. Results for the prediction model applied to the 
training data demonstrated 86% sensitivity and 87% specificity for the diagnosis of 
TB, whereas application to the test set resulted in 82% sensitivity and 76% specificity. 
Our suggested diagnostic rule was therefore: if the patient has a total diagnostic index 
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score of 6 or more, he or she has tuberculous pericarditis, and if the patient has a score 
of less than 6, he or she has non-tuberculous pericarditis. Our study demonstrates how 
basic clinical and laboratory features can help in the diagnosis of tuberculous 
pericarditis. In a setting with a similar HIV and TB prevalence to that of the Western 
Cape Province a diagnostic score of 6 or more will suffice to initiate empiric anti-
tuberculous therapy, whereas a score of less than 6 warrants further investigations. It 
needs to be emphasised that the usefulness of the diagnostic rule will depend on the 
prevalence of TB and HIV infection in a particular setting and we suggest that it 
should not be used in areas of substantially different TB and HIV prevalence to those 
of Southern Africa until prospectively assessed for diagnostic accuracy in such a 
setting.  
 
For areas with more sophisticated diagnostic infrastructure, we propose determining 
pericardial fluid adenosine deaminase (ADA) activity as the diagnostic test of choice. 
Using a pericardial fluid ADA activity >40U/L as a cut-off level for the diagnosis of 
pericardial TB resulted in 87% sensitivity and 89% specificity for the diagnosis of 
tuberculous pericarditis, and it was equally efficient in HIV positive as in HIV 
negative tuberculous pericarditis patients. In addition to the diagnostic usefulness, it 
provides the diagnosis rapidly and cost-effectively. It should, however, be noted that a 
number of other diseases are also associated with elevated pericardial ADA levels, 
including effusions caused by malignancy or by non-tuberculous bacterial infection. 
In the majority of cases, these aetiological causes could be differentiated by 
pericardial fluid cytology, differential white cell count, Gram stain and bacterial 
culture. We developed a diagnostic classification model or diagnostic algorithm that 
assisted in differentiating between tuberculous and non-tuberculous effusions and is 
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based on the predictive attributes of pericardial ADA levels, pericardial lymphocyte / 
neutrophil ratios, peripheral leukocyte counts and HIV status. Applying this 
prediction model to our entire data set of patients (n=233) resulted in 96% sensitivity 
and 97% specificity for the correct diagnosis of tuberculous pericarditis. As for the 
diagnostic rule, we suggest that this model should also not be used in areas of 
substantially different TB and HIV prevalence to those of Southern Africa until 
prospectively assessed.  
 
Our study suggests that determining pericardial gamma-interferon levels provides the 
optimal diagnostic results; a cut-off level of 50 pg/mL resulted in 92% sensitivity and 
100% specificity for the diagnosis of tuberculous pericarditis. However, before 
initiating anti-tuberculous therapy, pericardial fluid and sputum specimens should be 
sent for culture to exclude other bacterial, fungal and parasitic pericardial infections. 
Evidence of clinical and radiological improvement should be assessed at each visit 
and culture results checked regularly. Failure to improve must prompt a search for an 
alternative diagnosis.  
 
The most urgent step in the therapeutic management of individuals with pericardial 
effusions causing haemodynamic compromise is effective drainage to relieve or 
prevent cardiac tamponade. We recommend echocardiographically guided 
percutaneous pericardiocentesis with an indwelling catheter and intermittent daily 
aspiration. Skin sepsis and intrapericardial sepsis are rare, even in patients with severe 
immunodeficiency, provided that diligent care is taken of the patients with indwelling 
pericardial catheters. We recommend that an indwelling catheter should not be kept in 
situ for more than five days. Indications for removal of the catheter include any one of 
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the following (i) aspirate < 100 mL per day; (ii) catheter blockage not amenable to 
flushing with heparinised sterile saline and/or iii) any of signs of intrapericardial or 
skin sepsis.  
 
Anti-tuberculous chemotherapy is effective in the treatment of pericardial TB. In our 
experience, a rifampicin-containing short course of six months resulted in excellent 
cure rates in patients with tuberculous pericarditis and we did not observe any 
relapses. It is possible that the efficient drainage procedure and early initiation were 
responsible for the almost complete absence of pericardial constriction observed 
during this study. Intrapericardial and systemic corticosteroids were well tolerated, 
but did not improve the outcome in our patients. At present, corticosteroids should be 
reserved for critically ill patients with recurrent large effusions who do not respond to 
pericardial drainage and anti-tuberculous drugs alone (Lorell, 1997).   
 
The one-year all-cause mortality was higher in HIV positive patients than in HIV 
negative patients. The majority of deaths were caused by non-cardiac opportunistic 
infections and septicaemia with CD4+ lymphocyte counts <200 cells/μL predicting a 
poor prognosis. At the time of the study highly active antiretroviral therapy (HAART) 
was not available at Tygerberg Hospital and further research is warranted to 
investigate if the provision of HAART results in improved prognosis in HIV positive 
patients with tuberculous pericarditis.  
 
Tuberculous pericardial effusion results from the protective immune response to M. 
tuberculosis, which is characterised by elevated levels of pericardial fluid gamma-
interferon (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This response is 
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primarily orchestrated by CD4+ lymphocytes that produce IFN-γ and results in a 
cascade of monocyte recruitment and macrophage differentiation that results in the 
development and maintenance of granulomata, which are the hallmark of delayed 
hypersensitivity. Activated macrophages produce TNF-α which, in synergy with IFN-
γ, results in further attraction and activation of monocytes and macrophages, 
producing and releasing a number of factors that participate in the immune response. 
Th2 lymphocyte activity is suppressed by the high levels of IFN-γ and this is reflected 
by the low levels of interleukin-4 (IL-4) in the pericardial fluid of patients presenting 
with tuberculous pericarditis. Our study supports an immunoregulatory, tissue 
protective role for IL-10.  
 
In our study we observed significantly lower CD4+ T lymphocyte counts 
accompanied by increased CD8+ T lymphocyte counts in the peripheral blood and 
pericardial fluid of patients who were co-infected with HIV and TB compared to HIV 
negative TB patients. In addition, HIV infection also affected the numbers of B 
lymphocyte, NK cells, neutrophils, and monocytes. The observed widespread 
cytopenia probably results from HIV infection of haematopoietic stem cells and the 
release of endogenous cytokines within the haematopoietic micro-environment that 
affect the proliferation and differentiation of haematopoietic cells in the bone marrow 
and thymus. We found that the tuberculous effusions in HIV infected individuals were 
characterised by a Th1 dominant cytokine profile in spite of the significantly 
decreased numbers of pericardial fluid CD4+ lymphocytes. In these patients IFN-γ, 
may be produced by both CD8+ lymphocytes and γδ T lymphocytes, which are 
closely linked to anti-mycobacterial immunity.  
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The presence of adenosine deaminase (ADA) in pericardial fluids reflects the activity 
of this cellular immune response. We demonstrated significantly elevated ADA 
activity in tuberculous pericardial fluid compared to non-tuberculous disease. The 
elevated ADA levels reflect the prominence of lymphocytes and macrophages in the 
immune response to tuberculous infection. Granulomatous pericarditis, which is 
characterised by the presence of differentiated macrophages and prominent 
lymphocyte infiltration tended to be associated with higher ADA activity than 
serofibrinous pericarditis. In addition, we were also able to demonstrate a correlation 
between pericardial ADA levels and pericardial TNF-α, which is mainly produced by 
monocyte-macrophages. We identified two factors that predicted low ADA activity in 
tuberculous exudates, namely severe depletion of CD4+ lymphocytes (<100 cells/μL) 
and the use anti-tuberculous therapy.  
 
In conclusion, tuberculous exudates result from a Th1 mediated immune response 
characterised by elevated levels of IFN-γ and TNF-α. The anti-tuberculous immune 
response is furthermore accompanied by high serum globulin levels, relatively low 
peripheral leukocyte counts and pericardial lymphocytosis. We have demonstrated 
how these immunological features can be utilised to diagnose pericardial TB 
effeciently and thereby improve the patient care. 
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